Page last updated: 2024-11-09

terbinafine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID1549008
CHEMBL ID822
CHEBI ID9448
CHEBI ID94705
SCHEMBL ID36794
SCHEMBL ID37843

Synonyms (113)

Synonym
BIDD:GT0825
AB00698510-09
AB00698510-11
AB00698510-10
lamisil at
(2e)-n,6,6-trimethyl-n-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine
sf-86-327
brn 4256376
sf 86-327
1-naphthalenemethanamine, n-(6,6-dimethyl-2-hepten-4-ynyl)-n-methyl-, (e)-
lamasil
lamisil tablet
(e)-n-(6,6-dimethyl-2-hepten-4-ynyl)-n-methyl-1-naphthalene methanamine
terbinafine, sf-86-327, lamisil, tbnf
(e)-n,6,6-trimethyl-n-(1-naphthylmethyl)hept-2-en-4-yn-1-amine
C08079
91161-71-6
terbinafine ,
(e)-n-(6,6-dimethyl-2-hepten-4-ynyl)-n-methyl-1-naphthalenemethylamine
NCGC00159346-02
DB00857
terbinafine (usan/inn)
D02375
lamasil (tn)
NCGC00159346-03
tdt-067
HMS2089B20
chebi:9448 ,
CHEMBL822 ,
AKOS001451917
STK802069
((e)-6,6-dimethyl-hept-2-en-4-ynyl)-methyl-naphthalen-1-ylmethyl-amine
bdbm50018518
terbinafin
(6,6-dimethyl-hept-2-en-4-ynyl)-methyl-naphthalen-1-ylmethyl-amine
n-[(2e)-6,6-dimethyl-2-hepten-4-yn-1-yl]-n-methyl-1-naphthalenemethanamine
1n,6,6-trimethyl-1n-(1-naphthylmethyl)-(e)-2-hepten-4-yn-1-amine
(6,6-dimethyl-hept-2-en-4-ynyl)-methyl-naphthalen-1-ylmethyl-amine(terbinafine)
(e)-n,6,6-trimethyl-n-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine
A843743
NCGC00188975-01
[(e)-6,6-dimethyl-hept-2-en-4-ynyl]-methyl-(naphthalen-1-yl-methyl)-amine
(2e)-n,6,6-trimethyl-n-(1-naphthylmethyl)hept-2-en-4-yn-1-amine
terbinafine [usan:inn:ban]
unii-g7riw8s0xp
g7riw8s0xp ,
ec 618-706-8
tox21_111591
dtxcid703640
dtxsid2023640 ,
cas-91161-71-6
BBL010959
terbinafinum
terbinafina
terbinex
corbinal
zabel
terbinafine [green book]
terbinafine [usan]
terbinafine [who-dd]
terbinafine [mart.]
terbinafine [mi]
terbinafine [ema epar veterinary]
terbinafine [inn]
terbinafine component of osurnia
terbinafine [orange book]
osurnia component terbinafine
terbinafine [vandf]
S1725
CCG-221253
HY-17395A
CS-1944
n,6,6-trimethyl-n-(1-naphthylmethyl)hept-2-en-4-yn-1-amine hydrochloride
AB00698510-07
SCHEMBL36794
SCHEMBL37843
NCGC00159346-04
tox21_111591_1
T3677
smr004703509
MLS006011885
AB00698510_14
AB00698510_13
AB00698510_12
GS-3099
[(2e)-6,6-dimethylhept-2-en-4-yn-1-yl](methyl)[(naphthalen-1-yl)methyl]amine
AC-8561
CHEBI:94705
tdt 067
SBI-0206829.P001
HMS3715L08
SW197656-3
-ylmethyl)hept-2-en-4-yn-1-amine
(e)-n,6,6-trimethyl-n-(naphthalen-1
erbinafine hydrochloride
sf 86-327; sf-86-327; sf86-327; lamasil; lamisil at
BCP22896
Q415259
91161-71-6 (free base)
terbinafine free base
sf86-327
terbinafine (lamisil, terbinex)
mfcd00242672
BRD-K68132782-003-05-4
(6,6-dimethylhept-2-en-4-yn-1-yl)(methyl)[(naphthalen-1-yl)methyl]amine
EN300-25297578
EN300-832786
1-naphthalenemethanamine, n-[(2e)-6,6-dimethyl-2-hepten-4-yn-1-yl]-n-methyl-
Z2315576259
d01ae15
d01ba02
terbinafine (mart.)
terbinafine (ema epar veterinary)

Research Excerpts

Overview

Terbinafine hydrochloride is a synthetic allylamine. Its mechanism of action consists of inhibiting the enzyme squalene epoxidase. It is effective against many fungi, dermatophytes and moulds.

ExcerptReferenceRelevance
"Terbinafine is a therapeutically used inhibitor of fungal squalene epoxidase that has prompted extensive derivatization programs for structure-activity relationship studies. "( Synthesis and structure-activity relationships of side-chain-substituted analogs of the allylamine antimycotic terbinafine lacking the central amino function.
Leitner, I; Mraz, K; Nussbaumer, P; Stütz, A, 1995
)
1.95
"Terbinafine is a drug that can induce acute liver damage. "( [Terbinafine-induced liver toxicity in the context of a SARS-CoV-2 pandemic: a case report].
Asato Higa, C; Bustios Sanchez, C; Monge Zapata, V; Sumire Umeres, J,
)
2.48
"Terbinafine (TER) is a promising candidate medication for the topical treatment of fungal infections. "( Green formulation, characterization, antifungal and biological safety evaluation of terbinafine HCl niosomes and niosomal gels manufactured by eco-friendly green method.
Akbari, J; Babaei, A; Ghazanfari, M; Haghani, I; Hashemi, SMH; Hedayati, MT; Hedayati, S; Morteza-Semnani, K; Rahimnia, SM; Saeedi, M, 2022
)
2.39
"Terbinafine hydrochloride is a synthetic allylamine whose mechanism of action consists of inhibiting the enzyme squalene epoxidase that participates in the first stage of ergosterol synthesis, interfering with fungal membrane function. "( Polymeric Nanocapsules Containing Ozonated Oil and Terbinafine Hydrochloride as a Potential Treatment Against Dermatophytes.
Contri, RV; da Costa, BS; Dos Santos, FL; Fuentefria, AM; Kulkamp Guerreiro, IC; Machado, AU; Marques, MS; Zilles, JC, 2023
)
2.6
"Terbinafine is a commonly used antifungal agent, but safety data of its use in pregnancy are limited."( Evaluation of Association Between Oral and Topical Terbinafine Use in Pregnancy and Risk of Major Malformations and Spontaneous Abortion.
Andersen, JT; Andersson, NW; Thomsen, SF, 2020
)
2.25
"Terbinafine (Tbf) is a well-established anti-fungal agent used for management of a variety of dermal conditions including ringworm and athlete's foot. "( FT-IR investigation of Terbinafine interaction with stratum corneum constituents.
Flach, CR; Mendelsohn, R; Pyatski, Y, 2020
)
2.31
"Terbinafine is an allylamine antifungal that is effective against many fungi, dermatophytes and moulds. "( Simple and Fast Determination of Terbinafine in Human Urine by Dilute and Shoot HPLC-DAD Using a Core-Shell Column.
Demirdaş, G; Fidan, M; Yaşar, A; Yıldırım, S, 2021
)
2.35
"Terbinafine is an antifungal agent used in the treatment of hair, nail, and skin dermatophyte infections. "( Terbinafine-induced lichenoid drug eruption: case report and review of terbinafine-associated cutaneous adverse events.
Calame, A; Cohen, PR; Erickson, CP, 2020
)
3.44
"Terbinafine is a commonly used antifungal medication. "( Concurrent terbinafine-induced acute generalised exanthematous pustulosis and hepatitis.
Carnio, LR; Casadesus, D; Johnson Shaw, ME; Schnur, J, 2021
)
2.45
"Terbinafine is a first-line agent against Trichophyton-infections. "( Photodynamic therapy: A treatment option for terbinafine resistant Trichophyton species.
Arendrup, MC; Jemec, GBE; Saunte, DML; Shen, JJ, 2021
)
2.32
"Terbinafine is a potent CYP2D6 inhibitor."( Failure of Warfarin Anticoagulation Therapy after Administration of Oral Terbinafine.
Čupáková, J; Štětkářová, I, 2021
)
1.57
"Terbinafine is a common antifungal agent with few reports of liver injury. "( Terbinafine-induced liver injury.
Kaushal, M; Kumar, N; Sharma, S; Tolani, P,
)
3.02
"Terbinafine is an antifungal agent that has been associated with rare instances of hepatotoxicity. "( The role of HLA-A*33:01 in patients with cholestatic hepatitis attributed to terbinafine.
Barnhart, H; Chalasani, N; Cirulli, ET; Fontana, RJ; Gu, J; Hoofnagle, JH; Kleiner, D; Ostrov, D; Phillips, E; Schutte, R; Watkins, PB, 2018
)
2.15
"Terbinafine solution is a broad spectrum antifungal agent effective in the treatment of otomycosis. "( The ototoxic effect of intratympanic terbinafine applied in the middle ear of rats.
Akcadag, A; Korkmaz, F; Sagit, M; Somdas, MA, 2013
)
2.11
"Terbinafine is a fungicidal allylamine with documented in vitro and in vivo efficacy against Microsporum canis in pet cats and in cats with experimental infections."( Treatment of shelter cats with oral terbinafine and concurrent lime sulphur rinses.
Coyner, K; Kunder, D; Moriello, K; Newbury, S; Trimmer, A, 2013
)
1.39
"Terbinafine is an effective antimicrobial agent against dermatophytes, cryptococcus and other fungi. "( Systematic review of severe acute liver injury caused by terbinafine.
Chen, S; Wang, X; Yan, J, 2014
)
2.09
"Terbinafine is an antimycotic drug usually used against several superficial fungal infections and with a potential application in the treatment of human cancers. "( Genotoxic evaluation of terbinafine in human lymphocytes in vitro.
de Castro-Prado, MA; de Sant'Anna, JR; Della-Rosa, VA; Martins, AB; Tolomeotti, D, 2015
)
2.17
"Terbinafine is a commonly prescribed antifungal agent used in the treatment of trichophytic onychomycosis and chronic cutaneous mycosis that are resistant to other treatments. "( A curious case of cholestasis: oral terbinafine associated with cholestatic jaundice and subsequent erythema nodosum.
Gill, A; Kumar, K; Shafei, R; Wright, JL, 2014
)
2.12
"Terbinafine is a fungicidal agent that inhibits ergosterol, an essential fungal component."( DA 5505: a novel topical formulation of terbinafine that enhances skin penetration and retention.
Han, SD; Jun, JH; Kim, JO; Park, HG; Son, M; Thapa, RK, 2015
)
1.41
"Terbinafine (TER) is a CYP2D6 inhibitor and causes persistent drug interactions in the clinical setting; however, its inhibitory mechanism and the differences in its inhibitory potency among genetic variants of CYP2D6 remain to be investigated."( Variation in the inhibitory potency of terbinafine among genetic variants of CYP2D6.
Akiyoshi, T; Imaoka, A; Ishiuchi, M; Ohtani, H, 2015
)
1.41
"Terbinafine is an allylamine antifungal agent which is widely used for the treatment of fungal infections. "( Terbinafine induced pityriasis rosea-like eruption.
Bhatia, A; George, A; Kanish, B; Williams, A,
)
3.02
"Terbinafine is a recommended therapeutic alternative for patients with sporotrichosis who cannot use itraconazole due to drug interactions or side effects. "( Melanins Protect Sporothrix brasiliensis and Sporothrix schenckii from the Antifungal Effects of Terbinafine.
Almeida-Paes, R; Almeida-Silva, F; Brito-Santos, F; Figueiredo-Carvalho, MH; Oliveira, MM; Zancopé-Oliveira, RM, 2016
)
2.09
"Terbinafine is an antifungal agent that selectively inhibits fungal sterol synthesis by blocking squalene epoxidase. "( Terbinafine inhibits gap junctional intercellular communication.
Choi, EJ; Lee, J; Lee, JY; Yoon, SM, 2016
)
3.32
"Terbinafine is an allylamine antifungal agent, effective in the treatment of dermatomycoses. "( Terbinafine-induced acute generalized exanthematous pustulosis.
Fimiani, M; Mandato, F; Rubegni, P; Sbano, P, 2008
)
3.23
"Terbinafine is an excellent choice in diabetics due to its low risk of drug-drug interaction and proven efficacy against the typical pathogens that cause onychomycosis. "( Onychomycosis and diabetes.
Cantrell, W; Cathcart, S; Elewski, Be, 2009
)
1.8
"Terbinafine (TRB) is an allylamine antifungal agent that has been available for more than a decade. "( Terbinafine: a pharmacological and clinical review.
Krishnan-Natesan, S, 2009
)
3.24
"Terbinafine (TRB) is a potent antifungal drug used in therapy of fungal infections."( A novel homologous dominant selection marker for genetic transformation of Penicillium chrysogenum: overexpression of squalene epoxidase-encoding ergA.
Handler, M; Kürnsteiner, H; Sigl, C; Sprenger, G; Zadra, I, 2010
)
1.08
"Terbinafine is an allylamine antifungal prescribed for the treatment of mycoses in humans. "( Terbinafine pharmacokinetics after single dose oral administration in the dog.
Carlson, SA; Day, TA; Felz, C; Imerman, PM; May, ER; Noxon, JO; Sakai, MR, 2011
)
3.25
"Terbinafine is an effective alternative to griseofulvin against tinea capitis of Trichophyton infections."( A random comparative study of terbinafine versus griseofulvin in patients with tinea capitis in Western China.
Abliz, P; Cheng, W; Deng, S; Hu, H; Li, R; Wan, Z; Wang, A, 2011
)
1.38
"Terbinafine is an antifungal drug known to have also antibacterial activity against certain Gram-positive and Gram-negative bacteria. "( Mupirocin vs terbinafine in impetigo.
Aysev, AD; Ciftci, E; Guriz, H, 2002
)
2.13
"Oral terbinafine is a widely used antifungal agent. "( Terbinafine exacerbates psoriasis: case report with a literature review.
Szepietowski, JC, 2003
)
2.28
"Terbinafine is an allylamine fungicidal agent that is widely used for the treatment of onychomycoses and other fungal infections. "( Acute generalized exanthematous pustulosis induced by terbinafine.
Alomar, A; Gilaberte, M; Puig, L; Taberner, R,
)
1.82
"Terbinafine was found to be a well-tolerated and effective treatment of tinea of the skin and nails."( Use of terbinafine for tinea in Australian Aboriginal communities in the Top End.
Currie, BJ; Ellis, DH; Koh, KJ; Leysley, L; Parker, CJ; Pruim, B, 2003
)
1.5
"Terbinafine is an allylamine antifungal agent that has been effective and safe in the treatment of superficial and some deep mycotic infections in adults. "( The efficacy and safety of terbinafine in children.
Adamiak, A; Cooper, EA; Gupta, AK, 2003
)
2.06
"Terbinafine was shown to be an effective antimycotic drug, both fungicidal and immunostimulative."( Effect of infection with Trichophyton mentagrophytes varietas interdigitale on phagocytosis in humans.
Gregurek-Novak, T, 2004
)
1.04
"Terbinafine is an effective treatment for DSO when pulse-dosed for 7 days every 3 months but not every 4 months."( The successful treatment of Trichophyton rubrum nail bed (distal subungual) onychomycosis with intermittent pulse-dosed terbinafine.
Rebell, G; Zaias, N, 2004
)
1.97
"Terbinafine is an allylamine with fungicidal activity, first approved for the treatment of onychomycosis in the United Kingdom in the early 1990s, and in the US in 1996. "( The use of terbinafine in the treatment of onychomycosis in adults and special populations: a review of the evidence.
Gupta, AK; Lynch, LE; Ryder, JE; Tavakkol, A,
)
1.96
"Terbinafine is an established drug for the treatment of toenail onychomycosis. "( Intermittent versus continuous terbinafine in the treatment of toenail onychomycosis: a randomized, double-blind comparison.
Bakshi, R; Cai, B; Elewski, BE; Nyirady, J; Opper, C; Rich, PA; Sigurgeirsson, B, 2006
)
2.06
"Terbinafine seems to be an alternative drug for the treatment of tinea capitis caused by T."( An experience from an outbreak of tinea capitis gladiatorum due to Trichophyton tonsurans.
Erdoğan, BS; Ergin, C; Ergin, S; Evliyaoğlu, D; Kaleli, I, 2006
)
1.06
"Terbinafine is an allylamine antifungal agent that has been proven to have high clinical efficacy in the therapy of fungal infections, the mechanism of action of terbinafine involves the specific inhibition of fungal squalene epoxidase, resulting in ergosterol deficiency and accumulation of intracellular squalene."( Genome-wide expression profiling of the response to terbinafine in Candida albicans using a cDNA microarray analysis.
Gu, HN; Ma, L; Qian, YS; Zeng, YB, 2007
)
1.31
"Terbinafine 1% FFS is an effective, safe dose for the treatment of tinea pedis."( Novel, single-dose, topical treatment of tinea pedis using terbinafine: results of a dose-finding clinical trial.
de Chauvin, MF; Kienzler, JL; Larnier, C; Viguié-Vallanet, C, 2008
)
1.31
"Terbinafine is an effective alternative to griseofulvin against T."( Terbinafine hydrochloride oral granules versus oral griseofulvin suspension in children with tinea capitis: results of two randomized, investigator-blinded, multicenter, international, controlled trials.
Bakshi, R; Cáceres, HW; Cai, B; DeLeon, L; El Shimy, S; Elewski, BE; Friedlander, SF; Hunter, JA; Korotkiy, N; Nyirady, J; Rachesky, IJ; Sanchez-Bal, V; Tavakkol, A; Todd, G; Wraith, L, 2008
)
2.51
"Terbinafine is a synthetic oral allylamine that is used for systemic treatment of microscopy- or culture-proven dermatophyte infections of skin and nails. "( Terbinafine-induced subacute cutaneous lupus erythematosus.
Bonner, B; Hivnor, CM; Hudkins, ML, 2008
)
3.23
"Terbinafine is an antimycotic drug which has a much higher in vitro activity against dermatophytes than against yeasts. "( Systemic treatment of skin candidosis: a randomized comparison of terbinafine and ketoconazole.
Bräutigam, M; Haas, PJ; Jung, EG; Weidinger, G,
)
1.81
"Terbinafine is a recently introduced efficacious fungicidal drug."( Toxic epidermal necrolysis and erythema multiforme following therapy with terbinafine.
Carstens, J; Søgaard, H; Thestrup-Pedersen, K; Wendelboe, P, 1994
)
1.24
"Terbinafine is an antifungal agent of the allylamine class, which is fungicidal when administered per os. "( [Efficacy and tolerance of terbinafine (Lamisil) in a series of 50 cases of dermatophyte onychomycoses].
Cribier, B; Grosshans, E, 1994
)
2.03
"Terbinafine (Lamisil) is a new antifungal drug which is now available in many countries worldwide. "( Global overview of Lamisil.
Finlay, AY, 1994
)
1.73
"Terbinafine (Lamisil) is a synthetic allylamine antifungal which has been shown to be fungicidal against dermatophytes and a number of yeasts and moulds. "( A comparison of terbinafine (Lamisil) 1% cream given for one week with clotrimazole (Canesten) 1% cream given for four weeks, in the treatment of tinea pedis.
Evans, EG, 1994
)
2.08
"Terbinafine treatment is a safe therapeutical option in cyclosporin A-treated patients with dermatophyte nail infection."( Effect of oral terbinafine treatment on cyclosporin pharmacokinetics in organ transplant recipients with dermatophyte nail infection.
Fauchald, P; Jensen, P; Lehne, G; Simonsen, S, 1996
)
1.37
"Terbinafine is a highly potent drug against dermatophytes. "( Treatment of Candida nail infection with terbinafine.
Cividalli, L; David, M; Kritzman, A; Samra, Z; Segal, R; Tiqva, P, 1996
)
2
"Terbinafine is an orally and topically active allylamine antifungal derivative with a broad antifungal spectrum."( Pityriasis versicolor: clinical experience with Lamisil cream and Lamisil DermGel.
Faergemann, J; Hersle, K; Nordin, P, 1997
)
1.02
"Terbinafine is a synthetic antifungal agent that, because of its fungicidal action, provides high cure rates and low relapse rates after short periods of treatment."( Open clinical study of the efficacy and safety of terbinafine cream 1% in children with tinea corporis and tinea cruris.
Bakos, L; Brito, AC; Castro, LC; Gontijo, B; Lowy, G; Reis, CM; Ribeiro, AM; Souza, FH; Villar, Mdo L; Zaitz, C, 1997
)
1.27
"Terbinafine is considered to be a first-choice option for the treatment of dermatophyte onychomycosis in immunocompetent individuals."( Toenail onychomycosis in patients with acquired immune deficiency syndrome: treatment with terbinafine.
Casado, M; De Lucas, R; Díaz, R; García, J; González, J; Herranz, P; Peña, JM, 1997
)
1.24
"Oral terbinafine is a recently introduced antifungal drug with slight side effects that rarely includes liver involvement. "( [Acute hepatitis associated with terbinafine].
Cadenas, F; Lomo, J; Palacio, MA; Rodrigo, L; Rodríguez, M; Vivas, S, 1997
)
1.09
"Terbinafine is an allylamine antifungal agent widely used to treat dermatophyte onychomycosis and dermatomycoses. "( Cutaneous adverse effects associated with terbinafine therapy: 10 case reports and a review of the literature.
Braddock, SW; Del Rosso, JQ; Gupta, AK; Lauzon, GJ; Lynde, CW; Mehlmauer, MA; Miller, CA; Shear, NH, 1998
)
2.01
"Terbinafine is an allylamine antifungal agent used for the treatment of onychomycosis. "( Absence of effect of terbinafine on the activity of CYP1A2, NAT-2, and xanthine oxidase.
Amsden, GW; Kashuba, AD; Kearns, GL; Nafziger, AN; Trépanier, EF, 1998
)
2.06
"Terbinafine is an allylamine antifungal agent first launched in the USA in May 1996 with an estimated 7.5 million individuals worldwide having used the drug. "( Hepatitis associated with terbinafine therapy: three case reports and a review of the literature.
Brown, GH; del Rosso, JQ; Gupta, AK; Lynde, CW; Shear, NH, 1998
)
2.04
"Terbinafine is an effective, well tolerated and safe antifungal agent for the treatment of Tinea capitis in children. "( Efficacy, safety and tolerability of terbinafine for Tinea capitis in children: Brazilian multicentric study with daily oral tablets for 1,2 and 4 weeks.
Cucé, LC; Filho, ST; Foss, NT; Marques, SA; Santamaria, JR, 1998
)
2.02
"Terbinafine is an orally and topically active allylamine antifungal drug which is an effective and well tolerated therapy for a wide range of superficial dermatophyte infections. "( Terbinafine. A pharmacoeconomic evaluation of its use in superficial fungal infections.
Balfour, JA; Davis, R, 1995
)
3.18
"Terbinafine is an orally active antifungal used in the treatment of dermatophytoses. "( Investigation of terbinafine as a CYP2D6 inhibitor in vivo.
Abdel-Rahman, SM; Gotschall, RR; Kauffman, RE; Kearns, GL; Leeder, JS, 1999
)
2.09
"Terbinafine is a potent inhibitor of CYP2D6 with apparent Ki values well below plasma and tissue concentrations typically achieved during a therapeutic course."( Potent inhibition of cytochrome P-450 2D6-mediated dextromethorphan O-demethylation by terbinafine.
Abdel-Rahman, SM; Boge, T; Gotschall, RR; Kearns, GL; Leeder, JS; Marcucci, K, 1999
)
1.25
"Terbinafine is an allylamine antifungal agent which has fungicidal activity against a wide variety of dermatophytes, moulds and certain dimorphic fungi, and fungistatic activity against Candida albicans. "( Terbinafine. An update of its use in superficial mycoses.
Markham, A; McClellan, KJ; Wiseman, LR, 1999
)
3.19
"Terbinafine, however, is a competitive inhibitor of the CYP2D6 reaction, dextromethorphan O-demethylation (K(i) = 0.03 microM)."( Multiple cytochrome P-450s involved in the metabolism of terbinafine suggest a limited potential for drug-drug interactions.
Fischer, V; Glänzel, U; Heitz, F; Johanson, L; Sinclair, JR; Vickers, AE; Zollinger, M, 1999
)
1.27
"Terbinafine is an antifungal agent widely use in the treatment of onychomycosis. "( [Oral terbinafine-induced plantar pustular psoriasis].
Bosonnet, S; Lanternier, G; Le Guyadec, T; Le Vagueresse, R; Saint-Blancard, P, 2000
)
2.23
"Terbinafine is a synthetic antifungal agent which has recently been found to be highly effective against Pneumocystis carinii. "( Structural changes in rat Pneumocystis carinii surface antigens after terbinafine administration in experimental P. carinii pneumonia.
Angelici, E; Canipari, R; Contini, C, 1999
)
1.98
"Terbinafine is a drug that appears to infrequently induce SCLE with high titers of ANAs and anti-histone antibodies in genetically susceptible persons."( Terbinafine-induced subacute cutaneous lupus erythematosus.
Bonsmann, G; Luger, TA; Schiller, M; Ständer, S, 2001
)
3.2
"Oral terbinafine (Lamisil) is a widely used and effective therapy of dermatophyte infections. "( [Drug reaction to terbinafine simulating an acute generalized exanthematous pustulosis].
Burg, G; Hürlimann, A; Kempf, W; Rogalski, C; Wüthrich, B, 2001
)
1.16
"Terbinafine (Lamisil) is an allylamine antifungal agent."( Once daily treatment with terbinafine 1% cream (Lamisil) for one week is effective in the treatment of tinea corporis and cruris. A placebo-controlled study.
Basuki, S; Bramono, K; Budimulja, U; Paul, C; Rapatz, G; Urip, KS; Widodo, G, 2001
)
1.33
"Terbinafine is an allylamine antifungal agent that is highly lipophilic and keratophilic. "( Tissue distribution of terbinafine in rats.
Hosseini-Yeganeh, M; McLachlan, AJ, 2001
)
2.06
"Terbinafine is an orally and topically active allylamine antifungal agent with a primarily fungicidal action in vitro. "( Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses.
Balfour, JA; Faulds, D, 1992
)
3.17
"Terbinafine is a new antifungal agent for oral treatment of dermatomycosis. "( [Loss of taste sensation in terbinafine administration].
Bijlmer-Iest, JC; de Jong, PA; Herrmann, WA; Schreuder, F; Stricker, BH; van Ulsen, J, 1992
)
2.02
"Oral terbinafine is an effective therapy for dermatophyte onychomycosis, presumably because it reaches the infected areas of the nail rapidly and in fungicidal concentrations. "( Pharmacokinetics of terbinafine in the nail.
Finlay, AY, 1992
)
1.12
"Terbinafine is an allylamine antifungal compound shown to be effective in the oral treatment of onychomycosis. "( A randomized treatment duration-finding study of terbinafine in onychomycosis.
Cirkel, PK; Crijns, MB; De Wit, RF; Govaert, FJ; Groeneweg, DA; Tazelaar, DJ; van der Schroeff, JG; Van Dijk, TJ; Wuite, J, 1992
)
1.98
"Terbinafine is a potent non-competitive inhibitor of squalene epoxidase from Candida (Ki = 30 nM)."( Terbinafine: mode of action and properties of the squalene epoxidase inhibition.
Ryder, NS, 1992
)
2.45
"Terbinafine appears to be an effective and safe antifungal agent in the treatment of non-inflammatory tinea capitis."( An open clinical pilot study of the efficacy and safety of oral terbinafine in dry non-inflammatory tinea capitis.
Ahmad, I; Haroon, TS; Hussain, I; Mahmood, A; Nagi, AH; Zahid, M, 1992
)
1.24
"Terbinafine (Lamisil) is an antifungal drug, belonging to a class of drugs called the allylamines, which has recently become available for clinical use. "( Special features of the clinical use of oral terbinafine in the treatment of fungal diseases.
Jones, TC; Villars, VV, 1992
)
1.99
"Terbinafine is an orally and topically active fungicidal drug of the allylamine series. "( Treatment of chronic moccasin-type tinea pedis with terbinafine: a double-blind, placebo-controlled trial.
Savin, RC; Zaias, N, 1990
)
1.97
"Terbinafine is an allylamine derivative which is highly antifungal.(ABSTRACT TRUNCATED AT 250 WORDS)"( The successful treatment of finger Trichophyton rubrum onychomycosis with oral terbinafine.
Serrano, L; Zaias, N, 1989
)
1.23
"Terbinafine (SF 86-327) is a new antifungal agent derived from naftifine and effective by the oral route. "( [In vitro spectrum of action of a new antifungal derivative of naftifin: terbinafin (SF 86-327)].
Buffard, Y; Ferrari, H; Goudard, M; Regli, P, 1986
)
1.71

Effects

Terbinafine (Lamisil) has primarily fungicidal action against many fungi as a result of its specific mechanism of squalene epoxidase inhibition. It has been shown to be effective in tinea capitis, using different treatment durations.

ExcerptReferenceRelevance
"Terbinafine has a broad spectrum of action in vitro and primary fungicidal action against many pathogenic fungi. "( Inhibitory effect of terbinafine on the invasion of nails by Trichophyton mentagrophytes.
Rashid, A; Richardson, MD; Scott, EM, 1995
)
2.05
"Terbinafine (TRF) has been used in the treatment of fungal infections for more than 20 years. "( Epidemiological study of terbinafine-resistant dermatophytes isolated from Japanese patients.
Harada, K; Hase, M; Hiruma, J; Hiruma, M; Kano, R; Noguchi, H; Ogawa, T; Shimizu, T; Tokuhisa, Y, 2021
)
2.37
"Terbinafine resistance has been predominately attributed to point mutations in the squalene epoxidase (SQLE) target gene a key enzyme in the ergosterol biosynthetic pathway leading to single amino acid substitutions."( High terbinafine resistance in Trichophyton interdigitale isolates in Delhi, India harbouring mutations in the squalene epoxidase gene.
Chowdhary, A; Gupta, M; Hagen, F; Khurana, A; Masih, A; Meis, JF; Singh, A; Singh, PK, 2018
)
1.72
"Oral terbinafine has been approved for onychomycosis for 20 years in Europe and 15 years in the United States."( Recent updates in oral terbinafine: its use in onychomycosis and tinea capitis in the US.
Elewski, BE; Van Duyn Graham, L, 2011
)
1.14
"Terbinafine has demonstrated excellent fungicidal activity against the dermatophytes and variable activity against yeasts and non-dermatophyte molds in vitro."( Terbinafine: a review of its use in onychomycosis in adults.
Darkes, MJ; Goa, KL; Scott, LJ, 2003
)
2.48
"Oral terbinafine has demonstrated greater effectiveness than itraconazole, fluconazole and griseofulvin in randomized trials involving patients with onychomycosis caused by dermatophytes. "( Terbinafine: a review of its use in onychomycosis in adults.
Darkes, MJ; Goa, KL; Scott, LJ, 2003
)
2.28
"Terbinafine has been shown to be effective and safe in several studies of the treatment of tinea capitis and onychomycosis in children."( The efficacy and safety of terbinafine in children.
Cooper, EA; Gupta, AK; Lynde, CW, 2003
)
1.34
"Terbinafine has been approved for the treatment of tinea capitis in many countries worldwide, and provides good efficacy rates for Trichophyton tinea capitis using shorter regimens than the gold standard griseofulvin."( The efficacy and safety of terbinafine in children.
Adamiak, A; Cooper, EA; Gupta, AK, 2003
)
1.34
"Terbinafine has also been used to treat onychomycosis effectively and safely in special patient populations, such as children, the elderly, immunocompromised patients, diabetics, and those with Down syndrome."( The use of terbinafine in the treatment of onychomycosis in adults and special populations: a review of the evidence.
Gupta, AK; Lynch, LE; Ryder, JE; Tavakkol, A,
)
1.24
"Terbinafine has been widely used with major success as a topical antifungal therapy for tinea pedis (athlete's foot). "( Comparable efficacy and safety of various topical formulations of terbinafine in tinea pedis irrespective of the treatment regimen: results of a meta-analysis.
Kiencke, P; Korting, HC; Nelles, S; Rychlik, R, 2007
)
2.02
"Terbinafine has a broad spectrum of action in vitro and primary fungicidal action against many pathogenic fungi. "( Inhibitory effect of terbinafine on the invasion of nails by Trichophyton mentagrophytes.
Rashid, A; Richardson, MD; Scott, EM, 1995
)
2.05
"Terbinafine has partly solved the well-known problems in the treatment of dermatophyte nail infections. "( Short therapy for tinea unguium with terbinafine: four different courses of treatment.
Albanese, G; Di Cintio, R; Martini, C; Nicoletti, A,
)
1.85
"Terbinafine has been shown to be effective in short-term regimens."( Oral terbinafine in toenail dermatophytosis. A double-blind, placebo-controlled multicenter study with 12 months' follow-up.
Andersen, BL; Brandrup, F; Bro-Jørgensen, AV; Dahl, JC; Frentz, G; Graudal, C; Holst, M; Kamp, P; Kragballe, K; Kroman, N; Larsen, FS; Larsen, PO; Mikkelsen, F; Munkvad, JM; Olafsson, JH; Rothenborg, H; Staberg, B; Svejgaard, EL; Søndergaard, J; Thulin, H; Veien, NK, 1997
)
1.53
"Terbinafine (Lamisil) has been registered throughout the world for the treatment of finger and toenail onychomycosis. "( Evaluation of 6 weeks treatment of terbinafine in tinea unguium in a double-blind trial comparing 6 and 12 weeks therapy. The Lagos V Study Group.
Bräutigam, M; Jones, TC; Tausch, I; Weidinger, G, 1997
)
2.02
"Terbinafine has become the first line of therapy in Europe and Canada for onychomycosis, and it has recently been approved in the United States in oral form."( Current trends in onychomycosis therapy: a literature review.
Hecker, D, 1997
)
1.02
"Terbinafine has been found to be very effective and safe, and only a minority of dermatologists perform regular monitoring with this drug."( A questionnaire study on the management of onychomycosis: a Canadian perspective.
Gupta, AK; Shear, NH, 1998
)
1.02
"Terbinafine has the fewest drug interactions and the highest treatment success rate."( A cost/efficacy analysis of oral antifungals indicated for the treatment of onychomycosis: griseofulvin, itraconazole, and terbinafine.
Angello, JT; Jan, SA; Voytovich, RM, 1997
)
1.23
"Terbinafine has previously been shown to be highly active against dermatophytes and many other filamentous fungi. "( An evaluation of the in vitro activity of terbinafine.
Ghannoum, MA; Jessup, CJ; Ryder, NS, 2000
)
2.01
"Terbinafine has been shown to be effective in tinea capitis, using different treatment durations. "( Terbinafine in the treatment of Trichophyton tinea capitis: a randomized, double-blind, parallel-group, duration-finding study.
Abrams, B; Aly, R; Babel, DE; Blumer, J; Friedlander, SF; Gourmala, N; Gupta, AK; Honig, P; Krafchik, B; Lucky, AW; Paul, C; Stewart, D; Wraith, L, 2002
)
3.2
"Terbinafine (Lamisil) has primarily fungicidal action against many fungi as a result of its specific mechanism of squalene epoxidase inhibition. "( Terbinafine: mode of action and properties of the squalene epoxidase inhibition.
Ryder, NS, 1992
)
3.17

Actions

Terbinafine is shown to enhance the respiratory burst and superoxide anion release in human PMNLs stimulated by phorbol esters or chemotactic peptides. It also has a priming effect on PMNL functions.

ExcerptReferenceRelevance
"Terbinafine is shown to enhance the respiratory burst and superoxide anion release in human PMNLs stimulated by phorbol esters or chemotactic peptides, and to have a priming effect on PMNL functions."( Terbinafine induces the PMNL priming effect and enhances in vitro PMNL fungicidal activity against Candida albicans blastospores.
Barbareschi, M; Bevilacqua, M; Colombo, D; Vago, T,
)
2.3
"Terbinafine was found to inhibit the growth of T."( Effects of a squalene epoxidase inhibitor, terbinafine, on ether lipid biosyntheses in a thermoacidophilic archaeon, Thermoplasma acidophilum.
Kon, T; Nemoto, N; Oshima, T; Yamagishi, A, 2002
)
1.3
"Terbinafine displays a primary fungicidal action against dermatophytes, other filamentous fungi, and S."( Antifungal activity of the allylamine derivative terbinafine in vitro.
Meingassner, JG; Mieth, H; Petranyi, G, 1987
)
1.25

Treatment

Treatment with terbinafine (oral 125 mg/d) and sertaconazole nitrate cream (topical, twice daily) for 4 weeks achieved significant improvement of the skin lesions.

ExcerptReferenceRelevance
"Terbinafine treated S."( Antibiofilm and staphyloxanthin inhibitory potential of terbinafine against Staphylococcus aureus: in vitro and in vivo studies.
Askoura, M; Mansour, B; Yehia, FAA; Yousef, N, 2022
)
1.69
"All terbinafine-treated animals showed intact inner ear function when total dosage of terbinafine was <2.5 mg, which was further confirmed by morphological study. "( Eradicating Otomycosis with Terbinafine Solution: Basic and Clinical Investigation.
Yang, TH; Young, YH, 2019
)
1.37
"Terbinafine treatment stimulated the development of lipid droplets as lipid storage organelles and this effect was different in K."( Production of squalene by lactose-fermenting yeast Kluyveromyces lactis with reduced squalene epoxidase activity.
Csáky, Z; Drozdíková, E; Garaiová, M; Hapala, I; Obernauerová, M, 2015
)
1.14
"Terbinafine treatment is a safe therapeutical option in cyclosporin A-treated patients with dermatophyte nail infection."( Effect of oral terbinafine treatment on cyclosporin pharmacokinetics in organ transplant recipients with dermatophyte nail infection.
Fauchald, P; Jensen, P; Lehne, G; Simonsen, S, 1996
)
1.37
"Terbinafine treatment decreases the synthesis of type I collagen and leads to a partial reversal of the cutaneous fibrotic lesions, independently of the cure of the fungal infection."( Immunohistochemical study of type I collagen turn-over and of matrix metalloproteinases in chromoblastomycosis before and after treatment by terbinafine.
Esterre, P; Ricard-Blum, S; Risteli, L, 1998
)
1.22
"Oral terbinafine treatment for superficial fungal infections of toe and fingernails is associated with a low incidence (1:45000) of hepatobiliary dysfunction. "( Identification of a reactive metabolite of terbinafine: insights into terbinafine-induced hepatotoxicity.
Iverson, SL; Uetrecht, JP, 2001
)
1.09
"The terbinafine treatment will be a tool for dissecting tetraether lipid biosynthesis in T."( Effects of a squalene epoxidase inhibitor, terbinafine, on ether lipid biosyntheses in a thermoacidophilic archaeon, Thermoplasma acidophilum.
Kon, T; Nemoto, N; Oshima, T; Yamagishi, A, 2002
)
1.06
"Terbinafine treatment enhances and restores CMI to TRIPA in patients with Trichophyton rubrum onychomycosis and may thereby reduce susceptibility to reinfection. "( Reactivity to trichophytin antigen in patients with onychomycosis: effect of terbinafine.
Birnbaum, JE; Cooper, KD; El Charif, M; Elewski, BE; Ghannoum, M, 2002
)
1.99
"Terbinafine-treated mice had the same or poorer survival as control infected mice, despite documented drug absorption."( Efficacies of four antifungal agents in experimental murine sporotrichosis.
Bennett, JE; Kan, VL, 1988
)
1
"Treatment with terbinafine (oral 125 mg/d) and sertaconazole nitrate cream (topical, twice daily) for 4 weeks was initiated and achieved significant improvement of the skin lesions."( A case of Tinea Faciei caused by Trichophyton benhamiae: first report in China.
Gao, Z; Liu, X; Tan, J; Wen, H; Yang, H; Yang, L, 2020
)
0.9
"Treatment with terbinafine 250mg/d for 6months combined to cryotherapy resulted in complete remission with initial clinical improvement after only 3 weeks."( [Extensive cutaneous chromomycosis: Efficacy of combined terbinafine and cryotherapy].
Elbenaye, J; Elhaouri, M; Elkhachine, Y; Er-Rami, M; Jakar, A; Sakkah, A,
)
0.72
"Treatment with terbinafine or itraconazole was effective."( Microsporum spp. onychomycosis: disease presentation, risk factors and treatment responses in an urban population.
Ameen, M; Arenas, R; Martínez, E; Tejada, D,
)
0.47
"The treatment with terbinafine was successful."( Problems in the diagnosis of profound trichophytosis barbae.
Ciesielska, A; Gospodarek, E; Halota, W; Kozielewicz, D; Kruszynska, E; Mikucka, A; Pawlowska, M; Wernik, J,
)
0.45
"Treatment with terbinafine did not affect Cx43 phosphorylation status or intracellular Ca(2+) concentration, well-known action mechanisms of various GJIC blockers."( Terbinafine inhibits gap junctional intercellular communication.
Choi, EJ; Lee, J; Lee, JY; Yoon, SM, 2016
)
2.22
"Treatment with terbinafine plus ciclopiroxolamine was effective."( Nail infection by Aspergillus ochraceopetaliformis.
Brasch, J; Egberts, F; Jensen, JM; Tintelnot, K; Varga, J, 2009
)
0.69
"Treatment with terbinafine failed to improve the symptoms or radiographic appearance of chronic rhinosinusitis even when nasal irrigation samples were positive for fungus on culture. "( Treatment of chronic rhinosinusitis with high-dose oral terbinafine: a double blind, placebo-controlled study.
Butler, D; Hamilos, DL; Kennedy, DW; Kuhn, FA; Pfister, PJ; Tavakkol, A; Warsi, G; Zinreich, SJ, 2005
)
0.93
"A treatment with terbinafine is the most cost-effective, provided that onychomycosis has actually been established mycologically and all possible measures have been taken to prevent recurrence. "( [Oral treatment of onychomycosis of the toe nails; comparison of cost-effectiveness of griseofulvin, itraconazole, ketoconazole and terbinafine].
Bergman, W; Rutten, FF, 1994
)
0.83
"Treatment with terbinafine was administrated for 4 months."( [Apropos of 1 Ivoirian case of osseus and cutaneous histoplasmosis by Histoplasma capsulatum var. duboisii].
Bankolé Sanni, R; Coulibaly, B; Denoulet, C; Honde, M; Kassi, E; Mobiot, ML; Nandiolo, R, 1998
)
0.64
"Treatment for terbinafine emulsion-gel was applied once daily for 1 week, whereas ketoconazole cream was applied once daily for 2 weeks; patients were followed for 2 weeks."( Comparative study between terbinafine 1% emulsion-gel versus ketoconazole 2% cream in tinea cruris and tinea corporis.
Bonifaz, A; Saúl, A, 2000
)
0.95

Toxicity

Oral terbinafine is well tolerated and safe over a 56-day period. When treating onychomycosis with oral itraconazole, the results seemed to be just as safe as when using terBinafine.

ExcerptReferenceRelevance
" There were no adverse effects, and the drug was well tolerated."( Terbinafine: efficacy and safety in the treatment of dermatophytosis.
Kotogyan, A; Oguz, O; Tüzün, Y, 1992
)
1.73
" Terbinafine appears to be an effective and safe antifungal agent in the treatment of non-inflammatory tinea capitis."( An open clinical pilot study of the efficacy and safety of oral terbinafine in dry non-inflammatory tinea capitis.
Ahmad, I; Haroon, TS; Hussain, I; Mahmood, A; Nagi, AH; Zahid, M, 1992
)
1.43
" Terbinafine is well tolerated and safe over a 56-day period."( Pilot study of terbinafine in children suffering from tinea capitis: evaluation of efficacy, safety and pharmacokinetics.
Cabiac, MD; Guessous, N; Humbert, H; Lakhdar, H; Nejjam, F; Zagula, M, 1995
)
1.55
" Both terbinafine and terfenadine were well tolerated when coadministered during this study, as indicated by the low incidence of complaints, abnormalities, and adverse events."( Safe coadministration of terbinafine and terfenadine: a placebo-controlled crossover study of pharmacokinetic and pharmacodynamic interactions in healthy volunteers.
Chang, CT; Cramer, JA; Garreffa, S; Hafkin, B; Hunt, TL; Meligeni, J; Robbins, B, 1996
)
1.08
"To broaden the safety database for oral terbinafine by determining the incidence of adverse events, particularly rare risks, that accompany its uncontrolled use in actual clinical practice."( Safety of oral terbinafine: results of a postmarketing surveillance study in 25,884 patients.
Hall, M; Krupp, P; Monka, C; O'Sullivan, D, 1997
)
0.92
" Physicians monitored patients for adverse events at baseline, during treatment, and at the end of treatment."( Safety of oral terbinafine: results of a postmarketing surveillance study in 25,884 patients.
Hall, M; Krupp, P; Monka, C; O'Sullivan, D, 1997
)
0.65
"The incidence of adverse events as reported by physicians, with their opinions regarding relationship to terbinafine therapy."( Safety of oral terbinafine: results of a postmarketing surveillance study in 25,884 patients.
Hall, M; Krupp, P; Monka, C; O'Sullivan, D, 1997
)
0.86
"The incidence of adverse events was 10."( Safety of oral terbinafine: results of a postmarketing surveillance study in 25,884 patients.
Hall, M; Krupp, P; Monka, C; O'Sullivan, D, 1997
)
0.65
" Adverse events were reported in 674 (44."( Safety of oral terbinafine for toenail onychomycosis.
Billstein, SA; Pollak, R, 1997
)
0.65
" We report 10 severe cutaneous adverse reactions associated with terbinafine therapy which required discontinuation of the antifungal agent: erythema multiforme (five patients), erythroderma (one), severe urticaria (one), pityriasis rosea (one) and worsening of pre-existing psoriasis (two patients)."( Cutaneous adverse effects associated with terbinafine therapy: 10 case reports and a review of the literature.
Braddock, SW; Del Rosso, JQ; Gupta, AK; Lauzon, GJ; Lynde, CW; Mehlmauer, MA; Miller, CA; Shear, NH, 1998
)
0.8
" Safety and tolerability variables included data on adverse reaction and clinical laboratory evaluations."( Efficacy, safety and tolerability of terbinafine for Tinea capitis in children: Brazilian multicentric study with daily oral tablets for 1,2 and 4 weeks.
Cucé, LC; Filho, ST; Foss, NT; Marques, SA; Santamaria, JR, 1998
)
0.57
"Terbinafine is an effective, well tolerated and safe antifungal agent for the treatment of Tinea capitis in children."( Efficacy, safety and tolerability of terbinafine for Tinea capitis in children: Brazilian multicentric study with daily oral tablets for 1,2 and 4 weeks.
Cucé, LC; Filho, ST; Foss, NT; Marques, SA; Santamaria, JR, 1998
)
2.02
" The incidence of adverse events was low for both study agents."( A double-blind, randomized study to compare the efficacy and safety of terbinafine (Lamisil) with fluconazole (Diflucan) in the treatment of onychomycosis.
Havu, V; Heikkilä, H; Kuokkanen, K; Nuutinen, M; Rantanen, T; Saari, S; Stubb, S; Suhonen, R; Turjanmaa, K, 2000
)
0.54
" All follow-up visits included: (i) the reporting of adverse effects; (ii) assessment of efficacy by KOH preparation, mycologic culture, and investigator evaluation; and (iii) physician and patient global assessments of various quality of life parameters (except for the visit at week 36)."( Clinical trial: the safety of terbinafine in patients over the age of 60 years: a multicenter trial in onychomycosis of the feet.
Atillasoy, ES; Fivenson, DP; Smith, EB; Stein, LF, 2000
)
0.6
" Due to the rare and unpredictable nature of this adverse drug reaction, the mechanism of toxicity has been hypothesized to be either an uncommon immunological or metabolically mediated effect."( Identification of a reactive metabolite of terbinafine: insights into terbinafine-induced hepatotoxicity.
Iverson, SL; Uetrecht, JP, 2001
)
0.57
" There were no significant differences in the frequency of cutaneous adverse events between the 2 groups in either study."( Efficacy and safety of terbinafine 1% solution in the treatment of interdigital tinea pedis and tinea corporis or tinea cruris.
Eisen, D; Elewski, B; Lebwohl, M; Savin, RC, 2001
)
0.62
" In a safety population that included all randomized patients (N = 14), no subject experienced adverse events or significant changes in laboratory findings related to study medication."( Safety and efficacy of short-duration oral terbinafine for the treatment of tinea corporis or tinea cruris in subjects with HIV infection or diabetes.
Houpt, KR; LaMarca, A; Loven, KH; Marbury, TC; Matheson, R; Miller, B; Rich, P; Smith, S; Wolf, J, 2001
)
0.57
" We review the clinical experience with terbinafine in diabetic and HIV-positive subjects and conclude that terbinafine is safe and has a low drug interaction potential in these high-risk cohort studies."( The safety and efficacy of terbinafine in patients with diabetes and patients who are HIV positive.
Elewski, B; Smith, S, 2001
)
0.88
" Despite its fairly benign profile of adverse reactions, liver toxicity has occasionally been linked to terbinafine."( Terbinafine-associated hepatotoxicity.
Ajit, C; Munoz, SJ; Suvannasankha, A; Zaeri, N, 2003
)
1.98
" Terbinafine has been shown to be effective and safe in several studies of the treatment of tinea capitis and onychomycosis in children."( The efficacy and safety of terbinafine in children.
Cooper, EA; Gupta, AK; Lynde, CW, 2003
)
1.53
"Terbinafine is an allylamine antifungal agent that has been effective and safe in the treatment of superficial and some deep mycotic infections in adults."( The efficacy and safety of terbinafine in children.
Adamiak, A; Cooper, EA; Gupta, AK, 2003
)
2.06
" Adverse events (AEs), laboratory tests, vital signs and ophthalmological examinations were also assessed."( Comparative evaluation of the efficacy and safety of two doses of terbinafine (500 and 1000 mg day(-1)) in the treatment of cutaneous or lymphocutaneous sporotrichosis.
Bakshi, R; Bustamante, AB; Chapman, SW; Dietze, R; Emady-Azar, S; Kauffmann, C; Opper, C; Pappas, P; Restrepo, A; Smith, EB; Tiraboschi-Foss, N, 2004
)
0.56
" Safety evaluations included monitoring of adverse events, laboratory assessments, vital signs and physical examinations."( Clinical efficacy and safety of oral terbinafine in fungal mycetoma.
Bakshi, R; Dieng, MT; N'diaye, B; Perez, A; Stockmeyer, M, 2006
)
0.61
" The majority of adverse events reported were mild to moderate, and consistent with the known tolerability profile of terbinafine."( Clinical efficacy and safety of oral terbinafine in fungal mycetoma.
Bakshi, R; Dieng, MT; N'diaye, B; Perez, A; Stockmeyer, M, 2006
)
0.82
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" The frequency of adverse incident of A, B, C groups were 22."( [Study on the compliance and safety of the oral antifungal agents for the treatment of onychomycosis].
Dai, XY; Hu, Y; Hua, HK; Qi, J; Sun, H; Wei, L; Yang, LJ; Zheng, Y, 2005
)
0.33
" When treating onychomycosis with oral itraconazole, the results seemed to be just as safe as when using terbinafine."( [Study on the compliance and safety of the oral antifungal agents for the treatment of onychomycosis].
Dai, XY; Hu, Y; Hua, HK; Qi, J; Sun, H; Wei, L; Yang, LJ; Zheng, Y, 2005
)
0.54
" Safety and tolerability were assessed by adverse event (AE) rates based on changes in laboratory values, patient-volunteered information, answers to investigator questions, and physical examinations."( Safety and efficacy of oral terbinafine in the treatment of onychomycosis: analysis of the elderly subgroup in Improving Results in ONychomycosis-Concomitant Lamisil and Debridement (IRON-CLAD), an open-label, randomized trial.
Fellman, S; Kianifard, F; Tavakkol, A, 2006
)
0.63
"Terbinafine 1% FFS, single dose application is an effective, safe and convenient treatment for tinea pedis."( Efficacy and safety of a new single-dose terbinafine 1% formulation in patients with tinea pedis (athlete's foot): a randomized, double-blind, placebo-controlled study.
Korting, HC; Larnier, C; Ortonne, JP; Savaluny, E; Viguié-Vallanet, C, 2006
)
2.04
" Both treatment regimens were safe and well tolerated."( A multicentre, randomized, controlled study of the efficacy, safety and cost-effectiveness of a combination therapy with amorolfine nail lacquer and oral terbinafine compared with oral terbinafine alone for the treatment of onychomycosis with matrix invol
Baran, R; de Berker, D; Faergemann, J; Kaufmann, R; Kerrouche, N; Lecha, M; Sidou, F; Sigurgeirsson, B, 2007
)
0.54
"We estimated the absolute risks of treatment termination and incidence of adverse liver outcomes among all commonly used oral antifungal treatments for superficial dermatophytosis and onychomycosis."( The safety of oral antifungal treatments for superficial dermatophytosis and onychomycosis: a meta-analysis.
Chan, AK; Chang, CH; Kurth, T; Orav, JE; Young-Xu, Y, 2007
)
0.34
"Oral antifungal therapy against superficial dermatophytosis and onychomycosis, including intermittent and continuous terbinafine, itraconazole, and fluconazole, was associated with a low incidence of adverse events in an immunocompetent population."( The safety of oral antifungal treatments for superficial dermatophytosis and onychomycosis: a meta-analysis.
Chan, AK; Chang, CH; Kurth, T; Orav, JE; Young-Xu, Y, 2007
)
0.55
"Terbinafine pulse therapy is effective and safe alternative in treatment of onychomycosis due to dermatophytes; and combination therapy with topical ciclopirox or amorolfine do not show any significant difference in efficacy in comparison to monotherapy with oral terbinafine."( An open randomized comparative study to test the efficacy and safety of oral terbinafine pulse as a monotherapy and in combination with topical ciclopirox olamine 8% or topical amorolfine hydrochloride 5% in the treatment of onychomycosis.
Garg, AP; Jaiswal, A; Sharma, RP,
)
1.8
" In the present study, squalene production was achieved in a wild-type laboratory Saccharomyces cerevisiae strain by two safe chemical means using terbinafine (0."( Enhanced squalene production by wild-type Saccharomyces cerevisiae strains using safe chemical means.
Mantzouridou, F; Naziri, E; Tsimidou, MZ, 2011
)
0.57
" All adverse events were recorded."( Efficacy and safety of 1 % terbinafine film-forming solution in Chinese patients with tinea pedis: a randomized, double-blind, placebo-controlled, multicenter, parallel-group study.
Fu, MH; Gong, ZQ; Lai, W; Li, RY; Li, XQ; Liu, WD; Lu, XY; Wang, AP; Xi, LY; Xu, JH; Xu, ML; Zhu, M, 2014
)
0.7
" Both 1 % terbinafine FFS and placebo were safe and well tolerated based on adverse events and investigator and patient assessments."( Efficacy and safety of 1 % terbinafine film-forming solution in Chinese patients with tinea pedis: a randomized, double-blind, placebo-controlled, multicenter, parallel-group study.
Fu, MH; Gong, ZQ; Lai, W; Li, RY; Li, XQ; Liu, WD; Lu, XY; Wang, AP; Xi, LY; Xu, JH; Xu, ML; Zhu, M, 2014
)
1.1
"This double-blind, randomized, multicenter study demonstrated one single topical application of 1 % terbinafine FFS was safe and effective in the treatment of tinea pedis in the Chinese population."( Efficacy and safety of 1 % terbinafine film-forming solution in Chinese patients with tinea pedis: a randomized, double-blind, placebo-controlled, multicenter, parallel-group study.
Fu, MH; Gong, ZQ; Lai, W; Li, RY; Li, XQ; Liu, WD; Lu, XY; Wang, AP; Xi, LY; Xu, JH; Xu, ML; Zhu, M, 2014
)
0.92
" Adverse events were similar between groups."( A randomized placebo-controlled trial of the efficacy and safety of a terbinafine, florfenicol and betamethasone topical ear formulation in dogs for the treatment of bacterial and/or fungal otitis externa.
Doucette, KP; Forster, SL; King, SB; Real, T, 2018
)
0.71
"The application of two doses of Osurnia, one week apart, is effective and safe to treat microbial otitis externa in dogs."( A randomized placebo-controlled trial of the efficacy and safety of a terbinafine, florfenicol and betamethasone topical ear formulation in dogs for the treatment of bacterial and/or fungal otitis externa.
Doucette, KP; Forster, SL; King, SB; Real, T, 2018
)
0.71
" Adverse events attributable to the ear medications were not noted."( A randomized, controlled, single-blinded, multicenter evaluation of the efficacy and safety of a once weekly two dose otic gel containing florfenicol, terbinafine and betamethasone administered for the treatment of canine otitis externa.
Doucette, KP; Forster, SL; King, SB; Seewald, W, 2018
)
0.68
"Administering an otic gel twice at a one-week interval is an effective, safe and convenient way to treat canine otitis externa."( A randomized, controlled, single-blinded, multicenter evaluation of the efficacy and safety of a once weekly two dose otic gel containing florfenicol, terbinafine and betamethasone administered for the treatment of canine otitis externa.
Doucette, KP; Forster, SL; King, SB; Seewald, W, 2018
)
0.68
"This systematic review and network meta-analysis compared the efficacy (as per mycological cure) and adverse event rates of three oral antifungal medications in the treatment of dermatophyte toenail onychomycosis, namely terbinafine, itraconazole and fluconazole."( The efficacy and safety of pulse vs. continuous therapy for dermatophyte toenail onychomycosis.
Bamimore, MA; Foley, KA; Gupta, AK; Piguet, V; Shear, NH; Stec, N, 2020
)
0.74
" There were no significant differences in the likelihood of adverse events between any continuous and pulse regimens of terbinafine, itraconazole and fluconazole."( The efficacy and safety of pulse vs. continuous therapy for dermatophyte toenail onychomycosis.
Bamimore, MA; Foley, KA; Gupta, AK; Piguet, V; Shear, NH; Stec, N, 2020
)
0.77
" Our results indicate that in the treatment of dermatophyte toenail onychomycosis, the continuous and pulse regimens for terbinafine and itraconazole have similar efficacies and rates of adverse events."( The efficacy and safety of pulse vs. continuous therapy for dermatophyte toenail onychomycosis.
Bamimore, MA; Foley, KA; Gupta, AK; Piguet, V; Shear, NH; Stec, N, 2020
)
0.77
" Topical antifungal agents may be preferred over systemic agents due to lack of systemic adverse effects."( Efficacy and safety of topical terbinafine 10% solution (MOB-015) in the treatment of mild to moderate distal subungual onychomycosis: A randomized, multicenter, double-blind, vehicle-controlled phase 3 study.
Gupta, AK; Kempers, SE; Pariser, DM; Rensfeldt, K; Surprenant, MS; Tavakkol, A, 2021
)
0.91
"MOB-015 is a treatment option for onychomycosis with an adverse event profile similar to vehicle."( Efficacy and safety of topical terbinafine 10% solution (MOB-015) in the treatment of mild to moderate distal subungual onychomycosis: A randomized, multicenter, double-blind, vehicle-controlled phase 3 study.
Gupta, AK; Kempers, SE; Pariser, DM; Rensfeldt, K; Surprenant, MS; Tavakkol, A, 2021
)
0.91
" Mycological cure rate was the primary outcome; complete cure rate and adverse events were secondary outcomes."( A network meta-analysis on the efficacy and safety of monotherapies for tinea capitis, and an assessment of evidence quality.
Bamimore, MA; Gupta, AK; Piguet, V; Renaud, HJ; Shear, NH, 2020
)
0.56
" Lichenoid drug eruption is a medication-related adverse cutaneous event; the lesion morphology and pathology mimic lichen planus."( Terbinafine-induced lichenoid drug eruption: case report and review of terbinafine-associated cutaneous adverse events.
Calame, A; Cohen, PR; Erickson, CP, 2020
)
2
" We report the first case documenting the safe use of oral terbinafine in a 77-year-old woman with stable autoimmune hepatitis presenting with extensive tinea corporis."( Terbinafine used safely in autoimmune hepatitis for treatment of tinea corporis.
Ferguson, JE; Prouty, M, 2021
)
2.31
" Terbinafine was well-tolerated with no systemic adverse reactions identified; the most common topical adverse reactions were erythema and skin irritation."( A multicentre, randomised, parallel-group, double-blind, vehicle-controlled and open-label, active-controlled study (versus amorolfine 5%), to evaluate the efficacy and safety of terbinafine 10% nail lacquer in the treatment of onychomycosis.
Blume-Peytavi, U; Carreño, C; Falqués, M; Galván, J; Tamarit, ML; Tebbs, V; Tosti, A, 2022
)
1.82
"This study concluded that the test drugs (IHA and HK) were safe and effective in the treatment of PV."( Evaluation of the efficacy and safety of Unani Formulations in Pityriasis Versicolor: A randomized controlled trial.
Fatima, SH; Ismail, BA; Minhajuddin, A; Nawab, M; Rasheed Naikodi, MA, 2022
)
0.72
"This study concludes that the formulations QA and RN were effective and safe in the treatment of dermatophytosis."( Assessing the efficacy and safety of Unani pharmacopoeial formulations in dermatophytosis (quba) - a randomized controlled trial.
Fatima, SH; Khan, AA; Minhajuddin, A; Naseem, S; Nawab, M, 2023
)
0.91

Pharmacokinetics

Terbinafine is increasingly used in combination with other antifungal agents to treat resistant or refractory mycoses. High doses are commonly used, but limited data are available on systemic exposure.

ExcerptReferenceRelevance
" The study showed that increasing the number of applications from one to seven did not significantly increase the peak concentration (Cmax) in the stratum corneum."( An investigation of the pharmacokinetics of topical terbinafine (Lamisil) 1% cream.
Finlay, AY; Hill, S; Smith, SG; Thomas, R, 1992
)
0.53
"The dose-dependency of the pharmacokinetic parameters of terbinafine and its N-demethyl derivative was investigated in a randomized four-way crossover study in healthy volunteers following single oral administrations of 125, 250, 500 and 750 mg of terbinafine."( Dose-proportional pharmacokinetics of terbinafine and its N-demethylated metabolite in healthy volunteers.
Grass, P; Humbert, H; Kirkesseli, S; Kovarik, JM; Kutz, K, 1992
)
0.8
" Concentrations subsequently exhibited a triphasic decline, with a terminal deposition half-life of 16."( Multiple-dose pharmacokinetics and distribution in tissue of terbinafine and metabolites.
Caplain, H; Denouël, J; Kovarik, JM; Millerioux, L; Mueller, EA; Zehender, H, 1995
)
0.53
"The pharmacokinetic and pharmacodynamic interactions of terbinafine (Lamisil) and terfenadine (Seldane) were assessed in 26 healthy volunteers randomized to receive either terbinafine (250 mg tablet) or its placebo (terbinafine placebo), which were administered in a double-blind manner once daily for 18 days."( Safe coadministration of terbinafine and terfenadine: a placebo-controlled crossover study of pharmacokinetic and pharmacodynamic interactions in healthy volunteers.
Chang, CT; Cramer, JA; Garreffa, S; Hafkin, B; Hunt, TL; Meligeni, J; Robbins, B, 1996
)
0.84
" Demographic predictors of exposure were identified by a model-free, nonparametric approach applied to the sparse pharmacokinetic data from the onychomycosis studies."( Pharmacokinetics and pharmacodynamics of multiple-dose terbinafine.
Cramer, JA; Gibiansky, E; Lin, T; Meligeni, JA; Nedelman, JR; Riefler, JF; Robbins, BA, 1996
)
0.54
" No other statistically significant changes in the pharmacokinetic profile of cyclosporin A were seen."( Effect of oral terbinafine treatment on cyclosporin pharmacokinetics in organ transplant recipients with dermatophyte nail infection.
Fauchald, P; Jensen, P; Lehne, G; Simonsen, S, 1996
)
0.65
" Two analyses of the pharmacokinetic data were undertaken."( The effect of food on the pharmacokinetics of multiple-dose terbinafine in young and elderly healthy subjects.
Chang, CT; Cohen, A; Cramer, JA; Gareffa, S; Gibiansky, E; Meligeni, J; Nedelman, J; Robbins, B, 1997
)
0.54
" Although the time to maximum peak concentration with terbinafine was slightly reduced, the maximum concentration and area under the serum drug concentration-time curve from time zero to 120 hours were not significantly different with terbinafine than with placebo."( Effects of terbinafine on the pharmacokinetics of digoxin in healthy volunteers.
Francheteau, P; Guerret, M; Tarral, A,
)
0.77
" The pharmacokinetic and pharmacologic properties provide the basis of their activity and are related to their efficacy and safety in dermatophyte infections."( Pharmacokinetics and pharmacology of terbinafine and itraconazole.
Leyden, J, 1998
)
0.57
"The aim of this study was to develop a physiologically based pharmacokinetic (PB-PK) model capable of describing and predicting terbinafine concentrations in plasma and tissues in rats and humans."( Physiologically based pharmacokinetic model for terbinafine in rats and humans.
Hosseini-Yeganeh, M; McLachlan, AJ, 2002
)
0.78
"The pharmacokinetic interaction between nortriptyline and terbinafine is probably due to inhibition of CYP2D6 of the nortriptyline metabolism by terbinafine."( Pharmacokinetic interaction between nortriptyline and terbinafine.
Kempen, RW; Van Den Heuvel, HA; Van Der Kuy, PH; Vanmolkot, LM, 2002
)
0.81
"5 mg), and pharmacokinetic sampling was conducted after the first dose, at the midpoint of treatment and at steady state."( Pharmacokinetics of terbinafine in young children treated for tinea capitis.
Abdel-Rahman, SM; Fallon-Friedlander, S; Hauffe, S; Herron, J; Horowitz, A; Rivière, GJ, 2005
)
0.65
" Plasma concentrations of alfentanil were measured for 10 hours, and the pharmacokinetic parameters were calculated by use of noncompartmental methods."( Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life.
Laine, K; Leino, K; Neuvonen, PJ; Olkkola, KT; Saari, TI; Valtonen, M, 2006
)
0.65
"The SC pharmacokinetic profile of terbinafine 1% FFS indicates that this novel formulation is efficient in delivering high amounts of terbinafine to the skin for a prolonged time and supports its use in the treatment of dermatophytoses with a single application."( Stratum corneum pharmacokinetics of the anti-fungal drug, terbinafine, in a novel topical formulation, for single-dose application in dermatophytoses.
Kienzler, JL; Larnier, C; Mugglestone, C; Ortonne, JP; Queille-Roussel, C, 2007
)
0.86
"To study and establish an optimal administration method of oral antifungal, terbinafine (TBF), for hyperkeratotic type tinea pedis, from the pharmacokinetic point of view, 20 patients with hyperkeratotic type tinea pedis were given TBF 125 mg once daily for 4 weeks and observed over time for improvement in dermatological symptoms and mycological efficacy."( Usefulness and pharmacokinetic study of oral terbinafine for hyperkeratotic type tinea pedis.
Kawana, S; Kikuchi, I; Morimoto, K; Tanuma, H, 2008
)
0.84
"To study and establish an optimal administration method of oral antifungal, terbinafine (TBF), for hyperkeratotic-type tinea pedis from the pharmacokinetic point of view, 20 patients with hyperkeratotic-type tinea pedis were given TBF 125 mg once daily for 4 weeks and observed over time for improvement of dermatological symptoms and mycological efficacy."( Usefulness and pharmacokinetic study of oral terbinafine for hyperkeratotic-type tinea pedis.
Kawana, S; Kikuchi, I; Morimoto, K; Tanuma, H, 2008
)
0.84
" The pharmacokinetic parameters included AUC(0-t) AUC(0-infinity), C(max), t1/2, and T(max)."( Pharmacokinetics and comparative bioavailability of two terbinafine hydrochloride formulations after single-dose administration in Chinese healthy subjects.
Chen, Y; Jiang, X; Tian, Y; Wang, N; Zhang, ZJ, 2008
)
0.59
"The objective of this study was to determine the pharmacokinetic parameters of orally administered terbinafine hydrochloride based on 3, 7, and 15 mg/kg single- as well as multiple-dosage trials in order to calculate dosing requirements for potential treatment of aspergillosis in African penguins (Spheniscus demersus)."( Pharmacokinetics of orally administered terbinafine in African penguins (Spheniscus demersus) for potential treatment of aspergillosis.
Bechert, U; Christensen, JM; Le, H; Poppenga, R; Schmitt, T; Wyatt, J, 2010
)
0.84
"To determine pharmacokinetic parameters of orally administered terbinafine hydrochloride for potential treatment of aspergillosis in raptors, 10 adult red-tailed hawks (Buteo jamaicensis) were used in single dose trials by using 15, 30, and 60 mg/kg doses with a 2-week washout period between trials."( Pharmacokinetics of terbinafine after single oral dose administration in red-tailed hawks (Buteo jamaicensis).
Bechert, U; Christensen, JM; Fahmy, SA; Poppenga, R; Redig, P, 2010
)
0.92
" Six healthy horses and six healthy Greyhound dogs were included in the pharmacokinetic data."( Pharmacokinetics of oral terbinafine in horses and Greyhound dogs.
Davis, EG; KuKanich, B; Williams, MM, 2011
)
0.67
" The purpose of this study was to evaluate the pharmacokinetic properties of terbinafine in dogs after a single oral dose."( Terbinafine pharmacokinetics after single dose oral administration in the dog.
Carlson, SA; Day, TA; Felz, C; Imerman, PM; May, ER; Noxon, JO; Sakai, MR, 2011
)
2.04
" The area under the curve (AUC) and the maximum amounts of terbinafine absorption (Q(max)) were obtained from pharmacokinetic software."( In vitro-in vivo correlation study for the dermatopharmacokinetics of terbinafine hydrochloride topical cream.
Nosoongnoen, W; Saeheng, S; Sathirakul, K; Varothai, S, 2013
)
0.87
" After oral administration of terbinafine, the maximum concentration for the remaining 5 fed birds ranged from 109 to 671 ng/mL, half-life ranged from 6 to 13."( Pharmacokinetics of terbinafine after oral administration of a single dose to Hispaniolan Amazon parrots (Amazona ventralis).
Cox, SK; Emery, LC; Evans, EE; Souza, MJ, 2013
)
1
"Terbinafine is increasingly used in combination with other antifungal agents to treat resistant or refractory mycoses due to synergistic in vitro antifungal activity; high doses are commonly used, but limited data are available on systemic exposure, and no assessment of pharmacodynamic target attainment has been made."( Terbinafine in combination with other antifungal agents for treatment of resistant or refractory mycoses: investigating optimal dosing regimens using a physiologically based pharmacokinetic model.
Dolton, MJ; McLachlan, AJ; Perera, V; Pont, LG, 2014
)
3.29
" Terbinafine increased the peak concentration (C max) of tramadol by 53 % (P < 0."( Effects of terbinafine and itraconazole on the pharmacokinetics of orally administered tramadol.
Backman, JT; Hagelberg, NM; Laine, K; Neuvonen, PJ; Olkkola, KT; Saari, TI; Saarikoski, T; Scheinin, M, 2015
)
1.72
" Within each group and tissue type, terbinafine concentration data were pooled, and pharmacokinetic parameters were calculated by noncompartmental methods."( Pharmacokinetics of terbinafine in little brown myotis (Myotis lucifugus) infected with Pseudogymnoascus destructans.
Beck, EV; Court, MH; Reeder, DM; Robbins, AH; Tseng, FS; Whitford, AM, 2017
)
1.05
" The objective of this study was to determine the pharmacokinetic parameters of terbinafine administered through nebulization and a sustained subcutaneous implant as potential treatments of Ophidiomyces in reptiles."( Pharmacokinetics of nebulized and subcutaneously implanted terbinafine in cottonmouths (Agkistrodon piscivorus).
Allender, MC; Archer, G; Boers, K; Cox, S; Kane, LP; Leister, K; Rzadkowska, M; Souza, M, 2017
)
0.93
" To assess TBF's efficacy, we undertook treatment trials and pharmacokinetic studies to investigate drug absorption and persistence in frog skin; and then we correlated these data to the minimal lethal concentrations (MLC) against Bd."( The efficacy and pharmacokinetics of terbinafine against the frog-killing fungus (Batrachochytrium dendrobatidis).
Berger, L; Brannelly, LA; Glass, BD; Kosch, TA; McFadden, M; Motti, CA; Roberts, AA; Robertson, SG; Skerratt, LF; Webb, RJ, 2019
)
0.79
" Mean ± SD terminal half-life following oral administration was 21."( Single-dose pharmacokinetics of orally administered terbinafine in bearded dragons (Pogona vitticeps) and the antifungal susceptibility patterns of Nannizziopsis guarroi.
Cox, SK; Keller, KA; McEntire, MS; Reinhart, JM, 2021
)
0.87

Compound-Compound Interactions

Terbinafine is increasingly used in combination with other antifungal agents to treat resistant or refractory mycoses.

ExcerptReferenceRelevance
"Biotransformation pathways and the potential for drug-drug interactions of the orally active antifungal terbinafine were characterized using human liver microsomes and recombinant human cytochrome P-450s (CYPs)."( Multiple cytochrome P-450s involved in the metabolism of terbinafine suggest a limited potential for drug-drug interactions.
Fischer, V; Glänzel, U; Heitz, F; Johanson, L; Sinclair, JR; Vickers, AE; Zollinger, M, 1999
)
0.76
" In contrast, there are no drug-drug contraindications with terbinafine."( Drug interactions of the newer oral antifungal agents.
Katz, HI, 1999
)
0.55
" The study compared two different courses of terbinafine treatment combined with amorolfine 5% solution nail lacquer."( A randomized trial of amorolfine 5% solution nail lacquer combined with oral terbinafine compared with terbinafine alone in the treatment of dermatophytic toenail onychomycoses affecting the matrix region.
Badillet, G; Baran, R; Combernale, P; Czernielewski, J; Datry, A; Feuilhade, M; Goettmann, S; Larnier, C; Pietrini, P; Viguie, C, 2000
)
0.8
"A total of 147 patients were randomized to one of three treatment groups: 15 months of once-weekly topical amorolfine lacquer in combination with 6 weeks (Group AT6) or 12 weeks (Group AT12) of oral terbinafine, 250 mg once daily: or terbinafine monotherapy for 12 weeks (Group T12)."( Topical amorolfine for 15 months combined with 12 weeks of oral terbinafine, a cost-effective treatment for onychomycosis.
Baran, R, 2001
)
0.74
" Fully parametric approaches in combination with the modified colorimetric method might prove useful for testing the in vitro interaction of antifungal drugs against filamentous fungi."( In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates.
Meis, JF; Meletiadis, J; Mouton, JW; Verweij, PE, 2003
)
0.56
"The purpose of this randomized, single blinded clinical trial was to evaluate cytologically and clinically the efficacy of oral cephalexin alone and its combination with terbinafine or ketoconazole for the treatment of Malassezia dermatitis in dogs."( Comparison of the clinical efficacy of oral terbinafine and ketoconazole combined with cephalexin in the treatment of Malassezia dermatitis in dogs--a pilot study.
Harris, BL; Kunkle, G; Lopez, J; Marsella, R; Nicklin, CF; Rosales, MS, 2005
)
0.78
"This randomized, evaluator-blind, 3-arm parallel, comparator controlled, multicenter pilot study evaluated the safety and efficacy of ciclopirox nail lacquer topical solution, 8% in combination with oral terbinafine for the treatment of moderate to severe toenail onychomycosis (> or =60% disease involvement of target nail and/or lunula/matrix involvement) (N = 73)."( Ciclopirox topical solution, 8% combined with oral terbinafine to treat onychomycosis: a randomized, evaluator-blinded study.
Gupta, AK,
)
0.57
"Drugs with long terminal half-lives, such as terbinafine, have a potential for involvement in both long-lasting drug-drug interactions and interactions appearing weeks after discontinuation."( Prolonged pharmacokinetic drug interaction between terbinafine and amitriptyline.
Aamo, TO; Castberg, I; Helle, J, 2005
)
0.84
"To study the efficacy and safety of oral terbinafine pulse as a monotherapy and in combination with topical ciclopirox olamine 8% or topical amorolfine hydrochloride 5% in onychomycosis."( An open randomized comparative study to test the efficacy and safety of oral terbinafine pulse as a monotherapy and in combination with topical ciclopirox olamine 8% or topical amorolfine hydrochloride 5% in the treatment of onychomycosis.
Garg, AP; Jaiswal, A; Sharma, RP,
)
0.63
"In this text we evaluated the in vitro antifungal activities of terbinafine combined with caspofungin, miconazole, ketoconazole, and fluconazole against 17 Pythium insidiosum strains by using the microdilution checkerboard method."( In Vitro activity of terbinafine combined with caspofungin and azoles against Pythium insidiosum.
Alves, SH; Argenta, JS; Cavalheiro, AS; de Azevedo, MI; Maboni, G; Pereira, DI; Santurio, JM; Spader, TB, 2009
)
0.91
"Aim of our study was to investigate the in vitro effects of Tachyplesin III (TP), a potent disulfide-linked peptide, in dermatophytes infections, with respect to or in combination with terbinafine (TERB), against 20 clinical isolates of dermatophytes belonging to four species."( In vitro activity of Tachyplesin III alone and in combination with terbinafine against clinical isolates of dermatophytes.
Arzeni, D; Barchiesi, F; Campanati, A; Cirioni, O; Gabrielli, E; Ganzetti, G; Giacometti, A; Kamysz, E; Kamysz, W; Lenci, I; Marconi, B; Offidani, A; Scalise, G; Silvestri, C; Simonetti, O, 2009
)
0.78
"Studies have demonstrated excellent in vivo efficacy of terbinafine combined with other antifungal agents against dematiaceous molds; however, there is a lack of in vitro studies."( Susceptibility testing of terbinafine alone and in combination with amphotericin B, itraconazole, or voriconazole against conidia and hyphae of dematiaceous molds.
Biancalana, FS; Lyra, L; Moretti, ML; Schreiber, AZ, 2011
)
0.92
"Terbinafine is increasingly used in combination with other antifungal agents to treat resistant or refractory mycoses due to synergistic in vitro antifungal activity; high doses are commonly used, but limited data are available on systemic exposure, and no assessment of pharmacodynamic target attainment has been made."( Terbinafine in combination with other antifungal agents for treatment of resistant or refractory mycoses: investigating optimal dosing regimens using a physiologically based pharmacokinetic model.
Dolton, MJ; McLachlan, AJ; Perera, V; Pont, LG, 2014
)
3.29
"37 to 1 in combination with fluconazole/terbinafine."( Possible mechanisms of the antifungal activity of fluconazole in combination with terbinafine against Candida albicans.
Alizadeh, F; Chong, PP; Karimi, G; Khodavandi, A; Vanda, NA, 2014
)
0.9
" We treated one case of chromoblastomycosis by photodynamic therapy (PDT) of 5-aminolevulinic acid (ALA) irradiation combined with terbinafine 250 mg a day."( Photodynamic therapy combined with terbinafine against chromoblastomycosis and the effect of PDT on Fonsecaea monophora in vitro.
Hamblin, MR; Hu, Y; Huang, X; Lu, S; Mylonakis, E; Xi, L; Zhang, J, 2015
)
0.9
"The efficacy and safety of amorolfine 5% nail lacquer in combination with systemic antifungal agents in the treatment of the onychomycosis were evaluated."( Efficacy and tolerability of amorolfine 5% nail lacquer in combination with systemic antifungal agents for onychomycosis: A meta-analysis and systematic review.
Feng, X; Ran, Y; Xiong, X, 2017
)
0.46
"We treated 5 refractory and complex cases of chromoblastomycosis with 5-aminolevulinic acid photodynamic therapy (ALA-PDT) combined with oral antifungal drugs."( Photodynamic therapy combined with antifungal drugs against chromoblastomycosis and the effect of ALA-PDT on Fonsecaea in vitro.
Chen, X; Hu, Y; Liu, K; Lu, Y; Mao, Z; Qi, X; Sun, H; Wu, Z; Yang, Y; Zhou, X, 2019
)
0.51
"These results provide the basis for the development of a new therapeutic approach, and ALA-PDT combined with oral antifungal drugs constitutes a promising alternative method for the treatment of refractory and complex cases of chromoblastomycosis."( Photodynamic therapy combined with antifungal drugs against chromoblastomycosis and the effect of ALA-PDT on Fonsecaea in vitro.
Chen, X; Hu, Y; Liu, K; Lu, Y; Mao, Z; Qi, X; Sun, H; Wu, Z; Yang, Y; Zhou, X, 2019
)
0.51
" schenckii, either alone or in combination with amphotericin B, itraconazole, or terbinafine."( Anti-Sporothrix activity of ibuprofen combined with antifungal.
Borba-Santos, LP; Ferreira-Pereira, A; Nucci, M; Rozental, S, 2021
)
0.85
" In vitro experiments proved that terbinafine combined with itraconazole achieves better antifungal effects."( Terbinafine Hydrochloride Combined With Itraconazole for Fungal Skin Diseases: A Randomized Controlled Trial.
Chen, C; Lai, H; Liao, W; Liu, S; Zhang, D,
)
1.85
"Terbinafine combined with itraconazole achieves better therapeutic effects in fungal skin diseases."( Terbinafine Hydrochloride Combined With Itraconazole for Fungal Skin Diseases: A Randomized Controlled Trial.
Chen, C; Lai, H; Liao, W; Liu, S; Zhang, D,
)
3.02
"While the beneficial effects of medications are numerous, drug-drug interactions may lead to adverse drug reactions that are preventable causes of morbidity and mortality."( Drug interactions in hospital prescriptions in Denmark: Prevalence and associations with adverse outcomes.
Andersen, SE; Belling, KG; Biel, JH; Brunak, S; Eriksson, R; Kaas-Hansen, BS; Leal Rodríguez, C, 2022
)
0.72
" We measured the prevalence of potential drug-drug interactions in general and discouraged drug pairs in particular during admissions and associations with adverse outcomes: post-discharge all-cause mortality rate, readmission rate and length-of-stay."( Drug interactions in hospital prescriptions in Denmark: Prevalence and associations with adverse outcomes.
Andersen, SE; Belling, KG; Biel, JH; Brunak, S; Eriksson, R; Kaas-Hansen, BS; Leal Rodríguez, C, 2022
)
0.72
"Among 2 886 227 hospital admissions (945 475 patients; median age 62 years [IQR: 41-74]; 54% female; median number of drugs 7 [IQR: 4-11]), patients in 1 836 170 admissions were exposed to at least one potential drug-drug interaction (659 525 patients; median age 65 years [IQR: 49-77]; 54% female; median number of drugs 9 [IQR: 6-13]) and in 27 605 admissions to a discouraged drug pair (18 192 patients; median age 68 years [IQR: 58-77]; female 46%; median number of drugs 16 [IQR: 11-22])."( Drug interactions in hospital prescriptions in Denmark: Prevalence and associations with adverse outcomes.
Andersen, SE; Belling, KG; Biel, JH; Brunak, S; Eriksson, R; Kaas-Hansen, BS; Leal Rodríguez, C, 2022
)
0.72
"Well-described potential drug-drug interactions are still missed and alerts at point of prescription may reduce the risk of harming patients; prescribing clinicians should be alert when using strong inhibitor/inducer drugs (i."( Drug interactions in hospital prescriptions in Denmark: Prevalence and associations with adverse outcomes.
Andersen, SE; Belling, KG; Biel, JH; Brunak, S; Eriksson, R; Kaas-Hansen, BS; Leal Rodríguez, C, 2022
)
0.72

Bioavailability

The bioavailability of a new terbinafine (CAS 91161-71-6) preparation was compared with a commercially available original preparation (reference) of the drug in 19 Chinese healthy male volunteers. Reduced bioavailability resulting from binding by serum may at least partly account for the low efficacy of ter binafine in experimental models of systemic infection.

ExcerptReferenceRelevance
" Reduced bioavailability resulting from binding by serum may at least partly account for the low efficacy of terbinafine in experimental models of systemic infection, in contrast to its high efficacy in infections of the skin, nails and hair."( Interaction of terbinafine with human serum and serum proteins.
Frank, I; Ryder, NS, 1992
)
0.85
" It is concluded that a lack of bioavailability in the presence of serum may explain the lack of activity of terbinafine in experimental aspergillosis."( Inactivity of terbinafine in a rat model of pulmonary aspergillosis.
Andrade, J; Armstrong, D; Bernard, E; Edwards, F; Niki, Y; Schmitt, HJ, 1990
)
0.85
" When given orally, terbinafine is well absorbed and rapidly and extensively distributed to the skin and sebum in concentrations that exceed the minimum inhibitory concentrations of these organisms by several orders of magnitude."( Pharmacology of the allylamines.
Birnbaum, JE, 1990
)
0.6
"Our purpose was to determine the bioavailability of terbinafine in a nail fragment model."( Inhibitory effect of terbinafine on the invasion of nails by Trichophyton mentagrophytes.
Rashid, A; Richardson, MD; Scott, EM, 1995
)
0.86
" The improved effectiveness of these agents is probably related to their rapid penetration into the nails and prolonged bioavailability at the site of infection."( New approaches to the treatment of onychomycosis.
De Doncker, P; Roseeuw, D, 1993
)
0.29
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31
"The objective of this study was to evaluate, using attenuated total reflectance Fourier transform infrared spectroscopy, the stratum corneum (SC) bioavailability of terbinafine (TBF) following topical treatment with four different formulations."( In vivo assessment of enhanced topical delivery of terbinafine to human stratum corneum.
Alberti, I; Bonny, JD; Guy, RH; Kalia, YN; Naik, A, 2001
)
0.76
"A facile and minimally invasive methodology to evaluate an important aspect of topical drug bioavailability has been described."( In vivo assessment of enhanced topical delivery of terbinafine to human stratum corneum.
Alberti, I; Bonny, JD; Guy, RH; Kalia, YN; Naik, A, 2001
)
0.56
" General considerations that may be associated with recurrent infections are, a genetic predisposition and suboptimal bioavailability of drug, resulting in insufficient concentration at the target site."( Onychomycosis: strategies to improve efficacy and reduce recurrence.
Baran, R; Gupta, AK; Summerbell, R, 2002
)
0.31
" AUC0-infinity, AUC0-tlast, Cmax and tmax were calculated for both formulations and compared according to the currently valid CPMP Note for Guidance for the evaluation of Bioavailability and Bioequivalence."( Clinical relevance of bioequivalence acceptance criteria. The example of terbinafine.
Alpan, S; Erenmemisoglu, A; Koytchev, R; van der Meer, MJ, 2003
)
0.55
"An open-label, randomised, cross-over single dose study, using 2 periods x 2 sequences, with a minimum washout period of 21 days, was conducted in order to assess the comparative bioavailability of two formulations of terbinafine (CAS 78628-80-5) 250 mg tablets."( Comparative bioavailability of two formulations of terbinafine. Data from a cross-over, randomised, open-label bioequivalence study in healthy volunteers.
Almeida, S; Filipe, A; Lainesse, A; Larouche, R; Tanguay, M; Vallée, F, 2004
)
0.76
"The bioavailability of a new terbinafine (CAS 91161-71-6) preparation was compared with a commercially available original preparation (reference) of the drug in 19 Chinese healthy male volunteers."( Pharmacokinetics and comparative bioavailability of two terbinafine hydrochloride formulations after single-dose administration in Chinese healthy subjects.
Chen, Y; Jiang, X; Tian, Y; Wang, N; Zhang, ZJ, 2008
)
0.88
" The drug is highly lipophilic and keratophilic and is highly bound to plasma protein (>90%) with a bioavailability of 70% to 80%."( Update on antifungal therapy with terbinafine.
Gianni, C, 2010
)
0.64
" The absolute bioavailability of terbinafine hydrochloride tablets after oral administration was 31."( Single dose pharmacokinetics of terbinafine in cats.
Ding, H; Gao, Y; Liu, Y; Wang, A; Zeng, Z, 2012
)
0.94
" In conclusion, the easily prepared, small, physically stable and biocompatible TH-HNMs with good ocular bioavailability hold great promise as an efficient carrier for topical ocular delivery of TH."( Micelle carriers based on macrogol 15 hydroxystearate for ocular delivery of terbinafine hydrochloride: In vitro characterization and in vivo permeation.
He, J; He, S; Liu, S; Wang, L; Xia, H; Zhang, J; Zhou, T; Zhu, L, 2017
)
0.68
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" Specially formulated itraconazole enables high bioavailability despite lower dosage."( [Treatment of a terbinafine-resistant trichophyton mentagrophytes type VIII].
Gawaz, A; Nenoff, P; Schaller, M; Uhrlaß, S, 2021
)
0.97
" Given that ergosterol biosynthesis depends on iron as an essential cofactor, in this report, we used the yeast Saccharomyces cerevisiae to investigate how iron bioavailability influences Erg1 expression and terbinafine susceptibility."( Modulation of yeast Erg1 expression and terbinafine susceptibility by iron bioavailability.
Jordá, T; Martínez-Martín, A; Martínez-Pastor, MT; Puig, S, 2022
)
1.18
" Super bioavailability (SUBA) itraconazole was initially not tolerated."( [Recurrent tinea corporis generalisata due to Terbinafine-resistant Trichophyton rubrum strain : Long-term treatment with super bioavailability itraconazole].
Burmester, A; Ebert, A; Monod, M; Nenoff, P; Schaller, M; Stahl, M; Uhrlaß, S, 2023
)
1.17

Dosage Studied

The objective of this study was to determine the pharmacokinetic parameters of orally administered terbinafine hydrochloride based on 3, 7, and 15 mg/kg single- as well as multiple-dosage. Both oral itraconazole and terBinafine are effective in the treatment of onychomycosis when administered in the pulse dosage form.

ExcerptRelevanceReference
"A double-blind study with terbinafine was performed in 39 patients with dermatophyte infection, between 1987 and 1989, to compare the safety and efficacy of two dosage schedules of 125 mg twice daily versus 250 mg once daily."( Terbinafine: efficacy and safety in the treatment of dermatophytosis.
Kotogyan, A; Oguz, O; Tüzün, Y, 1992
)
2.03
" For planning optimal clinical dosage regimes, it is necessary to know the rate of terbinafine movement through the nail plate, the concentrations achieved, and the persistence in the nail plate after stopping treatment."( Pharmacokinetics of terbinafine in the nail.
Finlay, AY, 1992
)
0.83
" Daily dosage was 250 mg of terbinafine (Lamisil) orally for up to 6 months."( Treatment of onychomycosis with terbinafine.
Baudraz-Rosselet, F; Kenzelmann, R; Rakosi, T; Wili, PB, 1992
)
0.86
" Amphotericin B and terbinafine possessed intermediate ATP-suppressing activity, and the dose-response and pH-response curves for these compounds suggested their mechanism of ATP suppression differed from that of the active imidazole derivatives."( Suppression of ATP in Candida albicans by imidazole and derivative antifungal agents.
Abbott, AB; Cheesman, SL; Odds, FC, 1985
)
0.59
" The result of experiments demonstrated that oral TBF more or less prevented the development of the dermatophytic infection, depending on the dosage and the timing of administration, the complete prevention was achieved in the animals that were administered with 12."( [Prophylactic effect of oral terbinafine on the development of infection in guinea pigs inoculated with Trichophyton mentagrophytes].
Uchida, K; Yamaguchi, H, 1994
)
0.58
" Terbinafine accumulated approximately twofold over the 4-week dosing phase."( Multiple-dose pharmacokinetics and distribution in tissue of terbinafine and metabolites.
Caplain, H; Denouël, J; Kovarik, JM; Millerioux, L; Mueller, EA; Zehender, H, 1995
)
1.44
" Oral terbinafine at this dosage was therefore not thought an effective treatment for this indication in HIV-positive patients."( Use of terbinafine in HIV-positive subjects: pilot studies in onychomycosis and oral candidiasis.
Cartledge, J; Evans, EG; Hawkins, DA; Lacey, CJ; Midgley, J; Nandwani, R; Parnell, A; Youle, M, 1996
)
1.23
"In an open trial, long courses (6-12 months) of terbinafine at a dosage of 500 mg/day were administered orally to 43 patients with a diagnosis of chromomycosis."( Treatment of chromomycosis with terbinafine: preliminary results of an open pilot study.
Andriantsimahavandy, A; Esterre, P; Inzan, CK; Pecarrere, JL; Ramarcel, ER; Ratsioharana, M; Roig, P, 1996
)
0.83
" No changes in cyclosporin A dosage were made."( Effect of oral terbinafine treatment on cyclosporin pharmacokinetics in organ transplant recipients with dermatophyte nail infection.
Fauchald, P; Jensen, P; Lehne, G; Simonsen, S, 1996
)
0.65
" A sensitivity analysis assessing alternative dosing regimens and a rank order stability analysis investigating the effects of length of treatment, success rates, relapse rates, and drug acquisition costs on overall results were also conducted."( Pharmacoeconomic analysis of oral therapies for onychomycosis: a US model.
Marchetti, A; McGhan, WF; Neugut, AI; Piech, CT; Smith, BT,
)
0.13
" Firstly, the purpose of the study, the comparator drugs, their dosage regimens and the time frame of the analysis were defined."( Economic evaluation of antifungal agents in the treatment of toenail onychomycosis in Germany.
De Doncker, P; Dubois, DJ; Eggleston, A; Gupta, AK; Haneke, E; Tormans, G; Van Doorslaer, EK; Van Rossem, K, 1996
)
0.29
"To review the pharmacology, pharmacokinetics, efficacy, adverse effects, drug interactions, and dosage guidelines of terbinafine."( Oral terbinafine: a new antifungal agent.
Abdel-Rahman, SM; Nahata, MC, 1997
)
1.02
"Because of the lack of clinically significant interactions between terbinafine and warfarin during multiple-dose administration of terbinafine, no adjustment of warfarin dosage during concomitant therapy appears to be necessary."( Evaluation of effects of terbinafine on single oral dose pharmacokinetics and anticoagulant actions of warfarin in healthy volunteers.
Francheteau, P; Guerret, M; Hubert, M,
)
0.67
"No special dosage adjustments for digoxin appear to be necessary during concomitant therapy with terbinafine."( Effects of terbinafine on the pharmacokinetics of digoxin in healthy volunteers.
Francheteau, P; Guerret, M; Tarral, A,
)
0.74
" To find the optimal dosage and treatment periods for children, further prospective studies are necessary."( Systemic antifungal treatment of children with terbinafine.
Bruckbauer, HR; Hofmann, H, 1997
)
0.55
" The dosage of terbinafine was determined by the weight of the child: >40 kg, 250 mg/day, 20 to 40 kg, 125 mg/day and <20 kg, 62."( Terbinafine pulse therapy is effective in tinea capitis.
Adam, P; Gupta, AK,
)
1.93
" In addition, the short treatment times (< 3 months) and intermittent dosing schedules are likely to enhance compliance and reduce the costs of therapy."( Onychomycosis: pathogenesis, diagnosis, and management.
Elewski, BE, 1998
)
0.3
" These medications were continued during the episode and subsequently afterwards, with adjustment to the prednisone dosage only."( Hypersensitivity syndrome reaction to oral terbinafine.
Gupta, AK; Porges, AJ, 1998
)
0.56
" Terbinafine dosage (125 or 250 mg/day) was adjusted according to patient weight."( Efficacy, safety and tolerability of terbinafine for Tinea capitis in children: Brazilian multicentric study with daily oral tablets for 1,2 and 4 weeks.
Cucé, LC; Filho, ST; Foss, NT; Marques, SA; Santamaria, JR, 1998
)
1.48
" Short course and pulse dosing are particularly exciting options that may decrease cost and lower the risk of adverse side effects."( The evolving role of itraconazole, fluconazole and terbinafine in the treatment of tinea capitis.
Friedlander, SF, 1999
)
0.56
" First, the purpose of the study, the comparator drugs and their dosage regimens were defined."( Pharmacoeconomic analysis of oral antifungal therapies used to treat dermatophyte onychomycosis of the toenails. A US analysis.
Gupta, AK, 1998
)
0.3
" The drug is also effective in children with tinea capitis when administered orally in the dosage range 62."( Terbinafine. An update of its use in superficial mycoses.
Markham, A; McClellan, KJ; Wiseman, LR, 1999
)
1.75
"In this open, randomized, parallel-group, the efficacy and safety of itraconazole pulse therapy (1 week 400 mg daily, 3 months) was evaluated in comparison with continuous terbinafine dosing (250 mg daily, 3 months) for the treatment of toenail onychomycosis."( Itraconazole pulse therapy vs continuous terbinafine dosing for toenail onychomycosis.
Kejda, J, 1999
)
0.76
" Effective treatments for most superficial mycoses now exist, but new agents with convenient dosing regimens and a low level of adverse events are still needed to reduce morbidity and mortality from serious subcutaneous and systemic fungal infections."( Therapeutic potential of terbinafine in subcutaneous and systemic mycoses.
Hay, RJ, 1999
)
0.61
" When problems are known to arise, they can often be overcome or minimised by varying the dosage regimens, or by drug monitoring."( The implications and management of drug interactions with itraconazole, fluconazole and terbinafine.
Drake, L; Gupta, AK; Lambert, J; Shear, N; Yaniv, R, 2000
)
0.53
" Intermittent pulse dosing with itraconazole is as safe and effective as short-term continuous therapy but more economical and convenient."( Treating onychomycosis.
Bassler, M; Rodgers, P, 2001
)
0.31
" Given the amount of variability introduced by the dosage form, it takes plenty of trial and error to get the right drug in the right vehicle so it can reach the targeted tissue."( Pharmacokinetics of topical antifungal formulations.
Reitberg, D, 2001
)
0.31
" Terbinafine side effects were not correlated with dosage or duration of treatment."( Doubled dose of oral terbinafine is required for Microsporum canis tinea capitis.
Georgalla, S; Kakourou, T; Koumantaki, E; Rallis, E; Riga, P,
)
1.36
" However, these high rates were believed to be due to the high dosage of this drug and the prolonged course of treatment."( A randomized, double-blind, parallel-group, duration-finding study of oral terbinafine and open-label, high-dose griseofulvin in children with tinea capitis due to Microsporum species.
Chouela, E; Gourmala, N; Horvath, A; Lipozencic, J; Orofino-Costa, R; Paul, C; Romero, G; Skerlev, M; Zaitz, VC, 2002
)
0.54
" These agents differ in their dosing regimen, efficacy, adverse events profile, potential for drug interaction, and cost."( Economic analysis of oral and topical therapies for onychomycosis of the toenails and fingernails.
Amaya, K; Arikian, S; Casciano, J; Doyle, J; Haspel, M; Kahler, K; Shear, N, 2003
)
0.32
" It is possible that even higher cure rates and a shorter duration of therapy may be achieved following further optimization of treatment regimens that use a higher daily dosage of terbinafine than is currently recommended."( The efficacy and safety of terbinafine in children.
Cooper, EA; Gupta, AK; Lynde, CW, 2003
)
0.81
" Studies included in this meta-analysis required a standard accepted dosage regimen, treatment duration and follow-up period."( Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis.
Gupta, AK; Johnson, AM; Ryder, JE, 2004
)
0.32
"The pulsed regimen is at least as effective as continuous dosing and thus, at 50% less cost and more convenience, is preferable to a continuous regimen."( Pulsed versus continuous terbinafine dosing in the treatment of dermatophyte onychomycosis.
Armoni, G; Pavlotsky, F; Shemer, A; Trau, H, 2004
)
0.63
" Dosage adopted was 62."( Tinea capitis caused by Microsporum canis treated with terbinafine.
Aste, N; Pau, M, 2004
)
0.57
"To determine the optimal 1-week pulse dosing regimen for combination therapy of oral terbinafine with complementary 1% terbinafine cream for the treatment of onychomycosis."( Combination therapy consisting of week pulses of oral terbinafine plus topical application of terbinafine cream in the treatment of onychomycosis.
Hiruma, M; Mizoguchi, M; Ogawa, H; Sanmano, B, 2004
)
0.8
" The optimal terbinafine dosing regimen consisted of alternate 1-week pulses, with most patients on this regimen (19/20 cases; 95%) achieving total cure."( Combination therapy consisting of week pulses of oral terbinafine plus topical application of terbinafine cream in the treatment of onychomycosis.
Hiruma, M; Mizoguchi, M; Ogawa, H; Sanmano, B, 2004
)
0.94
" The total dosage of terbinafine was 37."( Treatment of chromoblastomycosis with terbinafine: a report of four cases.
Changxing, L; Quan, L; Xibao, Z; Yuqing, H, 2005
)
0.92
" The dosing scheme used in this investigation results in absolute exposure estimates at steady state and a safety profile that are not appreciably different from adults."( Pharmacokinetics of terbinafine in young children treated for tinea capitis.
Abdel-Rahman, SM; Fallon-Friedlander, S; Hauffe, S; Herron, J; Horowitz, A; Rivière, GJ, 2005
)
0.65
"Both oral itraconazole and terbinafine are effective in the treatment of onychomycosis when administered in the pulse dosage form."( An open randomized comparative study of oral itraconazole pulse and terbinafine pulse in the treatment of onychomycosis.
Mishra, K; Mishra, M; Panda, P; Sengupta, S; Tripathy, S,
)
0.66
"05) in favour of standard daily dosing with terbinafine."( Intermittent versus continuous terbinafine in the treatment of toenail onychomycosis: a randomized, double-blind comparison.
Bakshi, R; Cai, B; Elewski, BE; Nyirady, J; Opper, C; Rich, PA; Sigurgeirsson, B, 2006
)
0.88
"Pulsed dosing with terbinafine did not provide any clear safety advantages and was significantly less effective."( Intermittent versus continuous terbinafine in the treatment of toenail onychomycosis: a randomized, double-blind comparison.
Bakshi, R; Cai, B; Elewski, BE; Nyirady, J; Opper, C; Rich, PA; Sigurgeirsson, B, 2006
)
0.95
" Treatment arms with the same regimen in terms of drug, type (continuous or intermittent), and dosage were combined to estimate the risk of an outcome of interest."( The safety of oral antifungal treatments for superficial dermatophytosis and onychomycosis: a meta-analysis.
Chan, AK; Chang, CH; Kurth, T; Orav, JE; Young-Xu, Y, 2007
)
0.34
" Nineteen patients were treated with itraconazole 200 mg once daily for 12 weeks, and 17 patients were treated with terbinafine for 12 weeks in a dosage according to their body weight, respectively."( Onychomycosis: a new emerging infectious disease in childhood population and adolescents. Report on treatment experience with terbinafine and itraconazole in 36 patients.
Ginter-Hanselmayer, G; Smolle, J; Weger, W, 2008
)
0.76
" One study used daily dosing and the rest used once-weekly dosing."( Efficacy of fluconazole for the treatment of onychomycosis.
Brown, SJ, 2009
)
0.35
" However, fluconazole may be preferred in patients unable to tolerate other oral antifungal agents due to the dosing regimen, adverse effect profile, and drug interactions."( Efficacy of fluconazole for the treatment of onychomycosis.
Brown, SJ, 2009
)
0.35
" Phase 1 clinical data shows levels of drug delivery that differ unexpectedly from relative dosing level to multiple tissue types."( Studies in drug transport vs. current in iontophoretic onychomycosis treatment.
Barsness, M; Chang, K; Davis, SP; Etheredge, R; Kim, H, 2009
)
0.35
"The objective of this study was to determine the pharmacokinetic parameters of orally administered terbinafine hydrochloride based on 3, 7, and 15 mg/kg single- as well as multiple-dosage trials in order to calculate dosing requirements for potential treatment of aspergillosis in African penguins (Spheniscus demersus)."( Pharmacokinetics of orally administered terbinafine in African penguins (Spheniscus demersus) for potential treatment of aspergillosis.
Bechert, U; Christensen, JM; Le, H; Poppenga, R; Schmitt, T; Wyatt, J, 2010
)
0.84
" Calculations based on pharmacokinetic parameter values indicated that a dosage of 22 mg/kg terbinafine q24h would result in steady-state trough plasma concentrations above the minimum inhibitory concentration of terbinafine (0."( Pharmacokinetics of terbinafine after single oral dose administration in red-tailed hawks (Buteo jamaicensis).
Bechert, U; Christensen, JM; Fahmy, SA; Poppenga, R; Redig, P, 2010
)
0.9
"TDT 067 is a novel carrier-based dosage form (liquid spray) of 15 mg/ml of terbinafine in Transfersome that has been developed to deliver terbinafine to the nail bed to treat onychomycosis."( Activity of TDT 067 (terbinafine in Transfersome) against agents of onychomycosis, as determined by minimum inhibitory and fungicidal concentrations.
Ghannoum, M; Henry, W; Herbert, J; Isham, N; Yurdakul, S, 2011
)
0.92
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
" Suggestions for dosing regimens and laboratory monitoring are given."( Systemic drugs in patients with skin diseases.
Byekova, Y; Elewski, B; Hughey, L, 2011
)
0.37
"TDT 067 is a novel, carrier-based dosage form of terbinafine in Transfersome (1."( Evaluation of the morphological effects of TDT 067 (terbinafine in Transfersome) and conventional terbinafine on dermatophyte hyphae in vitro and in vivo.
Ghannoum, M; Henry, W; Isham, N; Kroon, HA; Yurdakul, S, 2012
)
0.88
" However, varying dosage schedules, changes in epidemiology, and rising drug resistance are factors that hamper treatment in some cases."( Comparative evaluation of griseofulvin, terbinafine and fluconazole in the treatment of tinea capitis.
Arora, P; Grover, C; Manchanda, V, 2012
)
0.65
" Response rates to griseofulvin are similar to rates seen in the 1970s, but require higher dosing and conversion to crushed tablets in partial responders."( Treatment outcomes for tinea capitis in a skin of color population.
Alexis, A; Bhanusali, D; Coley, M; Silverberg, JI; Silverberg, NB, 2012
)
0.38
" Two intermittent dosing regimens of terbinafine plus nail abrasion proved to be an alternative statistically effective, safe and with reduced drug costs for dermatophytes toenail onychomycosis."( Intermittent therapy with terbinafine and nail abrasion for dermatophyte toe onychomycosis: a pilot study.
Bernardes-Engemann, AR; Orofino-Costa, R; Succi, IB, 2013
)
0.96
"The influence of dosing regimens on the recurrence rates of onychomycosis has not been investigated."( Recurrences of dermatophyte toenail onychomycosis during long-term follow-up after successful treatments with mono- and combined therapy of terbinafine and itraconazole.
Cooper, EA; Gupta, AK; Paquet, M,
)
0.33
"To compare recurrence rates for toenail dermatophyte onychomycosis between four dosing regimens."( Recurrences of dermatophyte toenail onychomycosis during long-term follow-up after successful treatments with mono- and combined therapy of terbinafine and itraconazole.
Cooper, EA; Gupta, AK; Paquet, M,
)
0.33
" Since an enhanced effect of a combination respective of its components, does not necessarily indicate synergism, three-dimensional (3D) dose-response surfaces were constructed for each selected pair of extract/antifungal drug with the aid of CombiTool software."( Detection of synergistic combinations of Baccharis extracts with terbinafine against Trichophyton rubrum with high throughput screening synergy assay (HTSS) followed by 3D graphs. Behavior of some of their components.
Favier, LS; Gattuso, MA; Ivancovich, JJ; Pellegrino, JM; Raimondi, MP; Rodriguez, MV; Sortino, MA; Zacchino, SA, 2013
)
0.63
"Selection of excipients used is a critical step in the design of a pharmaceutical dosage form as it affects its behavior upon application, as during storage."( Comparative study between synthetic and phospholipids of natural origin: effect of phospholipid selection on the behavior of a topical liposomal dosage form incorporating terbinafine.
Koutsoulas, C; Suleiman, E; Wagner, A; Žabka, M, 2014
)
0.6
" The most successful treatment option for eumycetomas offers itraconazole in a dosage of 200 mg twice daily."( Eumycetoma and actinomycetoma--an update on causative agents, epidemiology, pathogenesis, diagnostics and therapy.
Fahal, AH; Nenoff, P; Reinel, D; Schöfer, H; van de Sande, WW, 2015
)
0.42
"To compare the efficacy of terbinafine in continuous and pulse dosing schedules in the treatment of toenail dermatophytosis."( Comparative efficacy of continuous and pulse dose terbinafine regimes in toenail dermatophytosis: A randomized double-blind trial.
Das, S; Pandhi, D; Singal, A; Yadav, P,
)
0.68
"Terbinafine in pulse dosing is as effective as continuous dosing in the treatment of dermatophyte toenail onychomycosis."( Comparative efficacy of continuous and pulse dose terbinafine regimes in toenail dermatophytosis: A randomized double-blind trial.
Das, S; Pandhi, D; Singal, A; Yadav, P,
)
1.83
"(i) Describe TBF accumulation in canine skin; (ii) Integrate pharmacokinetic data with historical minimum inhibitory concentration (MIC) results for Malassezia pachydermatis to verify the currently used dosage of TBF for the treatment of Malassezia dermatitis."( Determining canine skin concentrations of terbinafine to guide the treatment of Malassezia dermatitis.
Boothe, DM; Cruz-Espindola, C; Gimmler, JR; Kennis, RA; White, AG, 2015
)
0.68
"A novel and simple ultra-performance LC method was developed for the estimation of nadifloxacin (NAD), terbinafine hydrochloride (TBH), mometasone furoate (MMF), methyl paraben (MP), and propyl paraben (PP) in a topical pharmaceutical dosage formulation."( Stability-Indicating UPLC Method for the Estimation of Nadifloxacin, Terbinafine Hydrochloride, Mometasone Furoate, Methyl Paraben, and Propyl Paraben in Topical Pharmaceutical Dosage Form.
Bhosale, DM; Nikalje, APG, 2017
)
0.9
" Thus, bigels with ciclopirox olamine and terbinafine hydrochloride are a promising dosage form for topical use."( Topical antifungal bigels: Formulation, characterization and evaluation.
Briedis, V; Grigonis, A; Ivaskiene, M; Mazurkeviciute, A; Ramanauskiene, K, 2018
)
0.75
"Current dosing regimens of reported drugs are effective and safe for use in tinea capitis in children."( Tinea capitis in children: a systematic review of management.
Friedlander, SF; Gupta, AK; Mays, RR; Piguet, V; Piraccini, BM; Shear, NH; Tosti, A; Versteeg, SG, 2018
)
0.48
" Successful treatment included surgical resection in combination with postoperative terbinafine, which was pulse dosed to decrease its impact on hepatic function."( Pedal Fungal Mass in the Midwest.
Goldstein, W; Standish, SN; Stuart, CR, 2018
)
0.71
"All terbinafine-treated animals showed intact inner ear function when total dosage of terbinafine was <2."( Eradicating Otomycosis with Terbinafine Solution: Basic and Clinical Investigation.
Yang, TH; Young, YH, 2019
)
1.37
"Per-weight dosing regimens of systemic antifungal agents such as terbinafine, itraconazole, and fluconazole are found to be safe in children and are used off-label for the treatment of pediatric onychomycosis with high efficacy."( Onychomycosis in children - review on treatment and management strategies.
Gupta, AK; Piguet, V; Shear, NH; Venkataraman, M, 2022
)
0.96
" They were receiving a daily terbinafine dosage of either 125mg or 250mg to treat onychomycosis or tinea cruris."( Terbinafine-induced lichenoid drug eruption: case report and review of terbinafine-associated cutaneous adverse events.
Calame, A; Cohen, PR; Erickson, CP, 2020
)
2.29
" We have summarized the most appropriate dosing regimens of posaconazole, fosravuconazole, voriconazole, and oteseconazole (VT-1161) to treat onychomycosis and superficial fungal infections."( Review of the alternative therapies for onychomycosis and superficial fungal infections: posaconazole, fosravuconazole, voriconazole, oteseconazole.
Gupta, AK; Talukder, M; Venkataraman, M, 2022
)
0.72
" testavorans MIC throughout the entire dosing interval."( Bioencapsulation is a feasible method of terbinafine administration in Emydomyces testavorans-infected western pond turtles (Actinemys marmorata).
Cerreta, AJ; Cox, S; Forsythe, LR; Keller, KA; O'Connor, MR; Reinhart, JM; Tang, KN, 2022
)
0.99
" We found that an agent's dosage was associated with its efficacy; for example, the 1-year odds of mycological cure with terbinafine 250 mg daily for 24 weeks (SUCRA = 92."( Relative impact of traditional vs. newer oral antifungals for dermatophyte toenail onychomycosis: a network meta-analysis study.
Bamimore, MA; Gupta, AK; Venkataraman, M, 2023
)
1.12
"015 μg/mL as a minimum breakpoint for predicting clinically relevant terbinafine treatment failure to standard oral dosing for dermatophyte infections."( Reliable and rapid identification of terbinafine resistance in dermatophytic nail and skin infections.
Amarov, B; Blanchard, G; Bontems, O; Chang, YT; Fratti, M; Guenova, E; Künzle, N; Monod, M; Sabou, AM; Salamin, K, 2023
)
1.42
"The over-crowded day care centres and dense living make refugee children more susceptible to TC than the general population, and griseofulvin dosage adjustment is necessary."( Improved effectiveness of an increased dose of griseofulvin for treating Tinea capitis among refugee children in Israel: A retrospective cohort study.
Barzilai, A; Baum, S; Kassem, R; Kempfner, A; Pavlotsky, F, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
EC 1.14.13.132 (squalene monooxygenase) inhibitorAn EC 1.14.13.* (oxidoreductase acting on paired donors, incorporating 1 atom of oxygen, with NADH or NADPH as one donor) inhibitor that interferes with the action of squalene monooxygenase (EC 1.14.13.132).
P450 inhibitorAn enzyme inhibitor that interferes with the activity of cytochrome P450 involved in catalysis of organic substances.
sterol biosynthesis inhibitorAny compound that inhibits the biosynthesis of any sterol.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

ClassDescription
tertiary amineA compound formally derived from ammonia by replacing three hydrogen atoms by hydrocarbyl groups.
acetylenic compoundAny organic molecule containing a C#C bond.
naphthalenesAny benzenoid aromatic compound having a skeleton composed of two ortho-fused benzene rings.
enyneAn acetylenic and an olefinic compound containing a carbon chain that contains a carbon-carbon double bond and a carbon-carbon triple bond.
allylamine antifungal drugAn organonitrogen compound that contains an amino group that is attached to a carbon which is itself attached to an olefinic carbon and which has been used as an antifungal drug.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (41)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency35.47600.006038.004119,952.5996AID1159523
USP1 protein, partialHomo sapiens (human)Potency70.79460.031637.5844354.8130AID504865
TDP1 proteinHomo sapiens (human)Potency33.49830.000811.382244.6684AID686978; AID686979
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency14.10450.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency33.49150.000417.946075.1148AID1346784
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency25.56000.01237.983543.2770AID1346984; AID1645841
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency5.35380.000214.376460.0339AID720691
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency29.84930.003041.611522,387.1992AID1159552
retinoid X nuclear receptor alphaHomo sapiens (human)Potency7.56240.000817.505159.3239AID1159531
farnesoid X nuclear receptorHomo sapiens (human)Potency18.83220.375827.485161.6524AID743217
pregnane X nuclear receptorHomo sapiens (human)Potency20.36430.005428.02631,258.9301AID1346982; AID1346985
GVesicular stomatitis virusPotency13.80290.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency0.03470.00108.379861.1304AID1645840
activating transcription factor 6Homo sapiens (human)Potency2.39140.143427.612159.8106AID1159516
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency9.520519.739145.978464.9432AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency10.68220.057821.109761.2679AID1159526
Histone H2A.xCricetulus griseus (Chinese hamster)Potency61.93150.039147.5451146.8240AID1224845
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency12.58930.01789.637444.6684AID588834
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency30.04740.000323.4451159.6830AID743065; AID743067
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency33.48890.000627.21521,122.0200AID743219
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency14.12540.00798.23321,122.0200AID2551
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency20.31480.005612.367736.1254AID624032
lamin isoform A-delta10Homo sapiens (human)Potency0.01580.891312.067628.1838AID1487
Polyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)Potency25.11890.316212.765731.6228AID881
Interferon betaHomo sapiens (human)Potency13.80290.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency13.80290.01238.964839.8107AID1645842
Cellular tumor antigen p53Homo sapiens (human)Potency18.83360.002319.595674.0614AID651631
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency25.11890.00638.235039.8107AID881
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency39.81070.009610.525035.4813AID1479145
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency13.80290.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency13.80290.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
cystic fibrosis transmembrane conductance regulatorHomo sapiens (human)IC50 (µMol)25.00000.140016.625050.0000AID1224863
Aldo-keto reductase family 1 member B1Rattus norvegicus (Norway rat)IC50 (µMol)4.12950.00041.877310.0000AID625207
Aldo-keto reductase family 1 member B1Rattus norvegicus (Norway rat)Ki4.09540.00322.28879.3160AID625207
Alpha-2A adrenergic receptorHomo sapiens (human)IC50 (µMol)5.70290.00001.44217.3470AID625201
Alpha-2A adrenergic receptorHomo sapiens (human)Ki2.13860.00010.807410.0000AID625201
Cytochrome P450 2D6Homo sapiens (human)IC50 (µMol)0.20000.00002.015110.0000AID625249
Sodium-dependent noradrenaline transporter Homo sapiens (human)IC50 (µMol)4.12950.00081.541620.0000AID625207
Sodium-dependent noradrenaline transporter Homo sapiens (human)Ki4.09540.00031.465610.0000AID625207
C-8 sterol isomeraseSaccharomyces cerevisiae S288CKi50.00000.00000.90487.1500AID239296
Squalene monooxygenase Rattus norvegicus (Norway rat)IC50 (µMol)93.00000.06102.344610.0000AID204645
Squalene monooxygenaseHomo sapiens (human)IC50 (µMol)6.00006.00006.00006.0000AID204640
Squalene monooxygenaseHomo sapiens (human)Ki0.03000.03000.03000.0300AID204513
3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)Ki50.00000.00040.54906.7000AID239597
Sigma non-opioid intracellular receptor 1Homo sapiens (human)IC50 (µMol)0.56020.00030.70285.3660AID625223
Sigma non-opioid intracellular receptor 1Homo sapiens (human)Ki0.23540.00000.490110.0000AID625223
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (268)

Processvia Protein(s)Taxonomy
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
phospholipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
apoptotic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell population proliferationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell migrationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
prostate gland developmentPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
regulation of epithelial cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of chemokine productionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of keratinocyte differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell cyclePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of growthPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endocannabinoid signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cannabinoid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
positive regulation of cytokine productionAlpha-2A adrenergic receptorHomo sapiens (human)
DNA replicationAlpha-2A adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
Ras protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
Rho protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
female pregnancyAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell population proliferationAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-2A adrenergic receptorHomo sapiens (human)
actin cytoskeleton organizationAlpha-2A adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell migrationAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
cellular response to hormone stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2A adrenergic receptorHomo sapiens (human)
vasodilationAlpha-2A adrenergic receptorHomo sapiens (human)
glucose homeostasisAlpha-2A adrenergic receptorHomo sapiens (human)
fear responseAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of potassium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAP kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion-dependent exocytosisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretionAlpha-2A adrenergic receptorHomo sapiens (human)
intestinal absorptionAlpha-2A adrenergic receptorHomo sapiens (human)
thermoceptionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of lipid catabolic processAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of membrane protein ectodomain proteolysisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretion involved in cellular response to glucose stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of uterine smooth muscle contractionAlpha-2A adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
phospholipase C-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of wound healingAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transmembrane transporter activityAlpha-2A adrenergic receptorHomo sapiens (human)
xenobiotic metabolic processCytochrome P450 2D6Homo sapiens (human)
steroid metabolic processCytochrome P450 2D6Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2D6Homo sapiens (human)
estrogen metabolic processCytochrome P450 2D6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid catabolic processCytochrome P450 2D6Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2D6Homo sapiens (human)
isoquinoline alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2D6Homo sapiens (human)
retinol metabolic processCytochrome P450 2D6Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2D6Homo sapiens (human)
negative regulation of bindingCytochrome P450 2D6Homo sapiens (human)
oxidative demethylationCytochrome P450 2D6Homo sapiens (human)
negative regulation of cellular organofluorine metabolic processCytochrome P450 2D6Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 2D6Homo sapiens (human)
monoamine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transportSodium-dependent noradrenaline transporter Homo sapiens (human)
chemical synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
response to xenobiotic stimulusSodium-dependent noradrenaline transporter Homo sapiens (human)
response to painSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine uptakeSodium-dependent noradrenaline transporter Homo sapiens (human)
neuron cellular homeostasisSodium-dependent noradrenaline transporter Homo sapiens (human)
amino acid transportSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine uptake involved in synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
sodium ion transmembrane transportSodium-dependent noradrenaline transporter Homo sapiens (human)
response to organic substanceSqualene monooxygenaseHomo sapiens (human)
sterol biosynthetic processSqualene monooxygenaseHomo sapiens (human)
regulation of cell population proliferationSqualene monooxygenaseHomo sapiens (human)
lipid droplet formationSqualene monooxygenaseHomo sapiens (human)
cholesterol metabolic processSqualene monooxygenaseHomo sapiens (human)
cholesterol biosynthetic process3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
cholesterol metabolic process3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
hemopoiesis3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
cholesterol biosynthetic process via desmosterol3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
cholesterol biosynthetic process via lathosterol3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
ossification involved in bone maturation3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
lipid transportSigma non-opioid intracellular receptor 1Homo sapiens (human)
nervous system developmentSigma non-opioid intracellular receptor 1Homo sapiens (human)
G protein-coupled opioid receptor signaling pathwaySigma non-opioid intracellular receptor 1Homo sapiens (human)
regulation of neuron apoptotic processSigma non-opioid intracellular receptor 1Homo sapiens (human)
protein homotrimerizationSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (89)

Processvia Protein(s)Taxonomy
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
calcium ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 9S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein kinase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-1B adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-2C adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
thioesterase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
heterotrimeric G-protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein homodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
norepinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
guanyl-nucleotide exchange factor activityAlpha-2A adrenergic receptorHomo sapiens (human)
monooxygenase activityCytochrome P450 2D6Homo sapiens (human)
iron ion bindingCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activityCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2D6Homo sapiens (human)
heme bindingCytochrome P450 2D6Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
actin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
protein bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
alpha-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
metal ion bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
beta-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
squalene monooxygenase activitySqualene monooxygenaseHomo sapiens (human)
protein bindingSqualene monooxygenaseHomo sapiens (human)
FAD bindingSqualene monooxygenaseHomo sapiens (human)
C-8 sterol isomerase activity3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
steroid delta-isomerase activity3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
protein binding3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
identical protein binding3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
cholestenol delta-isomerase activity3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
G protein-coupled opioid receptor activitySigma non-opioid intracellular receptor 1Homo sapiens (human)
protein bindingSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (63)

Processvia Protein(s)Taxonomy
nucleusPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytoskeletonPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
adherens junctionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
focal adhesionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular exosomePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
cytoplasmAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
basolateral plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
neuronal cell bodyAlpha-2A adrenergic receptorHomo sapiens (human)
axon terminusAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic active zone membraneAlpha-2A adrenergic receptorHomo sapiens (human)
dopaminergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
postsynaptic density membraneAlpha-2A adrenergic receptorHomo sapiens (human)
glutamatergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
GABA-ergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
receptor complexAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
mitochondrionCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulumCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2D6Homo sapiens (human)
cytoplasmCytochrome P450 2D6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2D6Homo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
cell surfaceSodium-dependent noradrenaline transporter Homo sapiens (human)
membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
neuronal cell body membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
presynaptic membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
axonSodium-dependent noradrenaline transporter Homo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
endoplasmic reticulum membraneSqualene monooxygenaseHomo sapiens (human)
membraneSqualene monooxygenaseHomo sapiens (human)
intracellular membrane-bounded organelleSqualene monooxygenaseHomo sapiens (human)
endoplasmic reticulumSqualene monooxygenaseHomo sapiens (human)
nuclear envelope3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
endoplasmic reticulum3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
endoplasmic reticulum membrane3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
cytoplasmic vesicle3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
nuclear membrane3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
endoplasmic reticulum3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
nuclear envelopeSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear inner membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear outer membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulum membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
lipid dropletSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytosolSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic densitySigma non-opioid intracellular receptor 1Homo sapiens (human)
membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
growth coneSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytoplasmic vesicleSigma non-opioid intracellular receptor 1Homo sapiens (human)
anchoring junctionSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic density membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (695)

Assay IDTitleYearJournalArticle
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID532043Antifungal activity against Lichtheimia corymbifera clinical isolate after 24 hrs by EUCAST method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Antifungal susceptibility profile of human-pathogenic species of Lichtheimia.
AID519433Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-4420 obtained from nail of patient after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID303381Cytotoxicity against human THP1 cells after 48 hrs2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
In vivo anti-Chagas vinylthio-, vinylsulfinyl-, and vinylsulfonylbenzofuroxan derivatives.
AID563392Antifungal activity against Aspergillus niger isolate CM-3586 obtained from catheter of patient after 48 hrs by EUCAST broth dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID278211Growth inhibition in Saccharomyces cerevisiae KLN1 carrying erg1 pL37P allele at 0.2 ug/ml after 24 hrs at 30 degC2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Characterization of squalene epoxidase of Saccharomyces cerevisiae by applying terbinafine-sensitive variants.
AID530981Antifungal activity against Candida albicans ATCC 200955 after 48 hrs by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID575200Antifungal activity against Cunninghamella bertholletiae UTHSC 05-2275 after 24 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID575461Antifungal activity against 5 x 10'6 CFU/ml Trichophyton quinckeanum B68683 by resazurin based fluorimetry assay2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro profiling of pramiconazole and in vivo evaluation in Microsporum canis dermatitis and Candida albicans vaginitis laboratory models.
AID295700Antifungal activity against Syncephalastrum racemosum ATCC 18192 at 2.5 mg/mL by diffusion agar method2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
N- and S-alpha-l-arabinopyranosyl[1,2,4]triazolo[3,4-b][1,3,4]thiadiazoles. First synthesis and biological evaluation.
AID363982Antifungal activity against Trichophyton mentagrophytes C943 isolate2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
In vitro antifungal activity of polyfunctionalized 2-(hetero)arylquinolines prepared through imino Diels-Alder reactions.
AID563394Antifungal activity against Aspergillus niger isolate CM-3641 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID549317Antifungal activity against Cunninghamella bertholletiae after 48 hrs by microdilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID563397Antifungal activity against Aspergillus niger isolate CM-4213 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID563414Antifungal activity against Aspergillus tubingensis isolate CM-4001 after 48 hrs by EUCAST broth dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID563396Antifungal activity against Aspergillus niger isolate CM-4004 obtained from after 48 hrs by EUCAST broth dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID575465Antifungal activity against 5 x 10'6 CFU/ml Candida kefyr B46120 by resazurin based fluorimetry assay2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro profiling of pramiconazole and in vivo evaluation in Microsporum canis dermatitis and Candida albicans vaginitis laboratory models.
AID575208Antifungal activity against Cunninghamella echinulata UTHSC 01-2298 after 24 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID323064Antifungal activity against Microsporum gypseum C115 by microbroth dilution method2008Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
Antifungal and cytotoxic activities of some N-substituted aniline derivatives bearing a hetaryl fragment.
AID453082Antimicrobial activity against Pseudomonas aeruginosa at 2.5 ug/mL by agar diffusion method2009Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23
Synthesis, tautomerism, and antimicrobial, anti-HCV, anti-SSPE, antioxidant, and antitumor activities of arylazobenzosuberones.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1055721Antifungal activity against Candida tropicalis after 24 to 48 hrs by agar well diffusion method2013European journal of medicinal chemistry, , Volume: 70Solution-phase microwave assisted parallel synthesis of N,N'-disubstituted thioureas derived from benzoic acid: biological evaluation and molecular docking studies.
AID530988Antifungal activity against Candida albicans ATCC 90028 after 48 hrs by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID454775Antifungal activity against Saccharomyces cerevisiae ATCC 9763 after 48 hrs by broth microdilution technique2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
5-Nitrofuranes and 5-nitrothiophenes with anti-Trypanosoma cruzi activity and ability to accumulate squalene.
AID322547Antifungal activity against Trichophyton sp. after 7 days by broth microdilution test2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
In vitro activities of miltefosine and two novel antifungal biscationic salts against a panel of 77 dermatophytes.
AID363717Antifungal activity against Trichophyton rubrum C110 after 48 hrs by broth microdilution technique2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
In vitro antifungal activity of polyfunctionalized 2-(hetero)arylquinolines prepared through imino Diels-Alder reactions.
AID420661Antifungal activity against Cryptococcus neoformans ATCC 32609 after 72 hrs by micro-broth dilution method2009European journal of medicinal chemistry, May, Volume: 44, Issue:5
Design, synthesis, and biological evaluation of novel triazole derivatives as inhibitors of cytochrome P450 14alpha-demethylase.
AID214263In vitro antifungal activity against Trichophyton mentagrophytes expressed as MIC (mg/L)1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
Synthesis and structure-activity relationships of phenyl-substituted benzylamine antimycotics: a novel benzylbenzylamine antifungal agent for systemic treatment.
AID211469In vitro minimum inhibitory concentration at which no signs of fungal growth were detected against laboratory adapted strains of Torulopsis glabrata1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis and structure-activity relationships of benzo[b]thienylallylamine antimycotics.
AID417966Antimicrobial activity against Microsporum gypseum after 48 hrs by broth microdilution technique2009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
Relation between lipophilicity of alkyl gallates and antifungal activity against yeasts and filamentous fungi.
AID532041Antifungal activity against Lichtheimia ramosa clinical isolate after 24 hrs by EUCAST method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Antifungal susceptibility profile of human-pathogenic species of Lichtheimia.
AID91481Binding constant against human serum albumin (HSA)2001Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25
Cheminformatic models to predict binding affinities to human serum albumin.
AID1809907Fungicidal activity against Trichophyton mentagrophytes KCCM60449 at 8 times after 24 hrs by time-kill kinetics assay2021Journal of medicinal chemistry, 11-11, Volume: 64, Issue:21
Optimization and Evaluation of Novel Antifungal Agents for the Treatment of Fungal Infection.
AID575458Antifungal activity against 5 x 10'6 CFU/ml Trichophyton mentagrophytes B70554 by resazurin based fluorimetry assay2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro profiling of pramiconazole and in vivo evaluation in Microsporum canis dermatitis and Candida albicans vaginitis laboratory models.
AID284112Antifungal activity against Trichophyton rubrum C136 after 48 hrs2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
Synthesis and antifungal activity of (Z)-5-arylidenerhodanines.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID470903Antifungal activity against Penicillium italicum at 100 ug after 24 to 48 hrs by diffusion agar technique2009European journal of medicinal chemistry, Sep, Volume: 44, Issue:9
Convenient synthesis and antimicrobial evaluation of some novel 2-substituted-3-methylbenzofuran derivatives.
AID530970Antifungal activity against Fluconazole resistant Candida albicans clinical isolate 1 after 48 hrs by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID343558Antitrypanosomal activity against epimastigotes of Trypanosoma cruzi CL Brener2008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
New trypanocidal hybrid compounds from the association of hydrazone moieties and benzofuroxan heterocycle.
AID322543Antifungal activity against Trichophyton mentagrophytes after 7 days by broth microdilution test2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
In vitro activities of miltefosine and two novel antifungal biscationic salts against a panel of 77 dermatophytes.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID549329Antifungal activity against Apophysomyces spp. after 48 hrs by microdilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID214107In vitro minimum inhibitory concentration (MIC) against isolates of Trichophyton mentagrophytes in Sabouraud's dextrose broth1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Synthesis and antifungal activity of (E)-N-(6,6-dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphtha lenemethanamine (SF 86-327) and related allylamine derivatives with enhanced oral activity.
AID531206Antifungal activity against Candida albicans ATCC 60193 after 48 hrs by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID327198Antifungal activity against Aspergillus fumigatus after 24 hrs by agar diffusion test2008Bioorganic & medicinal chemistry, Apr-15, Volume: 16, Issue:8
Synthesis of new N-phenylpyrazole derivatives with potent antimicrobial activity.
AID415952Antimicrobial activity against Candida tropicalis by micro-broth dilution method2009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
Design, synthesis, and biological evaluation of novel 1-(1H-1,2,4-triazole-1-yl)-2-(2,4-difluorophenyl)-3-substituted benzylamino-2-propanols.
AID1329214Antifungal activity against Candida albicans SC5314 by CLSI broth microdilution method2016Journal of natural products, 09-23, Volume: 79, Issue:9
Heptaketides from an Endolichenic Fungus Biatriospora sp. and Their Antifungal Activity.
AID204348In vitro antifungal activity against Sporothrix schenck ii expressed as MIC (mg/L)1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
Synthesis and structure-activity relationships of phenyl-substituted benzylamine antimycotics: a novel benzylbenzylamine antifungal agent for systemic treatment.
AID530961Antifungal activity against Candida parapsilosis ATCC 22019 after 48 hrs by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID1055722Antifungal activity against Saccharomyces cerevisiae after 24 to 48 hrs by agar well diffusion method2013European journal of medicinal chemistry, , Volume: 70Solution-phase microwave assisted parallel synthesis of N,N'-disubstituted thioureas derived from benzoic acid: biological evaluation and molecular docking studies.
AID249263Minimum inhibitory concentration against Candida species (n=24)2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology.
AID563420Antifungal activity against Aspergillus foetidus isolate CM-4995 obtained from prosthesis after 48 hrs by EUCAST broth dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID278213Increased sensitivity to growth inhibition in Saccharomyces cerevisiae KLN1 carrying erg1 pL37P allele after 24 hrs relative to wild type at 30 degC2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Characterization of squalene epoxidase of Saccharomyces cerevisiae by applying terbinafine-sensitive variants.
AID202241In vitro minimum inhibitory concentration at which no signs of fungal growth were detected against laboratory adapted strains of Scopulariopsis brevicaulis.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis and structure-activity relationships of benzo[b]thienylallylamine antimycotics.
AID415948Antimicrobial activity against Candida krusei by micro-broth dilution method2009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
Design, synthesis, and biological evaluation of novel 1-(1H-1,2,4-triazole-1-yl)-2-(2,4-difluorophenyl)-3-substituted benzylamino-2-propanols.
AID547863Antimicrobial activity against Bacillus subtilis RCMB 101001 at 1 mg/ml by agar diffusion technique2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Efficient synthesis of novel 1,2,4-triazole fused acyclic and 21-28 membered macrocyclic and/or lariat macrocyclic oxaazathia crown compounds with potential antimicrobial activity.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID781329pKa (acid-base dissociation constant) as determined by other workers2014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID515013Antifungal activity against Trichophyton rubrum by micro-broth dilution method2010European journal of medicinal chemistry, Oct, Volume: 45, Issue:10
Synthesis and antifungal evaluation of novel triazole derivatives as inhibitors of cytochrome P450 14alpha-demethylase.
AID284119Antifungal activity against Trichophyton mentagrophytes C738 after 48 hrs2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
Synthesis and antifungal activity of (Z)-5-arylidenerhodanines.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID287716Cytotoxicity against human THP1 cells assessed as reduction of cell viability after 48 hrs2007Bioorganic & medicinal chemistry, Apr-01, Volume: 15, Issue:7
Second generation of 5-ethenylbenzofuroxan derivatives as inhibitors of Trypanosoma cruzi growth: synthesis, biological evaluation, and structure-activity relationships.
AID319757Antimicrobial activity against Fonsecaea compacta isolates2008Bioorganic & medicinal chemistry letters, Jun-01, Volume: 18, Issue:11
Synthesis and SAR studies of biaryloxy-substituted triazoles as antifungal agents.
AID530950Antifungal activity against Trichophyton mentagrophytes ATCC 9533 by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID249330Minimum inhibitory concentration against Aspergillus species (n=8)2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology.
AID515014Antifungal activity against Candida kefyr by micro-broth dilution method2010European journal of medicinal chemistry, Oct, Volume: 45, Issue:10
Synthesis and antifungal evaluation of novel triazole derivatives as inhibitors of cytochrome P450 14alpha-demethylase.
AID714985Antifungal activity against Saccharomyces cerevisiae MYH 500 assessed as growth inhibition in presence of 30 mM sodium fluoride after 9 hrs2012Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9
Fluoride enhances the activity of fungicides that destabilize cell membranes.
AID547864Antimicrobial activity against Bacillus subtilis RCMB 101001 at 2.5 mg/ml by agar diffusion technique2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Efficient synthesis of novel 1,2,4-triazole fused acyclic and 21-28 membered macrocyclic and/or lariat macrocyclic oxaazathia crown compounds with potential antimicrobial activity.
AID323066Antifungal activity against Trichophyton mentagrophytes ATCC 9972 by micro-broth dilution method2008Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
Antifungal and cytotoxic activities of some N-substituted aniline derivatives bearing a hetaryl fragment.
AID548857Antimicrobial activity against Syncephalastrum racemosum at 1 to 5 ug/ml by agar well diffusion method2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Antimicrobial, antitumor and 5α-reductase inhibitor activities of some hydrazonoyl substituted pyrimidinones.
AID322552Antifungal activity against Microsporum sp. after 7 days by broth microdilution test2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
In vitro activities of miltefosine and two novel antifungal biscationic salts against a panel of 77 dermatophytes.
AID687549Antifungal activity against Microsporum gypseum CCC 115 by NCCLS broth microdilution method2012Bioorganic & medicinal chemistry, Oct-15, Volume: 20, Issue:20
Structure-activity relationship study of nitrosopyrimidines acting as antifungal agents.
AID1055724Antifungal activity against Aspergillus niger after 24 to 48 hrs by agar well diffusion method2013European journal of medicinal chemistry, , Volume: 70Solution-phase microwave assisted parallel synthesis of N,N'-disubstituted thioureas derived from benzoic acid: biological evaluation and molecular docking studies.
AID262548Antifungal activity against Candida tropicalis2006Journal of medicinal chemistry, Apr-20, Volume: 49, Issue:8
Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.
AID1067043Antifungal activity against Trichophyton rubrum by micro-broth dilution method2014European journal of medicinal chemistry, Mar-03, Volume: 74Synthesis, antifungal activities and molecular docking studies of novel 2-(2,4-difluorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl dithiocarbamates.
AID575466Antifungal activity against 5 x 10'6 CFU/ml Candida krusei B68404 by resazurin based fluorimetry assay2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro profiling of pramiconazole and in vivo evaluation in Microsporum canis dermatitis and Candida albicans vaginitis laboratory models.
AID1495986Inhibition of Trichophyton rubrum keratinase activity at 10 ug/ml incubated for 5 days under non-shaking condition and subsequent incubation for 5 days under shaking condition by UV-vis spectrophotometric analysis relative to control2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Efficiency of newly prepared thiazole derivatives against some cutaneous fungi.
AID348154Cytotoxicity against mouse J774 cells at 400 uM after 48 hrs by MTT assay2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Synthesis, trypanocidal activity and docking studies of novel quinoxaline-N-acylhydrazones, designed as cruzain inhibitors candidates.
AID696538Antifungal activity against Saccharomyces cerevisiae ATCC 9763 after 48 hrs by broth microdilution technique2012Bioorganic & medicinal chemistry, Nov-01, Volume: 20, Issue:21
Synthesis and antifungal activity of diverse C-2 pyridinyl and pyridinylvinyl substituted quinolines.
AID249273Minimum inhibitory concentration against Trichophyton mentagrophytes (n=20)2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology.
AID29811Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID262547Antifungal activity against Candida parapsilosis2006Journal of medicinal chemistry, Apr-20, Volume: 49, Issue:8
Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID530947Antifungal activity against Trichophyton rubrum ATCC MYA-4438 by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID262552Antifungal activity against Trichophyton rubrum2006Journal of medicinal chemistry, Apr-20, Volume: 49, Issue:8
Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.
AID262549Antifungal activity against Cryptococcus neoformans2006Journal of medicinal chemistry, Apr-20, Volume: 49, Issue:8
Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.
AID415955Antimicrobial activity against Aspergillus fumigatus by micro-broth dilution method2009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
Design, synthesis, and biological evaluation of novel 1-(1H-1,2,4-triazole-1-yl)-2-(2,4-difluorophenyl)-3-substituted benzylamino-2-propanols.
AID530955Antifungal activity against Aspergillus flavus ATCC 204304 after 5 days by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID47885In vitro minimum inhibitory concentration which is the lowest concentration at which no signs of fungal growth were detected against Candida parapsilosis 39.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis and structure-activity relationships of benzo[b]thienylallylamine antimycotics.
AID563411Antifungal activity against Aspergillus niger isolate CM-3551 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID432803Antifungal activity against Sporothrix albicans after 72 hrs by microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro antifungal susceptibilities of five species of sporothrix.
AID510820Antifungal activity against Fusarium oxysporum ATCC 48112 after 24 hrs by AFSTEUCAST assay2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Synthesis and biological evaluation of (+)-labdadienedial, derivatives and precursors from (+)-sclareolide.
AID249335Minimum inhibitory concentration against Trichophyton tonsurans (n=18)2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology.
AID563389Antifungal activity against Aspergillus niger isolate CM-3506 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID1592225Antifungal activity against Candida albicans assessed as reduction in proportion of microbes at cell division phase at 25 to 250 nM/mL by polarizing microscopy2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
Design, synthesis and biological evaluation of amide-pyridine derivatives as novel dual-target (SE, CYP51) antifungal inhibitors.
AID530734Antifungal activity against Candida albicans ATCC 14053 at 68.3 uM after 48 hrs by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID454777Antifungal activity against Aspergillus niger ATCC 9029 after 48 hrs by broth microdilution technique2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
5-Nitrofuranes and 5-nitrothiophenes with anti-Trypanosoma cruzi activity and ability to accumulate squalene.
AID549320Antifungal activity against Rhizomucor pusillus after 24 hrs by microdilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID531183Antifungal activity against Candida albicans ATCC 32354 after 48 hrs by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID530987Antifungal activity against Aspergillus niger ATCC 16404 at 68.3 uM after 48 hrs by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID322542Antifungal activity against Trichophyton rubrum after 7 days by broth microdilution test2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
In vitro activities of miltefosine and two novel antifungal biscationic salts against a panel of 77 dermatophytes.
AID454779Antifungal activity against Aspergillus flavus ATCC 9170 after 48 hrs by broth microdilution technique2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
5-Nitrofuranes and 5-nitrothiophenes with anti-Trypanosoma cruzi activity and ability to accumulate squalene.
AID1112399Fungicidal activity against Zymoseptoria tritici isolate TAG1-18 with 120 bp insertion expressing CYP51 variant with combination of L50S, S188N, I381V, deltaY459/G460 and N513K mutations assessed as fungal growth inhibition2012Pest management science, Jul, Volume: 68, Issue:7
Overexpression of the sterol 14α-demethylase gene (MgCYP51) in Mycosphaerella graminicola isolates confers a novel azole fungicide sensitivity phenotype.
AID530958Antifungal activity against Cryptococcus neoformans ATCC 66031 after 72 hrs by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID519426Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-3538 obtained from sputum of patient after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID563416Antifungal activity against Aspergillus niger isolate CM-4262 after 48 hrs by EUCAST broth dilution method Ophthalmic2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID1592232Inhibition of SE/CYP51 in Candida albicans ATCC SC5314 assessed as effect on sterol composition by measuring Unidentified sterol level at 16 ug/ml incubated for 90 mins by HPLC analysis (Rvb = 16.51%)2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
Design, synthesis and biological evaluation of amide-pyridine derivatives as novel dual-target (SE, CYP51) antifungal inhibitors.
AID322549Antifungal activity against Microsporum canis after 7 days by broth microdilution test2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
In vitro activities of miltefosine and two novel antifungal biscationic salts against a panel of 77 dermatophytes.
AID204640Inhibitory activity against guinea pig Squalene Epoxidase1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Squalene analogues containing isopropylidene mimics as potential inhibitors of pig liver squalene epoxidase and oxidosqualene cyclase.
AID343556Antitrypanosomal activity against epimastigotes of Trypanosoma cruzi Tulahuen 2 at 25 uM relative to control2008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
New trypanocidal hybrid compounds from the association of hydrazone moieties and benzofuroxan heterocycle.
AID453084Antimicrobial activity against Escherichia coli at 2.5 ug/mL by agar diffusion method2009Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23
Synthesis, tautomerism, and antimicrobial, anti-HCV, anti-SSPE, antioxidant, and antitumor activities of arylazobenzosuberones.
AID319756Antimicrobial activity against Microsporum gypseum isolates2008Bioorganic & medicinal chemistry letters, Jun-01, Volume: 18, Issue:11
Synthesis and SAR studies of biaryloxy-substituted triazoles as antifungal agents.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID486240Antifungal activity against Aspergillus niger ATCC 9029 after 48 hrs2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Naftifine-analogues as anti-Trypanosoma cruzi agents.
AID204474In vitro minimum inhibitory concentration (MIC) against isolates of Sporothrix schenck ii in Sabouraud's dextrose broth1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Synthesis and antifungal activity of (E)-N-(6,6-dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphtha lenemethanamine (SF 86-327) and related allylamine derivatives with enhanced oral activity.
AID687550Antifungal activity against Trichophyton rubrum CCC 110 by NCCLS broth microdilution method2012Bioorganic & medicinal chemistry, Oct-15, Volume: 20, Issue:20
Structure-activity relationship study of nitrosopyrimidines acting as antifungal agents.
AID49640Tested in vitro for minimum inhibitory concentration against Candida albicans 91993Journal of medicinal chemistry, Sep-17, Volume: 36, Issue:19
Synthesis and structure-activity relationships of naphthalene-substituted derivatives of the allylamine antimycotic terbinafine.
AID530956Antifungal activity against Aspergillus fumigatus ATCC 90906 after 5 days by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID547860Antimicrobial activity against Pseudomonas aeruginosa RCMB 102002 at 1 mg/ml by agar diffusion technique2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Efficient synthesis of novel 1,2,4-triazole fused acyclic and 21-28 membered macrocyclic and/or lariat macrocyclic oxaazathia crown compounds with potential antimicrobial activity.
AID687503Antifungal activity against Aspergillus flavus ATCC 9170 by NCCLS broth microdilution method2012Bioorganic & medicinal chemistry, Oct-15, Volume: 20, Issue:20
Structure-activity relationship study of nitrosopyrimidines acting as antifungal agents.
AID547846Antimicrobial activity against Aspergillus fumigatus RCMB 002008 at 2.5 mg/ml by agar diffusion technique2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Efficient synthesis of novel 1,2,4-triazole fused acyclic and 21-28 membered macrocyclic and/or lariat macrocyclic oxaazathia crown compounds with potential antimicrobial activity.
AID453076Antimicrobial activity against Escherichia coli at 5 ug/mL by agar diffusion method2009Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23
Synthesis, tautomerism, and antimicrobial, anti-HCV, anti-SSPE, antioxidant, and antitumor activities of arylazobenzosuberones.
AID45151In vitro minimum inhibitory concentration at which no signs of fungal growth were detected against laboratory adapted strains of Candida albicans.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis and structure-activity relationships of benzo[b]thienylallylamine antimycotics.
AID432800Antifungal activity against Sporothrix schenckii after 72 hrs by microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro antifungal susceptibilities of five species of sporothrix.
AID547868Antimicrobial activity against Escherichia coli RCMB 103001 at 5 mg/ml by agar diffusion technique2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Efficient synthesis of novel 1,2,4-triazole fused acyclic and 21-28 membered macrocyclic and/or lariat macrocyclic oxaazathia crown compounds with potential antimicrobial activity.
AID531192Antifungal activity against Trichophyton rubrum ATCC MYA-4438 at 68.3 uM after 5 days by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID510817Antifungal activity against Aspergillus fumigatus ATCC 204305 after 24 hrs by AFSTEUCAST assay2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Synthesis and biological evaluation of (+)-labdadienedial, derivatives and precursors from (+)-sclareolide.
AID417968Antimicrobial activity against Trichophyton rubrum after 48 hrs by broth microdilution technique2009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
Relation between lipophilicity of alkyl gallates and antifungal activity against yeasts and filamentous fungi.
AID519422Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-1290 obtained from sputum of patient after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID420664Antifungal activity against Trichophyton rubrum by micro-broth dilution method2009European journal of medicinal chemistry, May, Volume: 44, Issue:5
Design, synthesis, and biological evaluation of novel triazole derivatives as inhibitors of cytochrome P450 14alpha-demethylase.
AID1592222Antifungal activity against Candida albicans assessed as reduction in cell division at 25 to 250 nM/mL by polarizing microscopy2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
Design, synthesis and biological evaluation of amide-pyridine derivatives as novel dual-target (SE, CYP51) antifungal inhibitors.
AID246926Effective dose was measured in guinea pig infected with Microsporum canis on 7th day2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology.
AID416849Antifungal activity against Trichophyton mentagrophytes DUMC112.02 by CLSI protocol2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Targeting the calcineurin pathway enhances ergosterol biosynthesis inhibitors against Trichophyton mentagrophytes in vitro and in a human skin infection model.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID575463Antifungal activity against 5 x 10'6 CFU/ml Candida albicans B2630 by resazurin based fluorimetry assay2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro profiling of pramiconazole and in vivo evaluation in Microsporum canis dermatitis and Candida albicans vaginitis laboratory models.
AID537734Antifungal activity against yeast AD1-8u expressing Candida albicans CaMdr1p by agar disk diffusion assay2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
AID1067047Antifungal activity against Cryptococcus neoformans after 72 hrs by micro-broth dilution method2014European journal of medicinal chemistry, Mar-03, Volume: 74Synthesis, antifungal activities and molecular docking studies of novel 2-(2,4-difluorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl dithiocarbamates.
AID245222Minimum inhibitory concentration against Candida B66126 parapsilosis by microdilution method2005Bioorganic & medicinal chemistry letters, Jul-15, Volume: 15, Issue:14
Pyrrolo[1,2-a][1,4]benzodiazepine: a novel class of non-azole anti-dermatophyte anti-fungal agents.
AID1157290Antifungal activity against Candida albicans Y0109 assessed as growth inhibition by automatic microplate reader analysis2014Journal of natural products, May-23, Volume: 77, Issue:5
Polyhydroxy cyclohexanols from a Dendrodochium sp. fungus associated with the sea cucumber Holothuria nobilis Selenka.
AID525140Antifungal activity against Fusarium moniliforme clade 2 by microdilution method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
In vitro antifungal susceptibility and molecular characterization of clinical isolates of Fusarium verticillioides (F. moniliforme) and Fusarium thapsinum.
AID1592223Antifungal activity against Candida albicans assessed as induction of microbial cell killing at 25 to 250 nM/mL by polarizing microscopy2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
Design, synthesis and biological evaluation of amide-pyridine derivatives as novel dual-target (SE, CYP51) antifungal inhibitors.
AID515009Antifungal activity against Candida albicans Y0109 after 24 hrs by micro-broth dilution method2010European journal of medicinal chemistry, Oct, Volume: 45, Issue:10
Synthesis and antifungal evaluation of novel triazole derivatives as inhibitors of cytochrome P450 14alpha-demethylase.
AID486233Selectivity index, ratio of ID50 for mouse J774 cells to ID50 for Trypanosoma cruzi Tulahuen 22010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Naftifine-analogues as anti-Trypanosoma cruzi agents.
AID547849Antimicrobial activity against Penicillium italicum RCMB 001018 at 2.5 mg/ml by agar diffusion technique2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Efficient synthesis of novel 1,2,4-triazole fused acyclic and 21-28 membered macrocyclic and/or lariat macrocyclic oxaazathia crown compounds with potential antimicrobial activity.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID454772Selectivity index, ratio of IC50 for mouse J774 cells to ID50 for Trypanosoma cruzi tulahuen 22009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
5-Nitrofuranes and 5-nitrothiophenes with anti-Trypanosoma cruzi activity and ability to accumulate squalene.
AID415949Antimicrobial activity against Candida albicans by micro-broth dilution method2009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
Design, synthesis, and biological evaluation of novel 1-(1H-1,2,4-triazole-1-yl)-2-(2,4-difluorophenyl)-3-substituted benzylamino-2-propanols.
AID45148In vitro minimum inhibitory concentration (MIC) against isolates of Candida albicans in Sabouraud's dextrose broth1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Synthesis and antifungal activity of (E)-N-(6,6-dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphtha lenemethanamine (SF 86-327) and related allylamine derivatives with enhanced oral activity.
AID432801Antifungal activity against Sporothrix globosa after 72 hrs by microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro antifungal susceptibilities of five species of sporothrix.
AID519446Antimicrobial activity against Neosartorya pseudofischeri isolate CNM-CM-4060 obtained from sputum of patient after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID529667Antimicrobial activity against Paecilomyces variotii by microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Susceptibility testing and molecular classification of Paecilomyces spp.
AID363981Antifungal activity against Trichophyton mentagrophytes C539 isolate2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
In vitro antifungal activity of polyfunctionalized 2-(hetero)arylquinolines prepared through imino Diels-Alder reactions.
AID530953Antifungal activity against Trichophyton mentagrophytes ATCC MYA-4439 by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID519549Antimicrobial activity against Aspergillus fumisynnematus isolate CNM-CM-2280 obtained from sputum of patient after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID532046Antifungal activity against Lichtheimia ornata clinical isolate after 48 hrs by EUCAST method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Antifungal susceptibility profile of human-pathogenic species of Lichtheimia.
AID542418Antimicrobial activity against Aspergillus terreus environmental isolate after 48 hrs by EUCAST test2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
In vitro activities of various antifungal drugs against Aspergillus terreus: Global assessment using the methodology of the European committee on antimicrobial susceptibility testing.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID249339Minimum inhibitory concentration against Epidermophyton floccosum (n=12)2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology.
AID566888Antifungal activity against Cladophialophora carrionii by microdilution test2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Synthesis and antifungal activity of some substituted phenothiazines and related compounds.
AID486232Cytotoxicity against mouse J774 cells after 48 hrs by MTT assay2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Naftifine-analogues as anti-Trypanosoma cruzi agents.
AID596528Antifungal activity against Trichophyton rubrum C 113 20002011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Antifungal, cytotoxic and SAR studies of a series of N-alkyl, N-aryl and N-alkylphenyl-1,4-pyrrolediones and related compounds.
AID39694In vitro antifungal activity against Aspergillus fumigatus1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
Synthesis and structure-activity relationships of side-chain-substituted analogs of the allylamine antimycotic terbinafine lacking the central amino function.
AID204513Inhibitory activity against Candida albicans Squalene Epoxidase1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Squalene analogues containing isopropylidene mimics as potential inhibitors of pig liver squalene epoxidase and oxidosqualene cyclase.
AID696541Antifungal activity against Aspergillus flavus ATCC 9170 after 48 hrs by broth microdilution technique2012Bioorganic & medicinal chemistry, Nov-01, Volume: 20, Issue:21
Synthesis and antifungal activity of diverse C-2 pyridinyl and pyridinylvinyl substituted quinolines.
AID510636Antifungal activity against Trichophyton mentagrophytes ATCC 24198 after 24 hrs by AFSTEUCAST assay2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Synthesis and biological evaluation of (+)-labdadienedial, derivatives and precursors from (+)-sclareolide.
AID453074Antimicrobial activity against Pseudomonas aeruginosa at 5 ug/mL by agar diffusion method2009Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23
Synthesis, tautomerism, and antimicrobial, anti-HCV, anti-SSPE, antioxidant, and antitumor activities of arylazobenzosuberones.
AID453077Antimicrobial activity against Aspergillus fumigatus at 2.5 ug/mL by agar diffusion method2009Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23
Synthesis, tautomerism, and antimicrobial, anti-HCV, anti-SSPE, antioxidant, and antitumor activities of arylazobenzosuberones.
AID563410Antifungal activity against Aspergillus tubingensis isolate CM-3177 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID39686In vitro minimum inhibitory concentration which is the lowest concentration at which no signs of fungal growth were detected against Aspergillus fumigatus1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis and structure-activity relationships of benzo[b]thienylallylamine antimycotics.
AID1157295Antifungal activity against Aspergillus fumigatus 07544 assessed as growth inhibition by automatic microplate reader analysis2014Journal of natural products, May-23, Volume: 77, Issue:5
Polyhydroxy cyclohexanols from a Dendrodochium sp. fungus associated with the sea cucumber Holothuria nobilis Selenka.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID566879Antifungal activity against Candida glabrata by microdilution test2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Synthesis and antifungal activity of some substituted phenothiazines and related compounds.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID322546Antifungal activity against Trichophyton violaceum after 7 days by broth microdilution test2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
In vitro activities of miltefosine and two novel antifungal biscationic salts against a panel of 77 dermatophytes.
AID295701Antifungal activity against Syncephalastrum racemosum ATCC 18192 at 1 mg/mL by diffusion agar method2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
N- and S-alpha-l-arabinopyranosyl[1,2,4]triazolo[3,4-b][1,3,4]thiadiazoles. First synthesis and biological evaluation.
AID322544Antifungal activity against Trichophyton tonsurans after 7 days by broth microdilution test2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
In vitro activities of miltefosine and two novel antifungal biscationic salts against a panel of 77 dermatophytes.
AID322548Antifungal activity against Epidermophyton floccosum after 7 days by broth microdilution test2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
In vitro activities of miltefosine and two novel antifungal biscationic salts against a panel of 77 dermatophytes.
AID343559Cytotoxicity against mouse J774 cells after 48 hrs by MTT assay2008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
New trypanocidal hybrid compounds from the association of hydrazone moieties and benzofuroxan heterocycle.
AID453078Antimicrobial activity against Penicillium italicum at 2.5 ug/mL by agar diffusion method2009Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23
Synthesis, tautomerism, and antimicrobial, anti-HCV, anti-SSPE, antioxidant, and antitumor activities of arylazobenzosuberones.
AID295695Antifungal activity against Aspergillus fumigatus ATCC 96918 at 5 mg/mL by diffusion agar method2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
N- and S-alpha-l-arabinopyranosyl[1,2,4]triazolo[3,4-b][1,3,4]thiadiazoles. First synthesis and biological evaluation.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1662683Lipophilicity, log P of the compound2020Journal of medicinal chemistry, 09-24, Volume: 63, Issue:18
Essential Medicinal Chemistry of Essential Medicines.
AID696542Antifungal activity against Aspergillus niger ATCC 9029 after 48 hrs by broth microdilution technique2012Bioorganic & medicinal chemistry, Nov-01, Volume: 20, Issue:21
Synthesis and antifungal activity of diverse C-2 pyridinyl and pyridinylvinyl substituted quinolines.
AID530941Antifungal activity against Trichophyton rubrum ATCC 10218 by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID454771Cytotoxicity against mouse J774 cells after 48 hrs by MTT assay2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
5-Nitrofuranes and 5-nitrothiophenes with anti-Trypanosoma cruzi activity and ability to accumulate squalene.
AID563418Antifungal activity against Aspergillus tubingensis isolate CM-4897 obtained from blood culture after 48 hrs by EUCAST broth dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID1112889Fungicidal activity against Oculimacula acuformis assessed as inhibition of mycelial growth in presence of 10 g glucose incubated at 19 degC in dark for 4 weeks2013Pest management science, Jan, Volume: 69, Issue:1
Fungicide resistance status in French populations of the wheat eyespot fungi Oculimacula acuformis and Oculimacula yallundae.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID302125Antifungal activity against fluconazole-resistant Candida albicans 25 after 24 hrs2007Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22
Synthesis and antifungal activities of novel 2-aminotetralin derivatives.
AID278212Growth inhibition in Saccharomyces cerevisiae KLN1 carrying erg1 pG30S allele at 0.5 ug/ml after 24 hrs at 30 degC2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Characterization of squalene epoxidase of Saccharomyces cerevisiae by applying terbinafine-sensitive variants.
AID1754263Antifungal activity against Cryptococcus neoformans ATCC 32609 by microplate reader assay2021Bioorganic & medicinal chemistry, 07-01, Volume: 41A new sulfated triterpene glycoside from the sea cucumber Colochirus quadrangularis, and evaluation of its antifungal, antitumor and immunomodulatory activities.
AID1196913Fungicidal activity against Trichophyton mentagrophytes B705542015Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3
2-(2-oxo-morpholin-3-yl)-acetamide derivatives as broad-spectrum antifungal agents.
AID204645Inhibitory activity against rat liver Squalene Epoxidase1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Squalene analogues containing isopropylidene mimics as potential inhibitors of pig liver squalene epoxidase and oxidosqualene cyclase.
AID70077In vitro minimum inhibitory concentration (MIC) against isolates of Epidermophyton floccosum in Sabouraud's dextrose broth1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Synthesis and antifungal activity of (E)-N-(6,6-dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphtha lenemethanamine (SF 86-327) and related allylamine derivatives with enhanced oral activity.
AID363980Antifungal activity against Trichophyton mentagrophytes C364 isolate2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
In vitro antifungal activity of polyfunctionalized 2-(hetero)arylquinolines prepared through imino Diels-Alder reactions.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID45150In vitro minimum inhibitory concentration at which no signs of fungal growth were detected against clinically isolated strains of Candida albicans.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis and structure-activity relationships of benzo[b]thienylallylamine antimycotics.
AID249331Minimum inhibitory concentration against Microsporum species (n=38)2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology.
AID563417Antifungal activity against Aspergillus tubingensis isolate CM-4352 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID249332Minimum inhibitory concentration against Trichophyton rubrum (n=14)2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology.
AID239296Affinity for ERG2 of Saccharomyces cerevisiae using [3H]ifenprodil or (+)-[3H]pentazocine radioligand2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Discovery of high-affinity ligands of sigma1 receptor, ERG2, and emopamil binding protein by pharmacophore modeling and virtual screening.
AID454783Increase in squalene biosynthesis in Trypanosoma cruzi tulahuen 2 epimastigotes at ID50 concentration per 8 x 10'6 cells/ml after 120 mins by HPLC analysis (Rvb=0.6 to 2.1 ug/ml)2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
5-Nitrofuranes and 5-nitrothiophenes with anti-Trypanosoma cruzi activity and ability to accumulate squalene.
AID48056Tested in vitro for minimum inhibitory concentration against candida parapsilosis 391994Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5
Synthesis and structure-activity relationships of the novel homopropargylamine antimycotics.
AID486239Antifungal activity against Aspergillus flavus ATCC 9170 after 48 hrs2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Naftifine-analogues as anti-Trypanosoma cruzi agents.
AID519449Antimicrobial activity against Aspergillus viridinutans isolate CNM-CM-4518 obtained from nail of patient after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID575206Antifungal activity against Cunninghamella echinulata FMR 10974 after 24 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID530940Antifungal activity against Candida krusei ATCC 6258 at 68.3 uM after 48 hrs by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID470904Antifungal activity against Syncephalastrum racemosum at 100 ug after 24 to 48 hrs by diffusion agar technique2009European journal of medicinal chemistry, Sep, Volume: 44, Issue:9
Convenient synthesis and antimicrobial evaluation of some novel 2-substituted-3-methylbenzofuran derivatives.
AID319751Antimicrobial activity against Cryptococcus parapsilosis isolates2008Bioorganic & medicinal chemistry letters, Jun-01, Volume: 18, Issue:11
Synthesis and SAR studies of biaryloxy-substituted triazoles as antifungal agents.
AID563407Antifungal activity against Aspergillus tubingensis isolate CM-4688 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID519431Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-4387 obtained from sputum of patient after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID49653In vitro antifungal activity against Candida albicans delta124 expressed as MIC (mg/L)1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
Synthesis and structure-activity relationships of phenyl-substituted benzylamine antimycotics: a novel benzylbenzylamine antifungal agent for systemic treatment.
AID204354Tested in vitro for minimum inhibitory concentration against sporothrix schenck ii1994Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5
Synthesis and structure-activity relationships of the novel homopropargylamine antimycotics.
AID1067046Antifungal activity against Candida parapsilosis by micro-broth dilution method2014European journal of medicinal chemistry, Mar-03, Volume: 74Synthesis, antifungal activities and molecular docking studies of novel 2-(2,4-difluorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl dithiocarbamates.
AID287714Antitrypanosomatid activity against Trypanosoma cruzi CL Brener epimastigotes assessed as reduction of growth after 5 days2007Bioorganic & medicinal chemistry, Apr-01, Volume: 15, Issue:7
Second generation of 5-ethenylbenzofuroxan derivatives as inhibitors of Trypanosoma cruzi growth: synthesis, biological evaluation, and structure-activity relationships.
AID454774Antifungal activity against Candida tropicalis C131-2000 after 48 hrs by broth microdilution technique2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
5-Nitrofuranes and 5-nitrothiophenes with anti-Trypanosoma cruzi activity and ability to accumulate squalene.
AID519429Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-4330 obtained from sputum of patient after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID262557Antifungal activity against Trichophyton mentagrophytes2006Journal of medicinal chemistry, Apr-20, Volume: 49, Issue:8
Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.
AID1216823Metabolic activation assessed as CYP2C9 activation-induced cytotoxicity in human HepG2 cells transfected with human AdCYP2C9 at MOI 10 for 2 days in presence of siScramble at 25 to 100 uM after 24 hrs by ATP assay2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay.
AID303382Selectivity index, ratio of IC50 for human THP1 cells to IC50 for Trypanosoma cruzi Tulahuen 22007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
In vivo anti-Chagas vinylthio-, vinylsulfinyl-, and vinylsulfonylbenzofuroxan derivatives.
AID519447Antimicrobial activity against Neosartorya pseudofischeri isolate CNM-CM-3914 obtained from nail of patient after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID753512Antidermatophytic activity against Microsporum gypseum isolate after 7 days by broth microdilution method2013Bioorganic & medicinal chemistry letters, Jun-15, Volume: 23, Issue:12
Evaluation of bioactivities of chlorokojic acid derivatives against dermatophytes couplet with cytotoxicity.
AID125936In vitro minimum inhibitory concentration which is the lowest concentration at which no signs of fungal growth were detected against Microsporum canis.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis and structure-activity relationships of benzo[b]thienylallylamine antimycotics.
AID696545Antifungal activity against Trichophyton mentagrophytes ATCC 9972 after 48 hrs by broth microdilution technique2012Bioorganic & medicinal chemistry, Nov-01, Volume: 20, Issue:21
Synthesis and antifungal activity of diverse C-2 pyridinyl and pyridinylvinyl substituted quinolines.
AID696539Antifungal activity against Cryptococcus neoformans ATCC 32264 after 48 hrs by broth microdilution technique2012Bioorganic & medicinal chemistry, Nov-01, Volume: 20, Issue:21
Synthesis and antifungal activity of diverse C-2 pyridinyl and pyridinylvinyl substituted quinolines.
AID525141Antifungal activity against Fusarium moniliforme clade 3 by microdilution method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
In vitro antifungal susceptibility and molecular characterization of clinical isolates of Fusarium verticillioides (F. moniliforme) and Fusarium thapsinum.
AID302122Antifungal activity against fluconazole-resistant Candida albicans 0511655 after 24 hrs2007Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22
Synthesis and antifungal activities of novel 2-aminotetralin derivatives.
AID547855Antimicrobial activity against Candida albicans RCMB 005003 at 2.5 mg/ml by agar diffusion technique2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Efficient synthesis of novel 1,2,4-triazole fused acyclic and 21-28 membered macrocyclic and/or lariat macrocyclic oxaazathia crown compounds with potential antimicrobial activity.
AID510637Antifungal activity against Trichophyton rubrum ATCC 28188 after 24 hrs by AFSTEUCAST assay2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Synthesis and biological evaluation of (+)-labdadienedial, derivatives and precursors from (+)-sclareolide.
AID262555Antifungal activity against Trichophyton violaceum2006Journal of medicinal chemistry, Apr-20, Volume: 49, Issue:8
Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.
AID322551Antifungal activity against Microsporum cookei after 7 days by broth microdilution test2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
In vitro activities of miltefosine and two novel antifungal biscationic salts against a panel of 77 dermatophytes.
AID1495984Inhibition of Trichophyton terrestre keratinase activity at 10 ug/ml incubated for 5 days under non-shaking condition and subsequent incubation for 5 days under shaking condition by UV-vis spectrophotometric analysis relative to control2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Efficiency of newly prepared thiazole derivatives against some cutaneous fungi.
AID453085Antimicrobial activity against Aspergillus fumigatus at 1.25 ug/mL by agar diffusion method2009Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23
Synthesis, tautomerism, and antimicrobial, anti-HCV, anti-SSPE, antioxidant, and antitumor activities of arylazobenzosuberones.
AID596529Antifungal activity against Trichophyton mentagrophytes ATCC 99722011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Antifungal, cytotoxic and SAR studies of a series of N-alkyl, N-aryl and N-alkylphenyl-1,4-pyrrolediones and related compounds.
AID1592214Antifungal activity against Candida albicans ATCC 10231 assessed as inhibition of microbial growth by NCCLS protocol based method2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
Design, synthesis and biological evaluation of amide-pyridine derivatives as novel dual-target (SE, CYP51) antifungal inhibitors.
AID1495987Inhibition of Epidermophyton floccosum keratinase activity at 10 ug/ml incubated for 5 days under non-shaking condition and subsequent incubation for 5 days under shaking condition by UV-vis spectrophotometric analysis relative to control2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Efficiency of newly prepared thiazole derivatives against some cutaneous fungi.
AID634087Antifungal activity against Candida albicans assessed as morphogenetic transformation after 3 hrs by phase-contrast microscopy2012European journal of medicinal chemistry, Jan, Volume: 47, Issue:1
Antifungal activities of novel non-azole molecules against S. cerevisiae and C. albicans.
AID415953Antimicrobial activity against Trichophyton rubrum by micro-broth dilution method2009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
Design, synthesis, and biological evaluation of novel 1-(1H-1,2,4-triazole-1-yl)-2-(2,4-difluorophenyl)-3-substituted benzylamino-2-propanols.
AID547862Antimicrobial activity against Pseudomonas aeruginosa RCMB 102002 at 5 mg/ml by agar diffusion technique2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Efficient synthesis of novel 1,2,4-triazole fused acyclic and 21-28 membered macrocyclic and/or lariat macrocyclic oxaazathia crown compounds with potential antimicrobial activity.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1184231Antifungal activity against Aspergillus flavus FCBP 0064 at 40 mg/mL after 7 days by disc diffusion method2014European journal of medicinal chemistry, Sep-12, Volume: 84Potentially bioactive organotin(IV) compounds: synthesis, characterization, in vitro bioactivities and interaction with SS-DNA.
AID1216814Metabolic activation assessed as CYP2C9 activation-induced cytotoxicity in human HepG2 cells transfected with human AdCYP2C9 at MOI 10 for 2 days in presence of siNrf2 at 25 to 100 uM after 24 hrs by WST-8 assay2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay.
AID39698In vitro antifungal activity against Aspergillus fumigatus expressed as MIC (mg/L)1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
Synthesis and structure-activity relationships of phenyl-substituted benzylamine antimycotics: a novel benzylbenzylamine antifungal agent for systemic treatment.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID284116Antifungal activity against Trichophyton mentagrophytes C108 after 48 hrs2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
Synthesis and antifungal activity of (Z)-5-arylidenerhodanines.
AID249329Minimum inhibitory concentration against Candida species (n=24)2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology.
AID537733Binding affinity to Candida albicans CaCdr1p expressed in yeast AD1-8u2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
AID454784Decrease in ergosterol biosynthesis in Trypanosoma cruzi tulahuen 2 epimastigotes at ID50 concentration per 8 x 10'6 cells/ml after 120 mins by HPLC analysis (Rvb=6.8 +/- 0.5 ug/ml)2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
5-Nitrofuranes and 5-nitrothiophenes with anti-Trypanosoma cruzi activity and ability to accumulate squalene.
AID1592228Inhibition of SE/CYP51 in Candida albicans ATCC SC5314 assessed as effect on sterol composition by measuring ergosterol level at 16 ug/ml incubated for 90 mins by HPLC analysis (Rvb = 64.2%)2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
Design, synthesis and biological evaluation of amide-pyridine derivatives as novel dual-target (SE, CYP51) antifungal inhibitors.
AID470902Antifungal activity against Aspergillus niger at 100 ug after 24 to 48 hrs by diffusion agar technique2009European journal of medicinal chemistry, Sep, Volume: 44, Issue:9
Convenient synthesis and antimicrobial evaluation of some novel 2-substituted-3-methylbenzofuran derivatives.
AID675033Inhibition of ergosterol biosynthesis in epimastigotes of Trypanosoma cruzi assessed as ratio of squalene/ergosterol at 25 uM after 24 hrs by TLC analysis (Rvb = 0.76)2012European journal of medicinal chemistry, Sep, Volume: 55Synthesis and biological evaluation of some novel 1-indanone thiazolylhydrazone derivatives as anti-Trypanosoma cruzi agents.
AID519440Antimicrobial activity against Neosartorya hiratsukae isolate CNM-CM-3305 obtained from skin of patient after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID530946Antifungal activity against Candida parapsilosis ATCC 22019 at 68.3 uM after 48 hrs by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID262546Antifungal activity against Candida albicans2006Journal of medicinal chemistry, Apr-20, Volume: 49, Issue:8
Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.
AID575457Antifungal activity against 5 x 10'6 CFU/ml Microsporum canis B68128 by resazurin based fluorimetry assay2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro profiling of pramiconazole and in vivo evaluation in Microsporum canis dermatitis and Candida albicans vaginitis laboratory models.
AID295697Antifungal activity against Penicillium italicum ATCC 48114 at 2.5 mg/mL by diffusion agar method2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
N- and S-alpha-l-arabinopyranosyl[1,2,4]triazolo[3,4-b][1,3,4]thiadiazoles. First synthesis and biological evaluation.
AID287719Ratio of IC50 for human THP1 cells to IC50 for Trypanosoma cruzi Y epimastigotes2007Bioorganic & medicinal chemistry, Apr-01, Volume: 15, Issue:7
Second generation of 5-ethenylbenzofuroxan derivatives as inhibitors of Trypanosoma cruzi growth: synthesis, biological evaluation, and structure-activity relationships.
AID563395Antifungal activity against Aspergillus niger isolate CM-3672 obtained from cutaneous layer of patient after 48 hrs by EUCAST broth dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID249272Minimum inhibitory concentration against Epidermophyton floccosum (n=12)2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology.
AID515015Antifungal activity against Aspergillus fumigatus by micro-broth dilution method2010European journal of medicinal chemistry, Oct, Volume: 45, Issue:10
Synthesis and antifungal evaluation of novel triazole derivatives as inhibitors of cytochrome P450 14alpha-demethylase.
AID303378Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 22007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
In vivo anti-Chagas vinylthio-, vinylsulfinyl-, and vinylsulfonylbenzofuroxan derivatives.
AID287713Antitrypanosomatid activity against Trypanosoma cruzi Tulahuen 2 epimastigotes assessed as reduction of growth after 5 days2007Bioorganic & medicinal chemistry, Apr-01, Volume: 15, Issue:7
Second generation of 5-ethenylbenzofuroxan derivatives as inhibitors of Trypanosoma cruzi growth: synthesis, biological evaluation, and structure-activity relationships.
AID519439Antimicrobial activity against Neosartorya hiratsukae isolate CNM-CM-3303 obtained from skin of patient after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID566889Antifungal activity against Exophiala spinifera by microdilution test2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Synthesis and antifungal activity of some substituted phenothiazines and related compounds.
AID530936Antifungal activity against Candida glabrata ATCC 90030 at 68.3 uM after 48 hrs by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID515010Antifungal activity against Cryptococcus neoformans after 72 hrs by micro-broth dilution method2010European journal of medicinal chemistry, Oct, Volume: 45, Issue:10
Synthesis and antifungal evaluation of novel triazole derivatives as inhibitors of cytochrome P450 14alpha-demethylase.
AID530932Antifungal activity against Fluconazole resistant Candida albicans isolate 17 at 68.3 uM after 48 hrs by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID575459Antifungal activity against 5 x 10'6 CFU/ml Trichophyton rubrum B68183 by resazurin based fluorimetry assay2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro profiling of pramiconazole and in vivo evaluation in Microsporum canis dermatitis and Candida albicans vaginitis laboratory models.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID753514Antidermatophytic activity against Trichophyton mentagrophytes var. erinacei isolate after 7 days by broth microdilution method2013Bioorganic & medicinal chemistry letters, Jun-15, Volume: 23, Issue:12
Evaluation of bioactivities of chlorokojic acid derivatives against dermatophytes couplet with cytotoxicity.
AID519428Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-3599 obtained from sputum of patient after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID239347Affinity for sigma receptor type 1 of guinea pig using [3H]ifenprodil or (+)-[3H]pentazocine radioligand2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Discovery of high-affinity ligands of sigma1 receptor, ERG2, and emopamil binding protein by pharmacophore modeling and virtual screening.
AID519423Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-3134 obtained from sputum of patient after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID322550Antifungal activity against Microsporum gypseum after 7 days by broth microdilution test2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
In vitro activities of miltefosine and two novel antifungal biscationic salts against a panel of 77 dermatophytes.
AID549315Antifungal activity against Mycocladus corymbifer after 48 hrs by microdilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID687548Antifungal activity against Aspergillus niger ATCC 9029 by NCCLS broth microdilution method2012Bioorganic & medicinal chemistry, Oct-15, Volume: 20, Issue:20
Structure-activity relationship study of nitrosopyrimidines acting as antifungal agents.
AID48063Tested in vitro for minimum inhibitory concentration against Candida parapsilosis 391993Journal of medicinal chemistry, Sep-17, Volume: 36, Issue:19
Synthesis and structure-activity relationships of naphthalene-substituted derivatives of the allylamine antimycotic terbinafine.
AID303384Selectivity index, ratio of IC50 for human THP1 cells to IC50 for Trypanosoma cruzi Y2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
In vivo anti-Chagas vinylthio-, vinylsulfinyl-, and vinylsulfonylbenzofuroxan derivatives.
AID1055723Antifungal activity against Aspergillus flavus after 24 to 48 hrs by agar well diffusion method2013European journal of medicinal chemistry, , Volume: 70Solution-phase microwave assisted parallel synthesis of N,N'-disubstituted thioureas derived from benzoic acid: biological evaluation and molecular docking studies.
AID563406Antifungal activity against Aspergillus tubingensis isolate CM-4005 after 48 hrs by EUCAST broth dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID486235Antifungal activity against Candida tropicalis C 131 2000 after 48 hrs2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Naftifine-analogues as anti-Trypanosoma cruzi agents.
AID453073Antimicrobial activity against Staphylococcus aureus at 5 ug/mL by agar diffusion method2009Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23
Synthesis, tautomerism, and antimicrobial, anti-HCV, anti-SSPE, antioxidant, and antitumor activities of arylazobenzosuberones.
AID327197Antibacterial activity against Pseudomonas aeruginosa after 24 hrs by agar diffusion test2008Bioorganic & medicinal chemistry, Apr-15, Volume: 16, Issue:8
Synthesis of new N-phenylpyrazole derivatives with potent antimicrobial activity.
AID245203Minimum inhibitory concentration against Trichophyton rubrum B68183 by microdilution method2005Bioorganic & medicinal chemistry letters, Jul-15, Volume: 15, Issue:14
Pyrrolo[1,2-a][1,4]benzodiazepine: a novel class of non-azole anti-dermatophyte anti-fungal agents.
AID768327Cytotoxicity against african green monkey Vero cells after 48 hrs by MTT assay2013European journal of medicinal chemistry, Sep, Volume: 67Synthesis and antifungal activity of terpenyl-1,4-naphthoquinone and 1,4-anthracenedione derivatives.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID696544Antifungal activity against Trichophyton rubrum CCC 113 after 48 hrs by broth microdilution technique2012Bioorganic & medicinal chemistry, Nov-01, Volume: 20, Issue:21
Synthesis and antifungal activity of diverse C-2 pyridinyl and pyridinylvinyl substituted quinolines.
AID249266Minimum inhibitory concentration against Microsporum species (n=38)2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology.
AID549318Antifungal activity against Rhizopus microsporus after 24 hrs by microdilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID319752Antimicrobial activity against Candida tropicalis isolates2008Bioorganic & medicinal chemistry letters, Jun-01, Volume: 18, Issue:11
Synthesis and SAR studies of biaryloxy-substituted triazoles as antifungal agents.
AID1592229Inhibition of SE/CYP51 in Candida albicans ATCC SC5314 assessed as effect on sterol composition by measuring Eburicol level at 16 ug/ml incubated for 90 mins by HPLC analysis (Rvb = 8.3%)2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
Design, synthesis and biological evaluation of amide-pyridine derivatives as novel dual-target (SE, CYP51) antifungal inhibitors.
AID74014Compound was evaluated in vivo for the activity (% mycological cure) by oral treatment of guinea pig dermatophytosis caused by Trichophyton mentagrophytes. Dose = 10 mg/kg/day1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Synthesis and antifungal activity of (E)-N-(6,6-dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphtha lenemethanamine (SF 86-327) and related allylamine derivatives with enhanced oral activity.
AID781330pKa (acid-base dissociation constant) as determined by potentiometric titration2014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID420666Antifungal activity against Microsporum gypseum by micro-broth dilution method2009European journal of medicinal chemistry, May, Volume: 44, Issue:5
Design, synthesis, and biological evaluation of novel triazole derivatives as inhibitors of cytochrome P450 14alpha-demethylase.
AID1196915Fungicidal activity against Microsporum canis B681282015Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3
2-(2-oxo-morpholin-3-yl)-acetamide derivatives as broad-spectrum antifungal agents.
AID1754262Antifungal activity against Candida albicans ATCC 76615 by microplate reader assay2021Bioorganic & medicinal chemistry, 07-01, Volume: 41A new sulfated triterpene glycoside from the sea cucumber Colochirus quadrangularis, and evaluation of its antifungal, antitumor and immunomodulatory activities.
AID295698Antifungal activity against Penicillium italicum ATCC 48114 at 5 mg/mL by diffusion agar method2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
N- and S-alpha-l-arabinopyranosyl[1,2,4]triazolo[3,4-b][1,3,4]thiadiazoles. First synthesis and biological evaluation.
AID284110Antifungal activity against Trichophyton rubrum C110 after 48 hrs2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
Synthesis and antifungal activity of (Z)-5-arylidenerhodanines.
AID420665Antifungal activity against Candida krusei by micro-broth dilution method2009European journal of medicinal chemistry, May, Volume: 44, Issue:5
Design, synthesis, and biological evaluation of novel triazole derivatives as inhibitors of cytochrome P450 14alpha-demethylase.
AID245170Minimum inhibitory concentration against Microsporum canis B68128 by microdilution method2005Bioorganic & medicinal chemistry letters, Jul-15, Volume: 15, Issue:14
Pyrrolo[1,2-a][1,4]benzodiazepine: a novel class of non-azole anti-dermatophyte anti-fungal agents.
AID49632Tested in vitro for minimum inhibitory concentration against Candida albicans 1241993Journal of medicinal chemistry, Sep-17, Volume: 36, Issue:19
Synthesis and structure-activity relationships of naphthalene-substituted derivatives of the allylamine antimycotic terbinafine.
AID246929Effective dose was measured in guinea pig infected with Microsporum canis on 14th day2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology.
AID303383Selectivity index, ratio of IC50 for human THP1 cells to IC50 for Trypanosoma cruzi CL Brener2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
In vivo anti-Chagas vinylthio-, vinylsulfinyl-, and vinylsulfonylbenzofuroxan derivatives.
AID519424Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-3364 obtained from bronchoalveolar lavage fluid of patient after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID245234Minimum inhibitory concentration against Aspergillus fumigatus B42928 by microdilution method2005Bioorganic & medicinal chemistry letters, Jul-15, Volume: 15, Issue:14
Pyrrolo[1,2-a][1,4]benzodiazepine: a novel class of non-azole anti-dermatophyte anti-fungal agents.
AID363716Antifungal activity against Microsporum gypseum C115 after 48 hrs by broth microdilution technique2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
In vitro antifungal activity of polyfunctionalized 2-(hetero)arylquinolines prepared through imino Diels-Alder reactions.
AID519450Antimicrobial activity against Aspergillus fumigatus ATCC 2004305 after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID249264Minimum inhibitory concentration against Aspergillus species (n=8)2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology.
AID1112397Fungicidal activity against Zymoseptoria tritici isolate TAG74-3 with 120 bp insertion expressing CYP51 variant with combination of L50S, S188N, I381V, deltaY459/G460 and N513K mutations assessed as fungal growth inhibition2012Pest management science, Jul, Volume: 68, Issue:7
Overexpression of the sterol 14α-demethylase gene (MgCYP51) in Mycosphaerella graminicola isolates confers a novel azole fungicide sensitivity phenotype.
AID1196914Fungicidal activity against Trichophyton rubrum B681832015Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3
2-(2-oxo-morpholin-3-yl)-acetamide derivatives as broad-spectrum antifungal agents.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID432802Antifungal activity against Sporothrix mexicana after 72 hrs by microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro antifungal susceptibilities of five species of sporothrix.
AID530952Antifungal activity against Candida tropicalis ATCC 750 at 68.3 uM after 48 hrs by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID563402Antifungal activity against Aspergillus niger isolate CM-5095 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID454782Antifungal activity against Trichophyton mentagrophytes ATCC 9972 after 48 hrs by broth microdilution technique2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
5-Nitrofuranes and 5-nitrothiophenes with anti-Trypanosoma cruzi activity and ability to accumulate squalene.
AID1112400Fungicidal activity against Zymoseptoria tritici isolate V18 with 120 bp insertion expressing CYP51 variant with combination of L50S, S188N, I381V, deltaY459/G460 and N513K mutations assessed as fungal growth inhibition2012Pest management science, Jul, Volume: 68, Issue:7
Overexpression of the sterol 14α-demethylase gene (MgCYP51) in Mycosphaerella graminicola isolates confers a novel azole fungicide sensitivity phenotype.
AID363977Antifungal activity against Trichophyton rubrum C137 isolate2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
In vitro antifungal activity of polyfunctionalized 2-(hetero)arylquinolines prepared through imino Diels-Alder reactions.
AID125937In vitro antifungal activity against Microsporum canis1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
Synthesis and structure-activity relationships of side-chain-substituted analogs of the allylamine antimycotic terbinafine lacking the central amino function.
AID454776Antifungal activity against Cryptococcus neoformans ATCC 32264 after 48 hrs by broth microdilution technique2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
5-Nitrofuranes and 5-nitrothiophenes with anti-Trypanosoma cruzi activity and ability to accumulate squalene.
AID486236Antifungal activity against Saccharomyces cerevisiae ATCC 9763 after 48 hrs2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Naftifine-analogues as anti-Trypanosoma cruzi agents.
AID532045Antifungal activity against Lichtheimia ornata clinical isolate after 24 hrs by EUCAST method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Antifungal susceptibility profile of human-pathogenic species of Lichtheimia.
AID547851Antimicrobial activity against Syncephalastrum racemosum RCMB 016001 at 1 mg/ml by agar diffusion technique2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Efficient synthesis of novel 1,2,4-triazole fused acyclic and 21-28 membered macrocyclic and/or lariat macrocyclic oxaazathia crown compounds with potential antimicrobial activity.
AID125940In vitro antifungal activity against Microsporum canis expressed as MIC (mg/L)1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
Synthesis and structure-activity relationships of phenyl-substituted benzylamine antimycotics: a novel benzylbenzylamine antifungal agent for systemic treatment.
AID432799Antifungal activity against Sporothrix brasiliensis after 72 hrs by microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro antifungal susceptibilities of five species of sporothrix.
AID714984Antifungal activity against Saccharomyces cerevisiae MYH 500 assessed as growth inhibition in presence of 80 mM sodium fluoride after 9 hrs2012Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9
Fluoride enhances the activity of fungicides that destabilize cell membranes.
AID566891Antifungal activity against Exophiala xenobiotica by microdilution test2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Synthesis and antifungal activity of some substituted phenothiazines and related compounds.
AID122903In vitro minimum inhibitory concentration (MIC) against isolates of Microsporum canis in Sabouraud's dextrose broth1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Synthesis and antifungal activity of (E)-N-(6,6-dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphtha lenemethanamine (SF 86-327) and related allylamine derivatives with enhanced oral activity.
AID1157293Antifungal activity against Candida glabrata 537 assessed as growth inhibition by automatic microplate reader analysis2014Journal of natural products, May-23, Volume: 77, Issue:5
Polyhydroxy cyclohexanols from a Dendrodochium sp. fungus associated with the sea cucumber Holothuria nobilis Selenka.
AID39684In vitro minimum inhibitory concentration at which no signs of fungal growth were detected against laboratory adapted strains of Aspergillus fumigatus.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis and structure-activity relationships of benzo[b]thienylallylamine antimycotics.
AID566881Antifungal activity against Candida guilliermondii by microdilution test2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Synthesis and antifungal activity of some substituted phenothiazines and related compounds.
AID519445Antimicrobial activity against Neosartorya pseudofischeri isolate CNM-CM-2270 obtained from sputum of patient after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID48064In vitro antifungal activity against Candida parapsilosis delta39 expressed as MIC (mg/L)1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
Synthesis and structure-activity relationships of phenyl-substituted benzylamine antimycotics: a novel benzylbenzylamine antifungal agent for systemic treatment.
AID204353Tested in vitro for minimum inhibitory concentration against Sporothrix schenck ii1993Journal of medicinal chemistry, Sep-17, Volume: 36, Issue:19
Synthesis and structure-activity relationships of naphthalene-substituted derivatives of the allylamine antimycotic terbinafine.
AID454780Antifungal activity against Microsporum gypseum C 115 after 48 hrs by broth microdilution technique2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
5-Nitrofuranes and 5-nitrothiophenes with anti-Trypanosoma cruzi activity and ability to accumulate squalene.
AID566884Antifungal activity against Aspergillus flavus by microdilution test2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Synthesis and antifungal activity of some substituted phenothiazines and related compounds.
AID1592217Antifungal activity against Candida tropicalis ATCC 1369 assessed as inhibition of microbial growth by NCCLS protocol based method2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
Design, synthesis and biological evaluation of amide-pyridine derivatives as novel dual-target (SE, CYP51) antifungal inhibitors.
AID1067044Antifungal activity against Candida glabrata by micro-broth dilution method2014European journal of medicinal chemistry, Mar-03, Volume: 74Synthesis, antifungal activities and molecular docking studies of novel 2-(2,4-difluorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl dithiocarbamates.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID284115Antifungal activity against Trichophyton rubrum C140 after 48 hrs2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
Synthesis and antifungal activity of (Z)-5-arylidenerhodanines.
AID214261In vitro antifungal activity against Trichophyton mentagrophytes1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
Synthesis and structure-activity relationships of side-chain-substituted analogs of the allylamine antimycotic terbinafine lacking the central amino function.
AID486241Antifungal activity against Microsporum gypseum C 115 after 48 hrs2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Naftifine-analogues as anti-Trypanosoma cruzi agents.
AID530959Antifungal activity against Cryptococcus neoformans ATCC 90113 after 72 hrs by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID519434Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-4426 obtained from sputum of patient after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID470905Antifungal activity against Candida albicans at 100 ug after 24 to 48 hrs by diffusion agar technique2009European journal of medicinal chemistry, Sep, Volume: 44, Issue:9
Convenient synthesis and antimicrobial evaluation of some novel 2-substituted-3-methylbenzofuran derivatives.
AID453070Antimicrobial activity against Penicillium italicum at 5 ug/mL by agar diffusion method2009Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23
Synthesis, tautomerism, and antimicrobial, anti-HCV, anti-SSPE, antioxidant, and antitumor activities of arylazobenzosuberones.
AID547858Antimicrobial activity against Staphylococcus aureus RCMB 106001 at 2.5 mg/ml by agar diffusion technique2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Efficient synthesis of novel 1,2,4-triazole fused acyclic and 21-28 membered macrocyclic and/or lariat macrocyclic oxaazathia crown compounds with potential antimicrobial activity.
AID542417Antimicrobial activity against Aspergillus terreus clinical isolate after 48 hrs by EUCAST test2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
In vitro activities of various antifungal drugs against Aspergillus terreus: Global assessment using the methodology of the European committee on antimicrobial susceptibility testing.
AID547856Antimicrobial activity against Candida albicans RCMB 005003 at 5 mg/ml by agar diffusion technique2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Efficient synthesis of novel 1,2,4-triazole fused acyclic and 21-28 membered macrocyclic and/or lariat macrocyclic oxaazathia crown compounds with potential antimicrobial activity.
AID566890Antifungal activity against Exophiala oligosperma by microdilution test2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Synthesis and antifungal activity of some substituted phenothiazines and related compounds.
AID453086Antimicrobial activity against Penicillium italicum at 1.25 ug/mL by agar diffusion method2009Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23
Synthesis, tautomerism, and antimicrobial, anti-HCV, anti-SSPE, antioxidant, and antitumor activities of arylazobenzosuberones.
AID575207Antifungal activity against Cunninghamella echinulata FMR 10973 after 24 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID363976Antifungal activity against Trichophyton rubrum C136 isolate2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
In vitro antifungal activity of polyfunctionalized 2-(hetero)arylquinolines prepared through imino Diels-Alder reactions.
AID214109In vitro minimum inhibitory concentration which is the lowest concentration at which no signs of fungal growth were detected against Trichophyton mentagrophytes.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis and structure-activity relationships of benzo[b]thienylallylamine antimycotics.
AID323065Antifungal activity against Trichophyton rubrum C113 by microbroth dilution method2008Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
Antifungal and cytotoxic activities of some N-substituted aniline derivatives bearing a hetaryl fragment.
AID519436Antimicrobial activity against Aspergillus fumisynnematus isolate CNM-CM-4063 obtained from bronchoalveolar aspirate of patient after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID453083Antimicrobial activity against Bacillus subtilis at 2.5 ug/mL by agar diffusion method2009Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23
Synthesis, tautomerism, and antimicrobial, anti-HCV, anti-SSPE, antioxidant, and antitumor activities of arylazobenzosuberones.
AID470901Antifungal activity against Aspergillus fumigatus at 100 ug after 24 to 48 hrs by diffusion agar technique2009European journal of medicinal chemistry, Sep, Volume: 44, Issue:9
Convenient synthesis and antimicrobial evaluation of some novel 2-substituted-3-methylbenzofuran derivatives.
AID566885Antifungal activity against Aspergillus niger by microdilution test2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Synthesis and antifungal activity of some substituted phenothiazines and related compounds.
AID753510Antidermatophytic activity against Epidermophyton floccosum isolate after 7 days by broth microdilution method2013Bioorganic & medicinal chemistry letters, Jun-15, Volume: 23, Issue:12
Evaluation of bioactivities of chlorokojic acid derivatives against dermatophytes couplet with cytotoxicity.
AID519448Antimicrobial activity against Aspergillus viridinutans isolate CNM-CM-3147 obtained from oropharyngeal exudate of patient after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID319755Antimicrobial activity against Trichophyton rubrum isolates2008Bioorganic & medicinal chemistry letters, Jun-01, Volume: 18, Issue:11
Synthesis and SAR studies of biaryloxy-substituted triazoles as antifungal agents.
AID575474Tmax in guinea pig infected with 10'6 CFU Microsporum canis B68128 at 10 mg/kg, po administered 2 hrs before infection for 5 days2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro profiling of pramiconazole and in vivo evaluation in Microsporum canis dermatitis and Candida albicans vaginitis laboratory models.
AID530920Antifungal activity against Candida albicans ATCC 90028 at 68.3 uM after 48 hrs by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID1324278Antifungal activity against Candida krusei after 24 hrs by microbroth dilution method2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Structure-activity of antifungal compounds inspired by aminobisabolenes from the sponge Halichondria sp.
AID363975Antifungal activity against Trichophyton rubrum C135 isolate2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
In vitro antifungal activity of polyfunctionalized 2-(hetero)arylquinolines prepared through imino Diels-Alder reactions.
AID566877Antifungal activity against Candida albicans by microdilution test2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Synthesis and antifungal activity of some substituted phenothiazines and related compounds.
AID547857Antimicrobial activity against Staphylococcus aureus RCMB 106001 at 1 mg/ml by agar diffusion technique2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Efficient synthesis of novel 1,2,4-triazole fused acyclic and 21-28 membered macrocyclic and/or lariat macrocyclic oxaazathia crown compounds with potential antimicrobial activity.
AID1324277Antifungal activity against Candida glabrata after 24 hrs by microbroth dilution method2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Structure-activity of antifungal compounds inspired by aminobisabolenes from the sponge Halichondria sp.
AID519443Antimicrobial activity against Neosartorya hiratsukae isolate CNM-CM-4328 obtained from cornea of patient after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID302123Antifungal activity against fluconazole-resistant Candida albicans 01010 after 24 hrs2007Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22
Synthesis and antifungal activities of novel 2-aminotetralin derivatives.
AID319754Antimicrobial activity against Aspergillus fumigatus isolates2008Bioorganic & medicinal chemistry letters, Jun-01, Volume: 18, Issue:11
Synthesis and SAR studies of biaryloxy-substituted triazoles as antifungal agents.
AID1592220Antifungal activity against fluconazole-resistant Candida albicans 103 assessed as inhibition of microbial growth by NCCLS protocol based method2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
Design, synthesis and biological evaluation of amide-pyridine derivatives as novel dual-target (SE, CYP51) antifungal inhibitors.
AID547866Antimicrobial activity against Escherichia coli RCMB 103001 at 1 mg/ml by agar diffusion technique2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Efficient synthesis of novel 1,2,4-triazole fused acyclic and 21-28 membered macrocyclic and/or lariat macrocyclic oxaazathia crown compounds with potential antimicrobial activity.
AID575204Antifungal activity against Cunninghamella bertholletiae UTHSC 06-1945 after 24 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID486243Antifungal activity against Trichophyton mentagrophytes ATCC 9972 after 48 hrs2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Naftifine-analogues as anti-Trypanosoma cruzi agents.
AID1592219Antifungal activity against fluconazole-resistant Candida albicans 100 assessed as inhibition of microbial growth by NCCLS protocol based method2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
Design, synthesis and biological evaluation of amide-pyridine derivatives as novel dual-target (SE, CYP51) antifungal inhibitors.
AID563398Antifungal activity against Aspergillus tubingensis isolate CM-4264 obtained from blood culture after 48 hrs by EUCAST broth dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID547845Antimicrobial activity against Aspergillus fumigatus RCMB 002008 at 1 mg/ml by agar diffusion technique2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Efficient synthesis of novel 1,2,4-triazole fused acyclic and 21-28 membered macrocyclic and/or lariat macrocyclic oxaazathia crown compounds with potential antimicrobial activity.
AID519427Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-3583 obtained from sputum of patient after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID530957Antifungal activity against Aspergillus fumigatus ATCC 204305 after 5 days by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID530975Antifungal activity against Aspergillus fumigatus ATCC 90906 at 68.3 uM after 48 hrs by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID625276FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of most concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID417967Antimicrobial activity against Epidermophyton floccosum after 48 hrs by broth microdilution technique2009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
Relation between lipophilicity of alkyl gallates and antifungal activity against yeasts and filamentous fungi.
AID486234Antifungal activity against Candida albicans ATCC 10231 after 48 hrs2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Naftifine-analogues as anti-Trypanosoma cruzi agents.
AID529668Antimicrobial activity against Paecilomyces lilacinus by microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Susceptibility testing and molecular classification of Paecilomyces spp.
AID563419Antifungal activity against Aspergillus tubingensis isolate CM-4899 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID549313Antifungal activity against Mucor circinelloides after 48 hrs by microdilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID549310Antifungal activity against Rhizopus oryzae after 24 hrs by microdilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID549325Antifungal activity against Cunninghamella spp. after 48 hrs by microdilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID1112402Fungicidal activity against Zymoseptoria tritici isolate R10-13 without 120 bp insertion expressing CYP51 variant with combination of L50S, S188N, I381V, deltaY459/G460 and N513K mutations assessed as fungal growth inhibition2012Pest management science, Jul, Volume: 68, Issue:7
Overexpression of the sterol 14α-demethylase gene (MgCYP51) in Mycosphaerella graminicola isolates confers a novel azole fungicide sensitivity phenotype.
AID486238Antifungal activity against Aspergillus fumigatus ATCC 26934 after 48 hrs2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Naftifine-analogues as anti-Trypanosoma cruzi agents.
AID416850Antifungal activity against Trichophyton mentagrophytes DUMC160.03 by CLSI protocol2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Targeting the calcineurin pathway enhances ergosterol biosynthesis inhibitors against Trichophyton mentagrophytes in vitro and in a human skin infection model.
AID1157297Antifungal activity against Microsporum gypseum Cmccfmza assessed as growth inhibition by automatic microplate reader analysis2014Journal of natural products, May-23, Volume: 77, Issue:5
Polyhydroxy cyclohexanols from a Dendrodochium sp. fungus associated with the sea cucumber Holothuria nobilis Selenka.
AID696537Antifungal activity against Candida albicans ATCC 10231 after 48 hrs by broth microdilution technique2012Bioorganic & medicinal chemistry, Nov-01, Volume: 20, Issue:21
Synthesis and antifungal activity of diverse C-2 pyridinyl and pyridinylvinyl substituted quinolines.
AID566882Antifungal activity against Cryptococcus neoformans by microdilution test2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Synthesis and antifungal activity of some substituted phenothiazines and related compounds.
AID278210Growth inhibition in Saccharomyces cerevisiae KLN1 carrying erg1 pR269G allele at 1 ug/ml after 24 hrs st 30 degC2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Characterization of squalene epoxidase of Saccharomyces cerevisiae by applying terbinafine-sensitive variants.
AID1112404Fungicidal activity against Zymoseptoria tritici isolate R03-29 without 120 bp insertion expressing CYP51 variant with combination of L50S, S188N, I381V, deltaY459/G460 and N513K mutations assessed as fungal growth inhibition2012Pest management science, Jul, Volume: 68, Issue:7
Overexpression of the sterol 14α-demethylase gene (MgCYP51) in Mycosphaerella graminicola isolates confers a novel azole fungicide sensitivity phenotype.
AID596527Antifungal activity against Microsporum gypseum C 115 20002011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Antifungal, cytotoxic and SAR studies of a series of N-alkyl, N-aryl and N-alkylphenyl-1,4-pyrrolediones and related compounds.
AID1067048Antifungal activity against Candida albicans SC5314 after 24 hrs by micro-broth dilution method2014European journal of medicinal chemistry, Mar-03, Volume: 74Synthesis, antifungal activities and molecular docking studies of novel 2-(2,4-difluorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl dithiocarbamates.
AID519438Antimicrobial activity against Aspergillus fumisynnematus isolate CNM-CM-3227 obtained from bronchoalveolar lavage fluid of patient after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID45153In vitro minimum inhibitory concentration which is the lowest concentration at which no signs of fungal growth were detected against Candida albicans 1241991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis and structure-activity relationships of benzo[b]thienylallylamine antimycotics.
AID530924Antifungal activity against Candida albicans ATCC 200955 at 68.3 uM after 48 hrs by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID1809906Fungicidal activity against Trichophyton rubrum KCCM60450 at 8 times after 24 hrs by time-kill kinetics assay2021Journal of medicinal chemistry, 11-11, Volume: 64, Issue:21
Optimization and Evaluation of Novel Antifungal Agents for the Treatment of Fungal Infection.
AID486237Antifungal activity against Cryptococcus neoformans ATCC 32264 after 48 hrs2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Naftifine-analogues as anti-Trypanosoma cruzi agents.
AID525139Antifungal activity against Fusarium moniliforme clade 1 by microdilution method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
In vitro antifungal susceptibility and molecular characterization of clinical isolates of Fusarium verticillioides (F. moniliforme) and Fusarium thapsinum.
AID563412Antifungal activity against Aspergillus tubingensis isolate CM-3654 obtained from blood culture after 48 hrs by EUCAST broth dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID322545Antifungal activity against Trichophyton soudanense after 7 days by broth microdilution test2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
In vitro activities of miltefosine and two novel antifungal biscationic salts against a panel of 77 dermatophytes.
AID575475Half life in guinea pig infected with 10'6 CFU Microsporum canis B68128 at 10 mg/kg, po administered 2 hrs before infection for 5 days2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro profiling of pramiconazole and in vivo evaluation in Microsporum canis dermatitis and Candida albicans vaginitis laboratory models.
AID420660Antifungal activity against Candida albicans ATCC 76615 after 24 hrs by micro-broth dilution method2009European journal of medicinal chemistry, May, Volume: 44, Issue:5
Design, synthesis, and biological evaluation of novel triazole derivatives as inhibitors of cytochrome P450 14alpha-demethylase.
AID454781Antifungal activity against Trichophyton rubrum C113 after 48 hrs by broth microdilution technique2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
5-Nitrofuranes and 5-nitrothiophenes with anti-Trypanosoma cruzi activity and ability to accumulate squalene.
AID768330Antifungal activity against Trichophyton rubrum ATCC 28188 after 6 days2013European journal of medicinal chemistry, Sep, Volume: 67Synthesis and antifungal activity of terpenyl-1,4-naphthoquinone and 1,4-anthracenedione derivatives.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID530742Antifungal activity against Candida albicans ATCC 32354 at 68.3 uM after 48 hrs by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID1525574Activation of human TASK3 expressed in human tsA201 cells at 1 uM by whole cell patch clamp assay relative to control2019Journal of medicinal chemistry, 11-27, Volume: 62, Issue:22
TASK Channels Pharmacology: New Challenges in Drug Design.
AID753513Antidermatophytic activity against Microsporum gypseum NCPF 580 after 7 days by broth microdilution method2013Bioorganic & medicinal chemistry letters, Jun-15, Volume: 23, Issue:12
Evaluation of bioactivities of chlorokojic acid derivatives against dermatophytes couplet with cytotoxicity.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID530960Antifungal activity against Candida tropicalis ATCC 750 after 48 hrs by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID249344Minimum inhibitory concentration against Trichophyton mentagrophytes (n=20)2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology.
AID214285Tested in vitro for minimum inhibitory concentration against Trichophyton mentagrophytes1994Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5
Synthesis and structure-activity relationships of the novel homopropargylamine antimycotics.
AID696540Antifungal activity against Aspergillus fumigatus ATCC 26934 after 48 hrs by broth microdilution technique2012Bioorganic & medicinal chemistry, Nov-01, Volume: 20, Issue:21
Synthesis and antifungal activity of diverse C-2 pyridinyl and pyridinylvinyl substituted quinolines.
AID1184229Antifungal activity against Aspergillus niger FCBP 0198 at 40 mg/mL after 7 days by disc diffusion method2014European journal of medicinal chemistry, Sep-12, Volume: 84Potentially bioactive organotin(IV) compounds: synthesis, characterization, in vitro bioactivities and interaction with SS-DNA.
AID575202Antifungal activity against Cunninghamella bertholletiae UTHSC 04-2581 after 24 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID262558Antifungal activity against Epidermophyton floccosum2006Journal of medicinal chemistry, Apr-20, Volume: 49, Issue:8
Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.
AID563387Antifungal activity against Aspergillus niger isolate CM-3236 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID1184230Antifungal activity against Aspergillus fumigatus FCBP 66 at 40 mg/mL after 7 days by disc diffusion method2014European journal of medicinal chemistry, Sep-12, Volume: 84Potentially bioactive organotin(IV) compounds: synthesis, characterization, in vitro bioactivities and interaction with SS-DNA.
AID204478In vitro minimum inhibitory concentration which is the lowest concentration at which no signs of fungal growth were detected against Sporothrix schenckii ii.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis and structure-activity relationships of benzo[b]thienylallylamine antimycotics.
AID530954Antifungal activity against Aspergillus niger ATCC 16404 after 5 days by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID47891In vitro antifungal activity against Candida parapsilosis 391995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
Synthesis and structure-activity relationships of side-chain-substituted analogs of the allylamine antimycotic terbinafine lacking the central amino function.
AID548641Antimicrobial activity against Aspergillus fumigatus at 1 to 5 ug/ml by agar well diffusion method2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Antimicrobial, antitumor and 5α-reductase inhibitor activities of some hydrazonoyl substituted pyrimidinones.
AID696543Antifungal activity against Microsporum gypseum CCC 115 after 48 hrs by broth microdilution technique2012Bioorganic & medicinal chemistry, Nov-01, Volume: 20, Issue:21
Synthesis and antifungal activity of diverse C-2 pyridinyl and pyridinylvinyl substituted quinolines.
AID563390Antifungal activity against Aspergillus tubingensis isolate CM-3507 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID566880Antifungal activity against Candida krusei by microdilution test2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Synthesis and antifungal activity of some substituted phenothiazines and related compounds.
AID1592218Antifungal activity against Aspergillus fumigatus KM8001 assessed as inhibition of microbial growth by NCCLS protocol based method2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
Design, synthesis and biological evaluation of amide-pyridine derivatives as novel dual-target (SE, CYP51) antifungal inhibitors.
AID284113Antifungal activity against Trichophyton rubrum C137 after 48 hrs2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
Synthesis and antifungal activity of (Z)-5-arylidenerhodanines.
AID246892Effective dose was measured in mice infected with Trichophyton mentagrophytes2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology.
AID515011Antifungal activity against Candida parapsilosis by micro-broth dilution method2010European journal of medicinal chemistry, Oct, Volume: 45, Issue:10
Synthesis and antifungal evaluation of novel triazole derivatives as inhibitors of cytochrome P450 14alpha-demethylase.
AID249271Minimum inhibitory concentration against Trichophyton tonsurans (n=18)2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology.
AID319753Antimicrobial activity against Cryptococcus neoformans ATCC 326092008Bioorganic & medicinal chemistry letters, Jun-01, Volume: 18, Issue:11
Synthesis and SAR studies of biaryloxy-substituted triazoles as antifungal agents.
AID1112888Fungicidal activity against Oculimacula yallundae assessed as inhibition of mycelial growth in presence of 10 g glucose incubated at 19 degC in dark for 4 weeks2013Pest management science, Jan, Volume: 69, Issue:1
Fungicide resistance status in French populations of the wheat eyespot fungi Oculimacula acuformis and Oculimacula yallundae.
AID262556Antifungal activity against Microsporum lanosum2006Journal of medicinal chemistry, Apr-20, Volume: 49, Issue:8
Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.
AID537735Binding affinity to Candida albicans CaMdr1p expressed in yeast AD1-8u2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
AID549323Antifungal activity against Rhizomucor variabilis after 48 hrs by microdilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID453072Antimicrobial activity against Candida albicans at 5 ug/mL by agar diffusion method2009Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23
Synthesis, tautomerism, and antimicrobial, anti-HCV, anti-SSPE, antioxidant, and antitumor activities of arylazobenzosuberones.
AID343557Antitrypanosomal activity against epimastigotes of Trypanosoma cruzi Tulahuen 22008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
New trypanocidal hybrid compounds from the association of hydrazone moieties and benzofuroxan heterocycle.
AID549311Antifungal activity against Rhizopus oryzae after 48 hrs by microdilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID453090Antimicrobial activity against Pseudomonas aeruginosa at 1.25 ug/mL by agar diffusion method2009Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23
Synthesis, tautomerism, and antimicrobial, anti-HCV, anti-SSPE, antioxidant, and antitumor activities of arylazobenzosuberones.
AID287718Ratio of IC50 for human THP1 cells to IC50 for Trypanosoma cruzi CL Brener epimastigotes2007Bioorganic & medicinal chemistry, Apr-01, Volume: 15, Issue:7
Second generation of 5-ethenylbenzofuroxan derivatives as inhibitors of Trypanosoma cruzi growth: synthesis, biological evaluation, and structure-activity relationships.
AID125943Tested in vitro for minimum inhibitory concentration against Microsporum canis1993Journal of medicinal chemistry, Sep-17, Volume: 36, Issue:19
Synthesis and structure-activity relationships of naphthalene-substituted derivatives of the allylamine antimycotic terbinafine.
AID497819Antifungal activity against Fusarium sp. clinical isolates after 48 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
In vitro activity of thimerosal against ocular pathogenic fungi.
AID566883Antifungal activity against Aspergillus fumigates by microdilution test2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Synthesis and antifungal activity of some substituted phenothiazines and related compounds.
AID753511Antidermatophytic activity against Epidermophyton floccosum RSKK 3027 after 7 days by broth microdilution method2013Bioorganic & medicinal chemistry letters, Jun-15, Volume: 23, Issue:12
Evaluation of bioactivities of chlorokojic acid derivatives against dermatophytes couplet with cytotoxicity.
AID532044Antifungal activity against Lichtheimia corymbifera clinical isolate after 48 hrs by EUCAST method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Antifungal susceptibility profile of human-pathogenic species of Lichtheimia.
AID547859Antimicrobial activity against Staphylococcus aureus RCMB 106001 at 5 mg/ml by agar diffusion technique2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Efficient synthesis of novel 1,2,4-triazole fused acyclic and 21-28 membered macrocyclic and/or lariat macrocyclic oxaazathia crown compounds with potential antimicrobial activity.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID701441Antifungal activity against Cryptococcus neoformans after 72 hrs by NCCLS broth microdilution method2012Bioorganic & medicinal chemistry, Oct-01, Volume: 20, Issue:19
The biology and chemistry of antifungal agents: a review.
AID532042Antifungal activity against Lichtheimia ramosa clinical isolate after 48 hrs by EUCAST method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Antifungal susceptibility profile of human-pathogenic species of Lichtheimia.
AID1067045Antifungal activity against Aspergillus fumigatus by micro-broth dilution method2014European journal of medicinal chemistry, Mar-03, Volume: 74Synthesis, antifungal activities and molecular docking studies of novel 2-(2,4-difluorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl dithiocarbamates.
AID687504Antifungal activity against Aspergillus fumigatus ATCC 26934 by NCCLS broth microdilution method2012Bioorganic & medicinal chemistry, Oct-15, Volume: 20, Issue:20
Structure-activity relationship study of nitrosopyrimidines acting as antifungal agents.
AID781326pKa (acid-base dissociation constant) as determined by Avdeef ref: DOI: 10.1002/047145026X2014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID415951Antimicrobial activity against Candida parapsilosis by micro-broth dilution method2009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
Design, synthesis, and biological evaluation of novel 1-(1H-1,2,4-triazole-1-yl)-2-(2,4-difluorophenyl)-3-substituted benzylamino-2-propanols.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID416851Toxicity to human skin assessed as damage of skin integrity at 2 fold MIC administered 30 mins post inoculation followed by once in every 2 days for 7 days by scanning electron microscopy2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Targeting the calcineurin pathway enhances ergosterol biosynthesis inhibitors against Trichophyton mentagrophytes in vitro and in a human skin infection model.
AID519430Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-4370 obtained from sputum of patient after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID575464Antifungal activity against 5 x 10'6 CFU/ml Candida glabrata B63155 by resazurin based fluorimetry assay2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro profiling of pramiconazole and in vivo evaluation in Microsporum canis dermatitis and Candida albicans vaginitis laboratory models.
AID563388Antifungal activity against Aspergillus niger isolate CM-3257 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID1112890Selectivity index, ratio of EC50 for Oculimacula acuformis to EC50 for Oculimacula yallundae by germ tube elongation inhibition assay2013Pest management science, Jan, Volume: 69, Issue:1
Fungicide resistance status in French populations of the wheat eyespot fungi Oculimacula acuformis and Oculimacula yallundae.
AID547867Antimicrobial activity against Escherichia coli RCMB 103001 at 2.5 mg/ml by agar diffusion technique2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Efficient synthesis of novel 1,2,4-triazole fused acyclic and 21-28 membered macrocyclic and/or lariat macrocyclic oxaazathia crown compounds with potential antimicrobial activity.
AID262550Antifungal activity against Aspergillus fumigatus2006Journal of medicinal chemistry, Apr-20, Volume: 49, Issue:8
Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.
AID1592226Antifungal activity against Candida albicans assessed as inhibition of microbial growth at 2.5 nM/mL by polarizing microscopy2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
Design, synthesis and biological evaluation of amide-pyridine derivatives as novel dual-target (SE, CYP51) antifungal inhibitors.
AID249269Minimum inhibitory concentration against Trichophyton species (n=80)2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology.
AID348155Cytotoxicity against mouse J774 cells after 48 hrs by MTT assay2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Synthesis, trypanocidal activity and docking studies of novel quinoxaline-N-acylhydrazones, designed as cruzain inhibitors candidates.
AID453088Antimicrobial activity against Candida albicans at 1.25 ug/mL by agar diffusion method2009Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23
Synthesis, tautomerism, and antimicrobial, anti-HCV, anti-SSPE, antioxidant, and antitumor activities of arylazobenzosuberones.
AID525142Antifungal activity against Fusarium thapsinum by microdilution method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
In vitro antifungal susceptibility and molecular characterization of clinical isolates of Fusarium verticillioides (F. moniliforme) and Fusarium thapsinum.
AID515012Antifungal activity against Candida tropicalis by micro-broth dilution method2010European journal of medicinal chemistry, Oct, Volume: 45, Issue:10
Synthesis and antifungal evaluation of novel triazole derivatives as inhibitors of cytochrome P450 14alpha-demethylase.
AID549312Antifungal activity against Mucor circinelloides after 24 hrs by microdilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID302124Antifungal activity against fluconazole-resistant Candida albicans 18 after 24 hrs2007Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22
Synthesis and antifungal activities of novel 2-aminotetralin derivatives.
AID549326Antifungal activity against Actinomucor spp. after 24 hrs by microdilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID343560Selectivity index, ratio of IC50 for mouse J774 cells to IC50 for epimastigotes of Trypanosoma cruzi Tulahuen 22008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
New trypanocidal hybrid compounds from the association of hydrazone moieties and benzofuroxan heterocycle.
AID327199Antifungal activity against Candida albicans after 24 hrs by agar diffusion test2008Bioorganic & medicinal chemistry, Apr-15, Volume: 16, Issue:8
Synthesis of new N-phenylpyrazole derivatives with potent antimicrobial activity.
AID563409Antifungal activity against Aspergillus tubingensis isolate CM-3125 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID49654In vitro antifungal activity against Candida albicans delta9 expressed as MIC (mg/L)1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
Synthesis and structure-activity relationships of phenyl-substituted benzylamine antimycotics: a novel benzylbenzylamine antifungal agent for systemic treatment.
AID563413Antifungal activity against Aspergillus tubingensis isolate CM-4000 after 48 hrs by EUCAST broth dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID453071Antimicrobial activity against Syncephalastrum racemosum at 5 ug/mL by agar diffusion method2009Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23
Synthesis, tautomerism, and antimicrobial, anti-HCV, anti-SSPE, antioxidant, and antitumor activities of arylazobenzosuberones.
AID768329Selectivity index, ratio of IC50 for african green monkey Vero cells to IC50 for Trichophyton rubrum ATCC 281882013European journal of medicinal chemistry, Sep, Volume: 67Synthesis and antifungal activity of terpenyl-1,4-naphthoquinone and 1,4-anthracenedione derivatives.
AID768331Antifungal activity against Trichophyton mentagrophytes ATCC 24198 after 6 days2013European journal of medicinal chemistry, Sep, Volume: 67Synthesis and antifungal activity of terpenyl-1,4-naphthoquinone and 1,4-anthracenedione derivatives.
AID563393Antifungal activity against Aspergillus niger isolate CM-3636 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID415954Antimicrobial activity against Microsporum gypseum by micro-broth dilution method2009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
Design, synthesis, and biological evaluation of novel 1-(1H-1,2,4-triazole-1-yl)-2-(2,4-difluorophenyl)-3-substituted benzylamino-2-propanols.
AID287715Antitrypanosomatid activity against Trypanosoma cruzi Y epimastigotes assessed as reduction of growth after 5 days2007Bioorganic & medicinal chemistry, Apr-01, Volume: 15, Issue:7
Second generation of 5-ethenylbenzofuroxan derivatives as inhibitors of Trypanosoma cruzi growth: synthesis, biological evaluation, and structure-activity relationships.
AID547848Antimicrobial activity against Penicillium italicum RCMB 001018 at 1 mg/ml by agar diffusion technique2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Efficient synthesis of novel 1,2,4-triazole fused acyclic and 21-28 membered macrocyclic and/or lariat macrocyclic oxaazathia crown compounds with potential antimicrobial activity.
AID453079Antimicrobial activity against Syncephalastrum racemosum at 2.5 ug/mL by agar diffusion method2009Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23
Synthesis, tautomerism, and antimicrobial, anti-HCV, anti-SSPE, antioxidant, and antitumor activities of arylazobenzosuberones.
AID249333Minimum inhibitory concentration against Trichophyton species (n=80)2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology.
AID519444Antimicrobial activity against Neosartorya pseudofischeri isolate CNM-CM-3769 obtained from sputum of patient after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID563399Antifungal activity against Aspergillus tubingensis isolate CM-4296 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID563405Antifungal activity against Aspergillus tubingensis isolate CM-4003 after 48 hrs by EUCAST broth dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID753515Antidermatophytic activity against Trichophyton mentagrophytes var. erinacei NCPF 375 after 7 days by broth microdilution method2013Bioorganic & medicinal chemistry letters, Jun-15, Volume: 23, Issue:12
Evaluation of bioactivities of chlorokojic acid derivatives against dermatophytes couplet with cytotoxicity.
AID547847Antimicrobial activity against Aspergillus fumigatus RCMB 002008 at 5 mg/ml by agar diffusion technique2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Efficient synthesis of novel 1,2,4-triazole fused acyclic and 21-28 membered macrocyclic and/or lariat macrocyclic oxaazathia crown compounds with potential antimicrobial activity.
AID549321Antifungal activity against Rhizomucor pusillus after 48 hrs by microdilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID245293Minimum inhibitory concentration against Trichophyton mentagrophytes B70554 by microdilution method2005Bioorganic & medicinal chemistry letters, Jul-15, Volume: 15, Issue:14
Pyrrolo[1,2-a][1,4]benzodiazepine: a novel class of non-azole anti-dermatophyte anti-fungal agents.
AID415950Antimicrobial activity against Cryptococcus neoformans by micro-broth dilution method2009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
Design, synthesis, and biological evaluation of novel 1-(1H-1,2,4-triazole-1-yl)-2-(2,4-difluorophenyl)-3-substituted benzylamino-2-propanols.
AID420663Antifungal activity against Candida tropicalis by micro-broth dilution method2009European journal of medicinal chemistry, May, Volume: 44, Issue:5
Design, synthesis, and biological evaluation of novel triazole derivatives as inhibitors of cytochrome P450 14alpha-demethylase.
AID1495985Inhibition of Microsporum gypseum keratinase activity at 10 ug/ml incubated for 5 days under non-shaking condition and subsequent incubation for 5 days under shaking condition by UV-vis spectrophotometric analysis relative to control2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Efficiency of newly prepared thiazole derivatives against some cutaneous fungi.
AID547850Antimicrobial activity against Penicillium italicum RCMB 001018 at 5 mg/ml by agar diffusion technique2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Efficient synthesis of novel 1,2,4-triazole fused acyclic and 21-28 membered macrocyclic and/or lariat macrocyclic oxaazathia crown compounds with potential antimicrobial activity.
AID1112403Fungicidal activity against Zymoseptoria tritici isolate R03-54 without 120 bp insertion expressing CYP51 variant with combination of L50S, S188N, I381V, deltaY459/G460 and N513K mutations assessed as fungal growth inhibition2012Pest management science, Jul, Volume: 68, Issue:7
Overexpression of the sterol 14α-demethylase gene (MgCYP51) in Mycosphaerella graminicola isolates confers a novel azole fungicide sensitivity phenotype.
AID687551Antifungal activity against Trichophyton mentagrophytes ATCC 9972 by NCCLS broth microdilution method2012Bioorganic & medicinal chemistry, Oct-15, Volume: 20, Issue:20
Structure-activity relationship study of nitrosopyrimidines acting as antifungal agents.
AID563415Antifungal activity against Aspergillus foetidus isolate CM-4002 after 48 hrs by EUCAST broth dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID603953In-vivo plasma to lung partition coefficients of the compound, logP(lung) in rat2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
AID287717Ratio of IC50 for human THP1 cells to IC50 for Trypanosoma cruzi Tulahuen 2 epimastigotes2007Bioorganic & medicinal chemistry, Apr-01, Volume: 15, Issue:7
Second generation of 5-ethenylbenzofuroxan derivatives as inhibitors of Trypanosoma cruzi growth: synthesis, biological evaluation, and structure-activity relationships.
AID563400Antifungal activity against Aspergillus niger isolate CM-4316 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID1324275Antifungal activity against Candida albicans ATCC 14503 after 24 hrs by microbroth dilution method2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Structure-activity of antifungal compounds inspired by aminobisabolenes from the sponge Halichondria sp.
AID537736Antifungal activity against yeast AD1-8u expressing Candida albicans CaCdr1p by agar disk diffusion assay2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
AID39856Tested in vitro for minimum inhibitory concentration against Aspergillus fumigatus1994Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5
Synthesis and structure-activity relationships of the novel homopropargylamine antimycotics.
AID420662Antifungal activity against Candida parapsilosis by micro-broth dilution method2009European journal of medicinal chemistry, May, Volume: 44, Issue:5
Design, synthesis, and biological evaluation of novel triazole derivatives as inhibitors of cytochrome P450 14alpha-demethylase.
AID687501Antifungal activity against Candida tropicalis after 48 hrs by NCCLS broth microdilution method2012Bioorganic & medicinal chemistry, Oct-15, Volume: 20, Issue:20
Structure-activity relationship study of nitrosopyrimidines acting as antifungal agents.
AID548858Antimicrobial activity against Candida albicans at 1 to 5 ug/ml by agar well diffusion method2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Antimicrobial, antitumor and 5α-reductase inhibitor activities of some hydrazonoyl substituted pyrimidinones.
AID453081Antimicrobial activity against Staphylococcus aureus at 2.5 ug/mL by agar diffusion method2009Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23
Synthesis, tautomerism, and antimicrobial, anti-HCV, anti-SSPE, antioxidant, and antitumor activities of arylazobenzosuberones.
AID1112892Fungicidal activity against Oculimacula acuformis assessed as inhibition of germ tube elongation incubated at 19 degC in dark for 48 hr2013Pest management science, Jan, Volume: 69, Issue:1
Fungicide resistance status in French populations of the wheat eyespot fungi Oculimacula acuformis and Oculimacula yallundae.
AID363718Antifungal activity against Trichophyton mentagrophytes ATCC 9972 after 48 hrs by broth microdilution technique2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
In vitro antifungal activity of polyfunctionalized 2-(hetero)arylquinolines prepared through imino Diels-Alder reactions.
AID214284Tested in vitro for minimum inhibitory concentration against Trichophyton mentagrophytes1993Journal of medicinal chemistry, Sep-17, Volume: 36, Issue:19
Synthesis and structure-activity relationships of naphthalene-substituted derivatives of the allylamine antimycotic terbinafine.
AID420667Antifungal activity against Aspergillus fumigatus by micro-broth dilution method2009European journal of medicinal chemistry, May, Volume: 44, Issue:5
Design, synthesis, and biological evaluation of novel triazole derivatives as inhibitors of cytochrome P450 14alpha-demethylase.
AID262551Antifungal activity against Fonsecaea pedrosoi2006Journal of medicinal chemistry, Apr-20, Volume: 49, Issue:8
Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.
AID575205Antifungal activity against Cunninghamella echinulata UTHSC 03-3725 after 24 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID1157292Antifungal activity against Candida parapsilosis 22019 assessed as growth inhibition by automatic microplate reader analysis2014Journal of natural products, May-23, Volume: 77, Issue:5
Polyhydroxy cyclohexanols from a Dendrodochium sp. fungus associated with the sea cucumber Holothuria nobilis Selenka.
AID284120Antifungal activity against Trichophyton mentagrophytes C943 after 48 hrs2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
Synthesis and antifungal activity of (Z)-5-arylidenerhodanines.
AID687500Antifungal activity against Candida albicans ATCC 10231 after 48 hrs by NCCLS broth microdilution method2012Bioorganic & medicinal chemistry, Oct-15, Volume: 20, Issue:20
Structure-activity relationship study of nitrosopyrimidines acting as antifungal agents.
AID519435Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-4428 obtained from skin of patient after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID204346In vitro antifungal activity against Sporothrix schenck ii1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
Synthesis and structure-activity relationships of side-chain-substituted analogs of the allylamine antimycotic terbinafine lacking the central amino function.
AID547852Antimicrobial activity against Syncephalastrum racemosum RCMB 016001 at 2.5 mg/ml by agar diffusion technique2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Efficient synthesis of novel 1,2,4-triazole fused acyclic and 21-28 membered macrocyclic and/or lariat macrocyclic oxaazathia crown compounds with potential antimicrobial activity.
AID284111Antifungal activity against Trichophyton rubrum C135 after 48 hrs2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
Synthesis and antifungal activity of (Z)-5-arylidenerhodanines.
AID549324Antifungal activity against Cunninghamella spp. after 24 hrs by microdilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID284117Antifungal activity against Trichophyton mentagrophytes C364 after 48 hrs2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
Synthesis and antifungal activity of (Z)-5-arylidenerhodanines.
AID39683In vitro minimum inhibitory concentration (MIC) against isolates of Aspergillus fumigatus in Sabouraud's dextrose broth1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Synthesis and antifungal activity of (E)-N-(6,6-dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphtha lenemethanamine (SF 86-327) and related allylamine derivatives with enhanced oral activity.
AID1754264Antifungal activity against clinical strain Candida tropicalis by microplate reader assay2021Bioorganic & medicinal chemistry, 07-01, Volume: 41A new sulfated triterpene glycoside from the sea cucumber Colochirus quadrangularis, and evaluation of its antifungal, antitumor and immunomodulatory activities.
AID284118Antifungal activity against Trichophyton mentagrophytes C539 after 48 hrs2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
Synthesis and antifungal activity of (Z)-5-arylidenerhodanines.
AID549314Antifungal activity against Mycocladus corymbifer after 24 hrs by microdilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID47883In vitro minimum inhibitory concentration at which no signs of fungal growth were detected against laboratory adapted strains of Candida parapsilosis.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis and structure-activity relationships of benzo[b]thienylallylamine antimycotics.
AID563404Antifungal activity against Aspergillus tubingensis isolate CM-3810 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID1067049Antifungal activity against Candida albicans Y0109 after 24 hrs by micro-broth dilution method2014European journal of medicinal chemistry, Mar-03, Volume: 74Synthesis, antifungal activities and molecular docking studies of novel 2-(2,4-difluorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl dithiocarbamates.
AID125944Tested in vitro for minimum inhibitory concentration against microsporum canis1994Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5
Synthesis and structure-activity relationships of the novel homopropargylamine antimycotics.
AID1112405Fungicidal activity against Zymoseptoria tritici isolate IPO323 without 120 bp insertion expressing wild type CYP51 assessed as fungal growth inhibition2012Pest management science, Jul, Volume: 68, Issue:7
Overexpression of the sterol 14α-demethylase gene (MgCYP51) in Mycosphaerella graminicola isolates confers a novel azole fungicide sensitivity phenotype.
AID575473Cmax in plasma of guinea pig infected with 10'6 CFU Microsporum canis B68128 at 10 mg/kg, po administered 2 hrs before infection for 5 days2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro profiling of pramiconazole and in vivo evaluation in Microsporum canis dermatitis and Candida albicans vaginitis laboratory models.
AID563401Antifungal activity against Aspergillus tubingensis isolate CM-5094 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID245256Minimum inhibitory concentration against Cryptococcus neoformans B66663 by microdilution method2005Bioorganic & medicinal chemistry letters, Jul-15, Volume: 15, Issue:14
Pyrrolo[1,2-a][1,4]benzodiazepine: a novel class of non-azole anti-dermatophyte anti-fungal agents.
AID453089Antimicrobial activity against Staphylococcus aureus at 1.25 ug/mL by agar diffusion method2009Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23
Synthesis, tautomerism, and antimicrobial, anti-HCV, anti-SSPE, antioxidant, and antitumor activities of arylazobenzosuberones.
AID549316Antifungal activity against Cunninghamella bertholletiae after 24 hrs by microdilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID486242Antifungal activity against Trichophyton rubrum C 113 after 48 hrs2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Naftifine-analogues as anti-Trypanosoma cruzi agents.
AID295696Antifungal activity against Penicillium italicum ATCC 48114 at 1 mg/mL by diffusion agar method2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
N- and S-alpha-l-arabinopyranosyl[1,2,4]triazolo[3,4-b][1,3,4]thiadiazoles. First synthesis and biological evaluation.
AID284114Antifungal activity against Trichophyton rubrum C139 after 48 hrs2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
Synthesis and antifungal activity of (Z)-5-arylidenerhodanines.
AID37709In vitro minimum inhibitory concentration at which no signs of fungal growth were detected against laboratory adapted strains of Aspergillus niger.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis and structure-activity relationships of benzo[b]thienylallylamine antimycotics.
AID1592231Inhibition of SE/CYP51 in Candida albicans ATCC SC5314 assessed as effect on sterol composition by measuring Squalene level at 16 ug/ml incubated for 90 mins by HPLC analysis2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
Design, synthesis and biological evaluation of amide-pyridine derivatives as novel dual-target (SE, CYP51) antifungal inhibitors.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID239597Affinity for human EMP expressed in ERG2 deficient strain of Saccharomyces cerevisiae using [3H]ifenprodil or (+)-[3H]pentazocine as radioligand2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Discovery of high-affinity ligands of sigma1 receptor, ERG2, and emopamil binding protein by pharmacophore modeling and virtual screening.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID262553Antifungal activity against Sporothrix schenckii2006Journal of medicinal chemistry, Apr-20, Volume: 49, Issue:8
Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.
AID417969Antimicrobial activity against Trichophyton mentagrophytes after 48 hrs by broth microdilution technique2009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
Relation between lipophilicity of alkyl gallates and antifungal activity against yeasts and filamentous fungi.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID454778Antifungal activity against Aspergillus fumigatus ATCC 26934 after 48 hrs by broth microdilution technique2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
5-Nitrofuranes and 5-nitrothiophenes with anti-Trypanosoma cruzi activity and ability to accumulate squalene.
AID549327Antifungal activity against Actinomucor spp. after 48 hrs by microdilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID566887Antifungal activity against Aspergillus terreus by microdilution test2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Synthesis and antifungal activity of some substituted phenothiazines and related compounds.
AID262554Antifungal activity against Microsporum gypseum2006Journal of medicinal chemistry, Apr-20, Volume: 49, Issue:8
Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.
AID549328Antifungal activity against Apophysomyces spp. after 24 hrs by microdilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID386134Induction of GFP tagged PagsA-H2B expression in Aspergillus niger RD6.47 at 104.2 ug/mL by fluorescence microscopy2007The Journal of biological chemistry, Nov-09, Volume: 282, Issue:45
Survival in the presence of antifungals: genome-wide expression profiling of Aspergillus niger in response to sublethal concentrations of caspofungin and fenpropimorph.
AID548642Antimicrobial activity against Penicillium italicum at 1 to 5 ug/ml by agar well diffusion method2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Antimicrobial, antitumor and 5α-reductase inhibitor activities of some hydrazonoyl substituted pyrimidinones.
AID575462Antifungal activity against 5 x 10'6 CFU/ml Candida albicans B59163 by resazurin based fluorimetry assay2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro profiling of pramiconazole and in vivo evaluation in Microsporum canis dermatitis and Candida albicans vaginitis laboratory models.
AID295693Antifungal activity against Aspergillus fumigatus ATCC 96918 at 1 mg/mL by diffusion agar method2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
N- and S-alpha-l-arabinopyranosyl[1,2,4]triazolo[3,4-b][1,3,4]thiadiazoles. First synthesis and biological evaluation.
AID45471In vitro antifungal activity against Candida albicans 1241995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
Synthesis and structure-activity relationships of side-chain-substituted analogs of the allylamine antimycotic terbinafine lacking the central amino function.
AID1112891Fungicidal activity against Oculimacula yallundae assessed as inhibition of germ tube elongation incubated at 19 degC in dark for 48 hr2013Pest management science, Jan, Volume: 69, Issue:1
Fungicide resistance status in French populations of the wheat eyespot fungi Oculimacula acuformis and Oculimacula yallundae.
AID453069Antimicrobial activity against Aspergillus fumigatus at 5 ug/mL by agar diffusion method2009Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23
Synthesis, tautomerism, and antimicrobial, anti-HCV, anti-SSPE, antioxidant, and antitumor activities of arylazobenzosuberones.
AID1592224Antifungal activity against Candida albicans assessed as reduction in cell volume at 25 to 250 nM/mL by polarizing microscopy2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
Design, synthesis and biological evaluation of amide-pyridine derivatives as novel dual-target (SE, CYP51) antifungal inhibitors.
AID26304Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID39855Tested in vitro for minimum inhibitory concentration against Aspergillus fumigatus1993Journal of medicinal chemistry, Sep-17, Volume: 36, Issue:19
Synthesis and structure-activity relationships of naphthalene-substituted derivatives of the allylamine antimycotic terbinafine.
AID386133Induction of GFP tagged PagsA expression in Aspergillus niger JvD1.1 at 104.2 ug/mL by fluorescence microscopy2007The Journal of biological chemistry, Nov-09, Volume: 282, Issue:45
Survival in the presence of antifungals: genome-wide expression profiling of Aspergillus niger in response to sublethal concentrations of caspofungin and fenpropimorph.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1324276Antifungal activity against Cryptococcus gattii after 24 hrs by microbroth dilution method2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Structure-activity of antifungal compounds inspired by aminobisabolenes from the sponge Halichondria sp.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID246930Effective dose was measured in guinea pig infected with Microsporum canis on 21st day2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology.
AID530964Antifungal activity against Fluconazole resistant Candida albicans clinical isolate 17 after 48 hrs by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID566878Antifungal activity against Candida parapsilosis by microdilution test2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Synthesis and antifungal activity of some substituted phenothiazines and related compounds.
AID687502Antifungal activity against Cryptococcus neoformans ATCC 32264 after 48 hrs by NCCLS broth microdilution method2012Bioorganic & medicinal chemistry, Oct-15, Volume: 20, Issue:20
Structure-activity relationship study of nitrosopyrimidines acting as antifungal agents.
AID519442Antimicrobial activity against Neosartorya hiratsukae isolate CNM-CM-3740 obtained from oropharyngeal exudate of patient after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID303379Antitrypanosomal activity against Trypanosoma cruzi CL Brener2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
In vivo anti-Chagas vinylthio-, vinylsulfinyl-, and vinylsulfonylbenzofuroxan derivatives.
AID1112401Fungicidal activity against Zymoseptoria tritici isolate OP6 without 120 bp insertion expressing CYP51 variant with combination of L50S, S188N, I381V, deltaY459/G460 and N513K mutations assessed as fungal growth inhibition2012Pest management science, Jul, Volume: 68, Issue:7
Overexpression of the sterol 14α-demethylase gene (MgCYP51) in Mycosphaerella graminicola isolates confers a novel azole fungicide sensitivity phenotype.
AID554733Inhibition of Candida krusei ABC1 expressed in Saccharomyces cerevisiae isolate ADdelta at 46 nM2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Abc1p is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candida krusei.
AID549322Antifungal activity against Rhizomucor variabilis after 24 hrs by microdilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID575460Antifungal activity against 5 x 10'6 CFU/ml Trichophyton rubrum J941704 by resazurin based fluorimetry assay2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro profiling of pramiconazole and in vivo evaluation in Microsporum canis dermatitis and Candida albicans vaginitis laboratory models.
AID531205Antifungal activity against Candida albicans ATCC 14053 after 48 hrs by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID363979Antifungal activity against Trichophyton mentagrophytes C132 isolate2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
In vitro antifungal activity of polyfunctionalized 2-(hetero)arylquinolines prepared through imino Diels-Alder reactions.
AID530738Antifungal activity against Candida albicans ATCC 60193 at 68.3 uM after 48 hrs by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID563408Antifungal activity against Aspergillus foetidus isolate CM-5264 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID319750Antimicrobial activity against Candida albicans ATCC 766152008Bioorganic & medicinal chemistry letters, Jun-01, Volume: 18, Issue:11
Synthesis and SAR studies of biaryloxy-substituted triazoles as antifungal agents.
AID547865Antimicrobial activity against Bacillus subtilis RCMB 101001 at 5 mg/ml by agar diffusion technique2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Efficient synthesis of novel 1,2,4-triazole fused acyclic and 21-28 membered macrocyclic and/or lariat macrocyclic oxaazathia crown compounds with potential antimicrobial activity.
AID453075Antimicrobial activity against Bacillus subtilis at 5 ug/mL by agar diffusion method2009Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23
Synthesis, tautomerism, and antimicrobial, anti-HCV, anti-SSPE, antioxidant, and antitumor activities of arylazobenzosuberones.
AID1592230Inhibition of SE/CYP51 in Candida albicans ATCC SC5314 assessed as effect on sterol composition by measuring Lanosterol level at 16 ug/ml incubated for 90 mins by HPLC analysis (Rvb = 10.99%)2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
Design, synthesis and biological evaluation of amide-pyridine derivatives as novel dual-target (SE, CYP51) antifungal inhibitors.
AID519432Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-4415 obtained from sputum of patient after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID48957Tested in vitro for minimum inhibitory concentration against candida albicans 1241994Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5
Synthesis and structure-activity relationships of the novel homopropargylamine antimycotics.
AID1196916Fungicidal activity against Sporothrix schenckii B624822015Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3
2-(2-oxo-morpholin-3-yl)-acetamide derivatives as broad-spectrum antifungal agents.
AID29359Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID519441Antimicrobial activity against Neosartorya hiratsukae isolate CNM-CM-3764 obtained from oropharyngeal exudate of patient after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID363961Antifungal activity against Trichophyton rubrum C133 isolate2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
In vitro antifungal activity of polyfunctionalized 2-(hetero)arylquinolines prepared through imino Diels-Alder reactions.
AID348156Selectivity index, ratio of IC50 for mouse J774 cells to IC50 for Trypanosoma cruzi Tulahuen 22009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Synthesis, trypanocidal activity and docking studies of novel quinoxaline-N-acylhydrazones, designed as cruzain inhibitors candidates.
AID278214Increased sensitivity to growth inhibition in Saccharomyces cerevisiae KLN1 carrying erg1 pR269G allele after 24 hrs relative to wild type at 30 degC2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Characterization of squalene epoxidase of Saccharomyces cerevisiae by applying terbinafine-sensitive variants.
AID575201Antifungal activity against Cunninghamella bertholletiae FMR-9598 after 24 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID47882In vitro minimum inhibitory concentration (MIC) against isolates of Candida parapsilosis in Sabouraud's dextrose broth1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Synthesis and antifungal activity of (E)-N-(6,6-dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphtha lenemethanamine (SF 86-327) and related allylamine derivatives with enhanced oral activity.
AID519425Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-3537 obtained from sputum of patient after 48 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1592215Antifungal activity against Candida glabrata ATCC 0001 assessed as inhibition of microbial growth by NCCLS protocol based method2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
Design, synthesis and biological evaluation of amide-pyridine derivatives as novel dual-target (SE, CYP51) antifungal inhibitors.
AID453091Antimicrobial activity against Bacillus subtilis at 1.25 ug/mL by agar diffusion method2009Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23
Synthesis, tautomerism, and antimicrobial, anti-HCV, anti-SSPE, antioxidant, and antitumor activities of arylazobenzosuberones.
AID56600In vitro minimum inhibitory concentration at which no signs of fungal growth were detected against laboratory adapted strains of dermatophytes.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis and structure-activity relationships of benzo[b]thienylallylamine antimycotics.
AID453092Antimicrobial activity against Escherichia coli at 1.25 ug/mL by agar diffusion method2009Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23
Synthesis, tautomerism, and antimicrobial, anti-HCV, anti-SSPE, antioxidant, and antitumor activities of arylazobenzosuberones.
AID74017Compound was evaluated in vivo for the activity (% mycological cure) by oral treatment of guinea pig dermatophytosis caused by Trichophyton mentagrophytes. Dose = 5 mg/kg/day1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Synthesis and antifungal activity of (E)-N-(6,6-dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphtha lenemethanamine (SF 86-327) and related allylamine derivatives with enhanced oral activity.
AID530962Antifungal activity against Candida krusei ATCC 6258 after 48 hrs by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID549319Antifungal activity against Rhizopus microsporus after 48 hrs by microdilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1592216Antifungal activity against Candida krusei ATCC 6258 assessed as inhibition of microbial growth by NCCLS protocol based method2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
Design, synthesis and biological evaluation of amide-pyridine derivatives as novel dual-target (SE, CYP51) antifungal inhibitors.
AID204345In vitro minimum inhibitory concentration at which no signs of fungal growth were detected against laboratory adapted strains of Sporothrix schenck ii1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis and structure-activity relationships of benzo[b]thienylallylamine antimycotics.
AID295699Antifungal activity against Syncephalastrum racemosum ATCC 18192 at 5 mg/mL by diffusion agar method2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
N- and S-alpha-l-arabinopyranosyl[1,2,4]triazolo[3,4-b][1,3,4]thiadiazoles. First synthesis and biological evaluation.
AID416852Antifungal activity against Trichophyton mentagrophytes DUMC160.03 infected in human skin at 2 fold MIC administered 30 mins post infection followed by once in every 2 days for 7 days by scanning electron microscopy relative to control2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Targeting the calcineurin pathway enhances ergosterol biosynthesis inhibitors against Trichophyton mentagrophytes in vitro and in a human skin infection model.
AID563391Antifungal activity against Aspergillus tubingensis isolate CM-3585 after 48 hrs by EUCAST broth dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID530969Antifungal activity against Aspergillus fumigatus ATCC 204305 at 68.3 uM after 48 hrs by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID547861Antimicrobial activity against Pseudomonas aeruginosa RCMB 102002 at 2.5 mg/ml by agar diffusion technique2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Efficient synthesis of novel 1,2,4-triazole fused acyclic and 21-28 membered macrocyclic and/or lariat macrocyclic oxaazathia crown compounds with potential antimicrobial activity.
AID22293Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1157296Antifungal activity against Trichophyton rubrum Cmccftla assessed as growth inhibition by automatic microplate reader analysis2014Journal of natural products, May-23, Volume: 77, Issue:5
Polyhydroxy cyclohexanols from a Dendrodochium sp. fungus associated with the sea cucumber Holothuria nobilis Selenka.
AID547854Antimicrobial activity against Candida albicans RCMB 005003 at 1 mg/ml by agar diffusion technique2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Efficient synthesis of novel 1,2,4-triazole fused acyclic and 21-28 membered macrocyclic and/or lariat macrocyclic oxaazathia crown compounds with potential antimicrobial activity.
AID454773Antifungal activity against Candida albicans ATCC 10231 after 48 hrs by broth microdilution technique2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
5-Nitrofuranes and 5-nitrothiophenes with anti-Trypanosoma cruzi activity and ability to accumulate squalene.
AID547853Antimicrobial activity against Syncephalastrum racemosum RCMB 016001 at 5 mg/ml by agar diffusion technique2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Efficient synthesis of novel 1,2,4-triazole fused acyclic and 21-28 membered macrocyclic and/or lariat macrocyclic oxaazathia crown compounds with potential antimicrobial activity.
AID1184232Antifungal activity against Mucor FCBP 0400 at 40 mg/mL after 7 days by disc diffusion method2014European journal of medicinal chemistry, Sep-12, Volume: 84Potentially bioactive organotin(IV) compounds: synthesis, characterization, in vitro bioactivities and interaction with SS-DNA.
AID1157291Antifungal activity against Candida albicans SC5314 assessed as growth inhibition by automatic microplate reader analysis2014Journal of natural products, May-23, Volume: 77, Issue:5
Polyhydroxy cyclohexanols from a Dendrodochium sp. fungus associated with the sea cucumber Holothuria nobilis Selenka.
AID245201Minimum inhibitory concentration against Sporothrix schenckii B64284 by microdilution method2005Bioorganic & medicinal chemistry letters, Jul-15, Volume: 15, Issue:14
Pyrrolo[1,2-a][1,4]benzodiazepine: a novel class of non-azole anti-dermatophyte anti-fungal agents.
AID453087Antimicrobial activity against Syncephalastrum racemosum at 1.25 ug/mL by agar diffusion method2009Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23
Synthesis, tautomerism, and antimicrobial, anti-HCV, anti-SSPE, antioxidant, and antitumor activities of arylazobenzosuberones.
AID295694Antifungal activity against Aspergillus fumigatus ATCC 96918 at 2.5 mg/mL by diffusion agar method2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
N- and S-alpha-l-arabinopyranosyl[1,2,4]triazolo[3,4-b][1,3,4]thiadiazoles. First synthesis and biological evaluation.
AID1112887Selectivity index, ratio of EC50 for Oculimacula acuformis to EC50 for Oculimacula yallundae in presence of 10 g glucose by mycelial growth inhibition assay2013Pest management science, Jan, Volume: 69, Issue:1
Fungicide resistance status in French populations of the wheat eyespot fungi Oculimacula acuformis and Oculimacula yallundae.
AID327196Antibacterial activity against Staphylococcus aureus after 24 hrs by agar diffusion test2008Bioorganic & medicinal chemistry, Apr-15, Volume: 16, Issue:8
Synthesis of new N-phenylpyrazole derivatives with potent antimicrobial activity.
AID48958Tested in vitro for minimum inhibitory concentration against candida albicans 91994Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5
Synthesis and structure-activity relationships of the novel homopropargylamine antimycotics.
AID303380Antitrypanosomal activity against Trypanosoma cruzi Y2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
In vivo anti-Chagas vinylthio-, vinylsulfinyl-, and vinylsulfonylbenzofuroxan derivatives.
AID1477763Antifungal activity against drug resistant Candida albicans DF2672R after 24 hrs by two fold serial dilution method2017Journal of medicinal chemistry, 12-28, Volume: 60, Issue:24
Semisynthesis and Biological Evaluation of Xanthone Amphiphilics as Selective, Highly Potent Antifungal Agents to Combat Fungal Resistance.
AID1157294Antifungal activity against Cryptococcus neoformans 32609 assessed as growth inhibition by automatic microplate reader analysis2014Journal of natural products, May-23, Volume: 77, Issue:5
Polyhydroxy cyclohexanols from a Dendrodochium sp. fungus associated with the sea cucumber Holothuria nobilis Selenka.
AID575456Cytotoxicity against human MRC5 cells2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro profiling of pramiconazole and in vivo evaluation in Microsporum canis dermatitis and Candida albicans vaginitis laboratory models.
AID515008Antifungal activity against Candida albicans SC5314 after 24 hrs by micro-broth dilution method2010European journal of medicinal chemistry, Oct, Volume: 45, Issue:10
Synthesis and antifungal evaluation of novel triazole derivatives as inhibitors of cytochrome P450 14alpha-demethylase.
AID563403Antifungal activity against Aspergillus tubingensis isolate CM-3123 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID1112398Fungicidal activity against Zymoseptoria tritici isolate OP7 with 120 bp insertion expressing CYP51 variant with combination of L50S, S188N, I381V, deltaY459/G460 and N513K mutations assessed as fungal growth inhibition2012Pest management science, Jul, Volume: 68, Issue:7
Overexpression of the sterol 14α-demethylase gene (MgCYP51) in Mycosphaerella graminicola isolates confers a novel azole fungicide sensitivity phenotype.
AID1592221Antifungal activity against Candida albicans assessed as inhibition of microbial growth at 25 to 250 nM/mL by polarizing microscopy2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
Design, synthesis and biological evaluation of amide-pyridine derivatives as novel dual-target (SE, CYP51) antifungal inhibitors.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID363978Antifungal activity against Trichophyton mentagrophytes C131 isolate2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
In vitro antifungal activity of polyfunctionalized 2-(hetero)arylquinolines prepared through imino Diels-Alder reactions.
AID575203Antifungal activity against Cunninghamella bertholletiae UTHSC 03-2241 after 24 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID249267Minimum inhibitory concentration against Trichophyton rubrum (n=14)2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology.
AID1067042Antifungal activity against Microsporum gypseum by micro-broth dilution method2014European journal of medicinal chemistry, Mar-03, Volume: 74Synthesis, antifungal activities and molecular docking studies of novel 2-(2,4-difluorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl dithiocarbamates.
AID530928Antifungal activity against Fluconazole resistant Candida albicans isolate 1 at 68.3 uM after 48 hrs by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID56599In vitro minimum inhibitory concentration at which no signs of fungal growth were detected against clinically isolated strains of dermatophytes.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis and structure-activity relationships of benzo[b]thienylallylamine antimycotics.
AID1754265Antifungal activity against clinical strain Candida parapsilosis by microplate reader assay2021Bioorganic & medicinal chemistry, 07-01, Volume: 41A new sulfated triterpene glycoside from the sea cucumber Colochirus quadrangularis, and evaluation of its antifungal, antitumor and immunomodulatory activities.
AID453080Antimicrobial activity against Candida albicans at 2.5 ug/mL by agar diffusion method2009Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23
Synthesis, tautomerism, and antimicrobial, anti-HCV, anti-SSPE, antioxidant, and antitumor activities of arylazobenzosuberones.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,002)

TimeframeStudies, This Drug (%)All Drugs %
pre-199053 (2.65)18.7374
1990's436 (21.78)18.2507
2000's636 (31.77)29.6817
2010's607 (30.32)24.3611
2020's270 (13.49)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 86.23

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index86.23 (24.57)
Research Supply Index7.80 (2.92)
Research Growth Index5.45 (4.65)
Search Engine Demand Index221.72 (26.88)
Search Engine Supply Index2.83 (0.95)

This Compound (86.23)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials280 (12.94%)5.53%
Reviews291 (13.45%)6.00%
Case Studies582 (26.89%)4.05%
Observational2 (0.09%)0.25%
Other1,009 (46.63%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]